<SEC-DOCUMENT>0001493152-21-000974.txt : 20210113
<SEC-HEADER>0001493152-21-000974.hdr.sgml : 20210113
<ACCEPTANCE-DATETIME>20210113172807
ACCESSION NUMBER:		0001493152-21-000974
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20210113
DATE AS OF CHANGE:		20210113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Enveric Biosciences, Inc.
		CENTRAL INDEX KEY:			0000890821
		STANDARD INDUSTRIAL CLASSIFICATION:	SEMICONDUCTORS & RELATED DEVICES [3674]
		IRS NUMBER:				954484725
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-233260
		FILM NUMBER:		21526887

	BUSINESS ADDRESS:	
		STREET 1:		4851 TAMIAMI TRAIL N, SUITE 200
		CITY:			NAPLES
		STATE:			FL
		ZIP:			34103
		BUSINESS PHONE:		239-302-1707

	MAIL ADDRESS:	
		STREET 1:		4851 TAMIAMI TRAIL N, SUITE 200
		CITY:			NAPLES
		STATE:			FL
		ZIP:			34103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMERI Holdings, Inc.
		DATE OF NAME CHANGE:	20150527

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SPATIALIZER AUDIO LABORATORIES INC
		DATE OF NAME CHANGE:	19950323
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>form424b5.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed
Pursuant to Rule 424(b)(5)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
No. 333-233260</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS
SUPPLEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(To
prospectus dated November 19, 2019)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENVERIC
BIOSCIENCES INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1,610,679
Shares of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pre-funded
Warrants to Purchase up to 610,679 Shares of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are offering 1,610,679 shares of our common stock pursuant to this prospectus supplement and accompanying prospectus to certain
institutional investors. Each share of common stock is being sold at a price per share equal to $4.5018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also offering pre-funded warrants to purchase up to 610,679 shares of common stock (the &ldquo;Pre-funded
Warrants&rdquo;) to each purchaser whose purchase of shares of common stock in this offering would otherwise result in such
purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% of our outstanding
common stock immediately following the consummation of this offering, in lieu of shares of common stock that would otherwise
result in such purchaser&rsquo;s beneficial ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of our
outstanding common stock. The purchase price of each Pre-funded Warrant will be equal to the price per share at which shares
of common stock are sold to the public in this offering, minus $0.01, and the exercise price of each Pre-funded Warrant will
be $0.01 per share. This offering also relates to the shares of common stock issuable upon exercise of any Pre-funded
Warrants sold in this offering. The Pre-funded Warrants will be exercisable immediately and may be exercised at any time
until all of the Pre-funded Warrants are exercised in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a concurrent private placement, we are also selling to such investors warrants to purchase up to 1,666,019 shares of our common
stock (the &ldquo;Warrants&rdquo;), exercisable for one share of our common stock at an exercise price of $4.9519 per share, and
exercisable immediately upon issuance with a term of five (5) years from the date of issuance. The Warrants and the shares of
our common stock issuable upon the exercise of the Warrants (the &ldquo;Warrant Shares&rdquo;) are being offered pursuant to the
exemptions provided in Section 4(a)(2) under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;) and Rule
506(b) promulgated thereunder, and they are not being offered pursuant to this prospectus supplement and the accompanying prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no established public trading market for the Pre-funded Warrants and Warrants and we do not expect a market to develop. In
addition, we do not intend to list the Pre-funded Warrants and Warrants on The Nasdaq Capital Market, any other national securities
exchange or any other nationally recognized trading system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is traded on The Nasdaq Capital Market under the symbol &ldquo;ENVB.&rdquo; On January 11, 2021, the closing sale
price of our common stock on The Nasdaq Capital Market was $4.87 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>This
investment involves a high degree of risk. See &ldquo;<U>Risk Factors</U>&rdquo; on page S-8 of this prospectus supplement
and any similar section contained in the accompanying prospectus and in the documents that are incorporated by reference herein
and therein.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) nor any state securities commission has approved or disapproved
of these securities or determined if this prospectus supplement is truthful or complete. Any representation to the contrary is
a criminal offense.</B></FONT></P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delivery
of the shares of common stock to investors is expected to occur on or about January 14, 2021, subject to satisfaction of customary
closing conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Effective
as of 4:02 pm Eastern Time on December 30, 2020, we filed an amendment to our Amended and Restated Certificate of Incorporation
to effect a reverse stock split of the issued and outstanding shares of our common stock, at a ratio of one share for four shares.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The net result of the reverse stock split was
a 1-for-4 reverse stock split. <FONT STYLE="background-color: white">All share and per share prices in this prospectus supplement
have been adjusted to reflect the reverse stock split.</FONT></FONT></P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
date of this prospectus supplement is January 12, 2021.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Prospectus Supplement</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#g_001">ABOUT THIS PROSPECTUS SUPPLEMENT</A></TD>
    <TD STYLE="width: 0.5in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#g_002">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-2</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#g_003">PROSPECTUS SUPPLEMENT SUMMARY</A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-</FONT>3</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#g_004">THE OFFERING</A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-</FONT>7</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#g_005">RISK FACTORS</A></TD>
    <TD STYLE="padding-left: -50pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-</FONT>8</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#g_006">USE OF PROCEEDS</A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-</FONT>10</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#g_007">DIVIDEND POLICY</A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-10</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#g_008">DILUTION</A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-11</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#g_009">MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-</FONT>12</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#g_010">DESCRIPTION OF SECURITIES WE ARE OFFERING</A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-</FONT>19</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#g_011">PRIVATE PLACEMENT</A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-21</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#g_012">PLAN OF DISTRIBUTION</A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-22</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#g_013">LEGAL MATTERS</A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-23</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#g_014">EXPERTS</A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-23</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#g_015">WHERE YOU CAN FIND MORE INFORMATION</A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-23</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#g_016">INCORPORATION BY REFERENCE</A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-24</FONT></TD></TR>
</TABLE>
  <div style="text-align: center; font-weight: bold;">&nbsp;</DIV>

<DIV STYLE="text-align: center; font-weight: bold"><a name="TABLEOFCONTENTS"><!--Anchor--></a>TABLE OF CONTENTS</div>
  <div> </div>
  <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="z18712f81671148cfb2bcf18c59d12d0e">

      <tr>
        <td style="width: 92%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
        <td style="width: 8%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
          <div style="text-align: center; font-weight: bold;">Page</div>
        </td>
      </tr>
      <tr>
        <td style="width: 92%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="color: rgb(0, 0, 0);"><a href="#ABOUTTHISPROSPECTUS">ABOUT THIS PROSPECTUS</a></div>
        </td>
        <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;">6<br>
        </td>
      </tr>
      <tr>
        <td style="width: 92%; vertical-align: top; background-color: rgb(255, 255, 255);">
          <div style="color: rgb(0, 0, 0);"><a href="#RISKFACTORS">RISK FACTORS</a></div>
        </td>
        <td style="width: 8%; vertical-align: top; background-color: rgb(255, 255, 255); text-align: center;">16<br>
        </td>
      </tr>
      <tr>
        <td style="width: 92%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="color: rgb(0, 0, 0);"><a href="#FORWARD-LOOKINGSTATEMENTS">DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS</a></div>
        </td>
        <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;">17</td>
      </tr>
      <tr>
        <td style="width: 92%; vertical-align: top; background-color: rgb(255, 255, 255);">
          <div style="color: rgb(0, 0, 0);"><a href="#USEOFPROCEEDS">USE OF PROCEEDS</a></div>
        </td>
        <td style="width: 8%; vertical-align: top; background-color: rgb(255, 255, 255); text-align: center;">18</td>
      </tr>
      <tr>
        <td style="width: 92%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="color: rgb(0, 0, 0);"><a href="#DESCRIPTIONOFCAPITALSTOCK">DESCRIPTION OF CAPITAL STOCK</a></div>
        </td>
        <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;">19<br>
        </td>
      </tr>
      <tr>
        <td style="width: 92%; vertical-align: top; background-color: rgb(255, 255, 255);">
          <div style="color: rgb(0, 0, 0);"><a href="#DESCRIPTIONOFDEBTSECURITI">DESCRIPTION OF DEBT SECURITIES</a></div>
        </td>
        <td style="width: 8%; vertical-align: top; background-color: rgb(255, 255, 255); text-align: center;">21</td>
      </tr>
      <tr>
        <td style="width: 92%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="color: rgb(0, 0, 0);"><a href="#OF">DESCRIPTION OF WARRANTS</a></div>
        </td>
        <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;">29</td>
      </tr>
      <tr>
        <td style="width: 92%; vertical-align: top; background-color: rgb(255, 255, 255);">
          <div style="color: rgb(0, 0, 0);"><a href="#DESCRIPTION">DESCRIPTION OF UNITS</a></div>
        </td>
        <td style="width: 8%; vertical-align: top; background-color: rgb(255, 255, 255); text-align: center;">31</td>
      </tr>
      <tr>
        <td style="width: 92%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="color: rgb(0, 0, 0);"><a href="#LEGAL">LEGAL OWNERSHIP OF SECURITIES</a></div>
        </td>
        <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;">32</td>
      </tr>
      <tr>
        <td style="width: 92%; vertical-align: top; background-color: rgb(255, 255, 255);">
          <div style="color: rgb(0, 0, 0);"><a href="#PLAN">PLAN OF DISTRIBUTION</a></div>
        </td>
        <td style="width: 8%; vertical-align: top; background-color: rgb(255, 255, 255); text-align: center;">36</td>
      </tr>
      <tr>
        <td style="width: 92%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="color: rgb(0, 0, 0);"><a href="#LEGALM">LEGAL MATTERS</a></div>
        </td>
        <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;">38</td>
      </tr>
      <tr>
        <td style="width: 92%; vertical-align: top; background-color: rgb(255, 255, 255);">
          <div style="color: rgb(0, 0, 0);"><a href="#EXP">EXPERTS</a></div>
        </td>
        <td style="width: 8%; vertical-align: top; background-color: rgb(255, 255, 255); text-align: center;">38</td>
      </tr>
      <tr>
        <td style="width: 92%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="color: rgb(0, 0, 0);"><a href="#CAN">WHERE YOU CAN FIND MORE INFORMATION</a></div>
        </td>
        <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;">39</td>
      </tr>
      <tr>
        <td style="width: 92%; vertical-align: top; background-color: rgb(255, 255, 255);">
          <div style="color: rgb(0, 0, 0);"><a href="#DOCUMENTS">INCORPORATION OF DOCUMENTS BY REFERENCE</a></div>
        </td>
        <td style="width: 8%; vertical-align: top; background-color: rgb(255, 255, 255); text-align: center;">39</td>
      </tr>

  </table>
  <div> <br>
  </div>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="g_001"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ABOUT
THIS PROSPECTUS SUPPLEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
document is part of the registration statement that we filed with the Securities and Exchange Commission, or the SEC, using a
&ldquo;shelf&rdquo; registration process and consists of two parts. The first part is this prospectus supplement, including the
documents incorporated by reference, which describes the specific terms of this offering. The second part, the accompanying prospectus,
including the documents incorporated by reference, gives more general information, some of which may not apply to this offering.
Generally, when we refer only to the &ldquo;prospectus,&rdquo; we are referring to both parts combined. This prospectus supplement
may add to, update or change information in the accompanying prospectus and the documents incorporated by reference into this
prospectus supplement or the accompanying prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
information in this prospectus supplement is inconsistent with the accompanying prospectus or with any document incorporated by
reference that was filed with the SEC before the date of this prospectus supplement, you should rely on this prospectus supplement.
This prospectus supplement, the accompanying prospectus and the documents incorporated into each by reference include important
information about us, the securities being offered and other information you should know before investing in our securities. You
should also read and consider information in the documents we have referred you to in the section of this prospectus supplement
and the accompanying prospectus entitled &ldquo;Incorporation by Reference&rdquo; and &ldquo;Where You Can Find More Information&rdquo;
as well as any free writing prospectus provided in connection with this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should rely only on this prospectus supplement, the accompanying prospectus, and any free writing prospectus provided in connection
with this offering and the information incorporated or deemed to be incorporated by reference in this prospectus supplement and
the accompanying prospectus. We have not authorized anyone to provide you with information that is in addition to or different
from that contained or incorporated by reference in this prospectus supplement, the accompanying prospectus, and any free writing
prospectus provided in connection with this offering. If anyone provides you with different or inconsistent information, you should
not rely on it. We are not offering to sell these securities in any jurisdiction where the offer or sale is not permitted. You
should not assume that the information contained or incorporated by reference in this prospectus supplement, the accompanying
prospectus, or any free writing prospectus provided in connection with this offering is accurate as of any date other than as
of the date of this prospectus supplement, the accompanying prospectus, or such free writing prospectus, as the case may be, or
in the case of the documents incorporated by reference, the date of such documents regardless of the time of delivery of this
prospectus supplement and the accompanying prospectus or any sale of our securities. Our business, financial condition, liquidity,
results of operations and prospects may have changed since those dates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
the context otherwise indicates, references in this prospectus to &ldquo;Enveric&rdquo;, &ldquo;we&rdquo;, &ldquo;our&rdquo;,
&ldquo;us&rdquo; and &ldquo;the Company&rdquo; refer, collectively, to Enveric Biosciences, Inc. and its subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No
action is being taken in any jurisdiction outside the United States to permit a public offering of the securities or possession
or distribution of this prospectus supplement, the accompanying prospectus, or any free writing prospectus provided in connection
with this offering in that jurisdiction. Persons who come into possession of this prospectus supplement, the accompanying prospectus,
or any free writing prospectus provided in connection with this offering in jurisdictions outside the United States are required
to inform themselves about and to observe any restrictions as to this offering and the distribution of this prospectus supplement,
the accompanying prospectus, or any free writing prospectus provided in connection with this offering applicable to that jurisdiction.
This prospectus supplement and the accompanying prospectus do not constitute, and may not be used in connection with, an offer
to sell, or a solicitation of an offer to buy, any securities offered by this prospectus supplement and the accompanying prospectus
by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="g_002"></A>SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement and the accompanying prospectus, including the documents that we incorporate by reference herein and therein,
contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities
Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Any statements about our expectations,
beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking. These
statements are often, but are not always, made through the use of words or phrases such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo;
&ldquo;contemplate,&rdquo; &ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo;
&ldquo;may,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;seek,&rdquo;
&ldquo;should,&rdquo; &ldquo;target,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo; and similar expressions, or the negative
of these terms, or similar expressions. Accordingly, these statements involve estimates, assumptions and uncertainties which could
cause actual results to differ materially from those expressed in them. Any forward-looking statements are qualified in their
entirety by reference to the factors discussed throughout this prospectus supplement and the accompanying prospectus, and in particular
those factors referenced in the sections entitled &ldquo;Risk Factors.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement and the accompanying prospectus contain forward-looking statements that are based on our management&rsquo;s
belief and assumptions and on information currently available to our management. These statements relate to future events or our
future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results,
levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance
or achievements expressed or implied by these forward-looking statements. Numerous factors could cause our actual results to differ
materially from those described in forward-looking statements, including, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         impact of the novel coronavirus (COVID-19) on our ongoing and planned clinical trials;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         geographic, social and economic impact of COVID-19 on our ability to conduct our
                                         business and raise capital in the future when needed;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
                                         in planned clinical trials; the ability to establish that potential products are efficacious
                                         or safe in preclinical or clinical trials;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         ability to establish or maintain collaborations on the development of therapeutic candidates;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         ability to obtain appropriate or necessary governmental approvals to market potential
                                         products;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         ability to obtain future funding for developmental products and working capital and to
                                         obtain such funding on commercially reasonable terms;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to manufacture product candidates on a commercial scale or in collaborations
                                         with third parties; changes in the size and nature of competitors;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         ability to retain key executives and scientists; and the ability to secure and enforce
                                         legal rights related to our products, including patent protection;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         expected use of proceeds from this offering; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
                                         factors discussed in this prospectus supplement and the accompanying prospectus and the
                                         documents incorporated by reference herein and therein, including those set forth under
                                         &ldquo;Risk Factors&rdquo; in our Registration Statement on Form S-4 filed with the SEC
                                         on May 28, 2020, as amended (the &ldquo;Form S-4&rdquo;).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have included important factors in the cautionary statements included in this prospectus supplement and the accompanying prospectus
and the documents we incorporate by reference herein and therein, including from the Form S-4, particularly in the &ldquo;Risk
Factors&rdquo; sections of these documents, that we believe could cause actual results or events to differ materially from the
forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions,
mergers, dispositions, joint ventures or investments we may make. No forward-looking statement is a guarantee of future performance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read this prospectus supplement and the accompanying prospectus and the documents that we incorporate by reference herein
and therein completely and with the understanding that our actual future results may be materially different from what we expect.
The forward-looking statements in this prospectus supplement and the accompanying prospectus and the documents we incorporate
by reference herein and therein represent our views as of the date of this prospectus supplement. We anticipate that subsequent
events and developments will cause our views to change. However, while we may elect to update these forward-looking statements
at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should,
therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this
prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 8.7pt; text-align: center">&nbsp;</P>

<DIV STYLE="padding-right: 10pt; padding-left: 10pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 8.7pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 8.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="g_003"></A>PROSPECTUS
SUPPLEMENT SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 8.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following summary of our business highlights some of the information contained elsewhere in, or incorporated by reference into,
this prospectus supplement. Because this is only a summary, however, it does not contain all of the information that may be important
to you. You should carefully read this prospectus supplement and the accompanying prospectus, including the documents incorporated
by reference, which are described under &ldquo;Incorporation of Certain Information by Reference&rdquo; in this prospectus supplement.
You should also carefully consider the matters discussed in the section of this prospectus supplement entitled &ldquo;Risk Factors&rdquo;
and under similar sections of the accompanying prospectus and other periodic reports incorporated herein and therein by reference.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>In this prospectus supplement, unless the
context otherwise requires, references to &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; &ldquo;our company&rdquo; and
&ldquo;Enveric&rdquo; refer to Enveric Biosciences, Inc. and its subsidiaries. We were previously known as AMERI Holdings, Inc.
(&ldquo;Ameri&rdquo;). Following the completion of our offer to purchase all of the issued and outstanding shares of
Jay Pharma, Inc. on December 30, 2020, we changed the name of our company from AMERI Holdings, Inc. to Enveric Biosciences,
Inc. For more detail on the transaction with Jay Pharma, Inc. and related transactions, see section titled &ldquo;Recent
Development&rdquo; below.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 8.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company
Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an early-development-stage biosciences company that is seeking to develop innovative, evidence-based prescription products
and combination therapies containing cannabinoids to address unmet needs in cancer care. We seek to improve the lives of patients
suffering from cancer, initially by developing palliative and supportive care products for persons suffering from certain side
effects of cancer and cancer treatment such as pain or skin irritation. We currently intend to offer such palliative and supportive
care products in the United States, following approval through established regulatory pathways.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also aiming to advance a pipeline of novel cannabinoid combination therapies for hard-to-treat cancers, including glioblastoma
multiforme (GBM) and several other indications which are currently being researched.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to bring together leading oncology clinicians and researchers, academic and industry partners so as to develop both external
proprietary products and a robust internal pipeline of product candidates aimed at improving quality of life and outcomes for
cancer patients. We intend to evaluate options to out-license our proprietary technology as we move along the regulatory pathway
instead of building a small targeted selling organization and will potentially utilize a hybrid approach based on the indication
and the results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
developing our product candidates, we intend to focus solely on cannabinoids derived from hemp and synthetic materials containing
no tetrahydrocannabinol (THC) in order to comply with U.S. federal regulations. Of the potential cannabinoids to be used in therapeutic
formulations, THC, which is responsible for the psychoactive properties of marijuana, can result in undesirable mood effects.
Cannabidiol (CBD) and cannabigerol (CBG), on the other hand, are not psychotropic and are therefore more attractive candidates
for translation into therapeutic practice. In the future, we may utilize cannabinoids that are derived from cannabis plants, which
may contain THC; however, we only intend to do so in jurisdictions where THC is legal. These product candidates will then be studied
through a typical FDA drug approval process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<DIV STYLE="padding-right: 10pt; padding-left: 10pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Product
Candidates</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
pipeline of product candidates and key ongoing development programs are shown in the tables below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 26%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Product
    Candidate</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 18%"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Targeted</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Indications</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Partner(s)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Status</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; width: 19%"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expected Next</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Steps</B></FONT></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cannabinoid-Infused
    Topical Product</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncology-
    related skincare conditions (e.g., radiodermatitis)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.-Based
    Center of Excellence</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    &amp; Development / Discovery</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IND submission; Exploratory Phase</FONT></P>
                                                                           <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1/2 trial with patient enrollment</FONT></P>
                                                                           <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">anticipated in the second half of 2020</FONT></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cannabinoid
        + Chemotherapy Combination Therapy</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Oral
        synthetic CBD</I></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>extract given alone or in combination with</I></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>clomiphene, concurrently</I></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>with dose-dense</I></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Temolozomide</I></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>chemotherapy</I></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Glioblastoma
        Multiforme</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Recurrent
        or progressive</I></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
        Tali</FONT></P>
                                                         <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Siegal,</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rabin</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Medical</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Center,</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Davidoff Institute of Oncology</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    &amp; Development / Discovery</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IND submission; Exploratory Phase</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1/2 trial with patient enrollment</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">anticipated during the second half of</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2020</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 78%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Additional
    Potential Development Programs</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Potential
    Target Indications</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cannabinoid
        + Chemotherapy Combination Therapy</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Clomiphene
        in combination with CBD in patients with selected locally advanced or metastatic breast cancer treated with standard adjuvant
        chemotherapy regimens</I></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Breast
    Cancer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
Developments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Closing
of the Offer</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 30, 2020, pursuant
to the previously announced Tender Offer Support Agreement and Termination of Amalgamation Agreement dated August 12, 2020, as
amended by that certain Amendment No. 1 to the Tender Offer Support Agreement and Termination of Amalgamation Agreement dated December
18, 2020 (as amended, the &ldquo;Tender Agreement&rdquo;), by and among us, Jay Pharma Inc., a Canada corporation and a wholly
owned subsidiary of the Company (&ldquo;Jay Pharma&rdquo;), and certain other signatories thereto, we completed a tender offer
(the &ldquo;Offer&rdquo;) to purchase all of the outstanding common shares of Jay. Following the effective time of the Offer, we
changed the name of our company from AMERI Holdings, Inc. to Enveric Biosciences, Inc. and effected a 1-for-4 reverse stock split
of the issued and outstanding common stock. Immediately following completion of the Offer and the transactions contemplated in
the Tender Agreement, but without giving effect to the issuance of the Series B Warrants (as defined below) (i) the former Jay
Pharma equity holders (including certain investors in private placements that closed prior to the completion of the Offer) own
approximately 82.3% of the Company; (ii) former Ameri equity holders own approximately 14.5% of the Company; and (iii) a financial
advisor to Jay Pharma and Ameri owns approximately 3.2% of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of approximately 62%&nbsp; of outstanding shares of common stock as of January 11, 2020 are subject to lock-up/leak-out
agreements pursuant to which such stockholders have agreed, except in limited circumstances, not to sell or transfer, or engage
in swap or similar transactions with respect to, certain shares of common stock, including, as applicable, shares received in
the Offer and issuable upon exercise of certain warrants and options. The lock-up period begins at the time of the completion
of the Offer and ends on the date that is 180 days after such time. The leak-out period begins on the date that is the end of
the lock-up period and ends on a date that is 180 days after such date. During the leak-out period, such holders may only sell
up to 15% of the aggregate amount of our securities owned by such holder as of the expiration of the lock-up period per month.
Notwithstanding the foregoing, the lock-up and leak-out restrictions are subject to value and trading thresholds set forth in
the lock-up/leak-out agreements which, if met, would cause the lock-up and leak-out restrictions to expire. In addition, we
may, in our discretion, waive the lock-up and leak-out restrictions with respect to one or more stockholders at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.7pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.7pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.7pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.7pt; text-align: justify">&nbsp;</P>

<DIV STYLE="padding-right: 10pt; padding-left: 10pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
common stock on The Nasdaq Capital Market, previously trading through the close of business on December 30, 2020 under the ticker
symbol &ldquo;AMRH,&rdquo; commenced trading on The Nasdaq Capital Market, on a post-Reverse Stock Split adjusted basis, under
the ticker symbol &ldquo;ENVB&rdquo; on December 31, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Closing
of Spin-Off</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
previously reported, on January 10, 2020, Ameri and Ameri100 Inc. (&ldquo;Private Ameri&rdquo;) entered into a Share Purchase
Agreement (the &ldquo;Ameri Share Purchase Agreement&rdquo;) pursuant to which Ameri agreed to contribute, transfer and convey
to Private Ameri all of the issued and outstanding equity interests of the existing subsidiaries of Ameri, constituting the entire
business and operations of Ameri and its subsidiaries, and wherein Private Ameri agreed to assume the liabilities of such subsidiaries
(the &ldquo;Spin-Off&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 30, 2020, pursuant to the Ameri Share Purchase Agreement, Ameri consummated the Spin-Off and all of the issued and outstanding
shares of Series A preferred stock of Ameri (the &ldquo;Series A Preferred Stock&rdquo;) were redeemed for an equal number of
shares of Series A preferred stock of Private Ameri (&ldquo;Private Ameri Preferred Stock&rdquo;). Ameri contributed, transferred
and conveyed to Private Ameri all of the issued and outstanding equity interests of the existing subsidiaries of Ameri, constituting
the entire business and operations of Ameri and its subsidiaries, and Private Ameri assumed the liabilities of such subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Series
B Warrants</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Tender Agreement, on December 31, 2020, we issued Series B Warrants (the &ldquo;Series B Warrants&rdquo;) to purchase
1,791,923 shares of common stock at an exercise price of $0.01 to Alpha Capital Anstalt (&ldquo;Alpha&rdquo;). We are
obligated, among other things, to file a registration statement with SEC for purposes of registering the resale of the shares
of common stock issuable upon exercise of the Series B Warrants by the investors. The issuance of the Series B Warrants was
exempt from the registration requirements of the Securities Act pursuant to an exemption provided by Section 4(a)(2) thereof
as a transaction by an issuer not involving a public offering. As described below under &ldquo;<I>Letter Agreement with
Alpha</I>&rdquo;, on January 12, 2021, we have waived the lock-up restrictions on Alpha with respect to dispositions of the
shares of common stock issuable upon exercise of the Series B Warrants (the &ldquo;Series B Warrant Shares&rdquo;), and Alpha
agreed to limit its sales of shares of our common stock on each trading day to no more than 10% of the daily reported trading
volume of common stock on the Nasdaq Stock Market for such trading day, provided, such limitation shall terminate if the
closing price of our shares of common stock on the Nasdaq Stock Market exceeds $5.29 per share for five consecutive
trading days.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Director
and Officer Resignations and Appointments</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
upon completion of the Offer, Srinidhi &ldquo;Dev&rdquo; Devanur, our former Executive Chairman and a former director of the board
of directors, Brent Kelton, our former Chief Executive Officer, Barry Kostiner, our former Chief Financial Officer, Carmo Martella,
a former director of the board of directors, Thoranath Sukumaran, a former director of the board of directors and Dimitrios Angelis,
a former director of the board of directors, all tendered their resignations from their respective positions as officers and directors
of our company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Tender Agreement, and as disclosed in the Form S-4, the board of directors appointed David Johnson, George
Kegler, Sol Mayer and Marcus Schabacker to the board of directors at the effective time of the Offer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
upon the completion of the Offer, the board of directors appointed David Johnson as our Chief Executive Officer and Chairman,
Avani Kanubaddi as our Chief Operating Officer, John Van Buiten as our Chief Financial Officer, and Robert Wilkins as our Chief
Medical Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Amended
and Restated Certificate of incorporation and Bylaws</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Tender Agreement, we filed an Amended and Restated Certificate of Incorporation and adopted amended and restated
bylaws on December 30, 2020. For additional information regarding our organizational documents, please refer to our Current Report
on Form 8-K filed with the SEC on January 6, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.7pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<DIV STYLE="padding-right: 10pt; padding-left: 10pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Delisting
of Ameri Warrants</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 30, 2020, we received a written notice (the &ldquo;Notice&rdquo;) from Listing Qualifications Department of The Nasdaq
Stock Market LLC (&ldquo;Nasdaq&rdquo;) indicating that our listed warrants (the &ldquo;AMRHW Warrants&rdquo;) would be suspended
from listing on the Nasdaq Capital Market. A Form 25-NSE was filed with the SEC on December 30, 2020, which removed the AMRHW
Warrants from listing and registration on the Nasdaq Capital Market. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
terms of the AMRHW Warrants are not affected by the delisting, and the AMRHW Warrants may still be exercised in accordance with
their terms to purchase common stock of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
listing of the common stock, which is traded on the Nasdaq Capital Market under the symbol ENVB, is not affected by the delisting
of the AMRHW Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Change
in Certifying Accountant</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 5, 2021, our Audit Committee of the board of directors approved the dismissal of Ram Associates, CPA (&ldquo;Ram&rdquo;)
as our independent registered public accounting firm, effective December 31, 2020, and engaged Marcum LLP (&ldquo;Marcum&rdquo;)
as our independent registered public accounting firm for the year ending December 31, 2020. Prior to the completion of the Offer,
Marcum served as the independent registered public accounting firm of Jay Pharma, and we believe the change in auditors will be
more efficient for reporting purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Letter
Agreement with Alpha</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 12, 2021 we entered into a letter
agreement (the &ldquo;Letter Agreement&rdquo;) with Alpha. Under the Letter Agreement, (i) we agreed to register 1,791,923
of the Series B Warrant Shares issuable upon the exercise of Series B Warrants, (ii) the Series B Warrant Shares will not be subject
to an existing lock-up agreement between us and Alpha, and Alpha will no longer be subject to any limitations on its ability to
dispose of the Series B Warrant Shares that are imposed by us to the extent permitted by applicable rules and regulations, (iii)
Alpha agreed to limit its sales of common stock on each trading day to no more than 10% of the daily reported trading volume of
common stock on the Nasdaq Stock Market for such trading day, provided, such limitation shall terminate if the closing price of
our shares of common stock on the Nasdaq Stock Market exceeds $5.29 per share for five consecutive trading days and (iv)
we will be free to waive the terms and conditions of any lock-up agreement between us and any of the former shareholders of Jay
Pharma Inc. without the consent of, or notice to, Alpha once the registration statement registering the Series B Warrant Shares
is declared effective by the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reverse
Stock Split</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Effective
as of 4:02 pm Eastern Time on December 30, 2020, we filed an amendment to our Amended and Restated Certificate of Incorporation
to effect a reverse stock split of the issued and outstanding shares of our common stock, at a ratio of one share for four shares.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The net result of the reverse stock split was
a 1-for-4 reverse stock split. <FONT STYLE="background-color: white">We made proportionate adjustments to the per share exercise
price and/or the number of shares issuable upon the exercise or vesting of all stock options, restricted stock units (if any)
and warrants outstanding as of the effective times of the reverse stock split in accordance with the terms of each security based
on the split ratio. Also, we reduced the number of shares reserved for issuance under our equity compensation plans proportionately
based on the split ratios. Except for adjustments that resulted from the rounding up of fractional shares to the next whole share,
the reverse stock split affected all stockholders uniformly and did not change any stockholder&rsquo;s percentage ownership interest
in our company. All share and related option and warrant information presented in this prospectus supplement have been retroactively
adjusted to reflect the reduced number of shares outstanding and the increase in share price which resulted from these actions;
however, common stock share and per share amounts in the accompanying prospectus and certain of the documents incorporated by
reference herein have not been adjusted to give effect to the reverse stock split.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Company
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
were incorporated under the laws of the State of Delaware in February 1994 as Spatializer Audio Laboratories, Inc., which was
a shell company immediately prior to the completion of a &ldquo;reverse merger&rdquo; transaction on May 26, 2015, whereby Ameri100
Acquisition, Inc., a Delaware corporation and newly created, wholly owned subsidiary, was merged with and into Ameri and Partners
Inc. (&ldquo;Ameri and Partners&rdquo;), a Delaware corporation (the &ldquo;2015 Merger&rdquo;). As a result of the 2015 Merger,
Ameri and Partners became Ameri&rsquo;s wholly owned subsidiary with Ameri and Partners&rsquo; former stockholders acquiring a
majority of the outstanding shares of Ameri common stock. The 2015 Merger was consummated under Delaware law pursuant to an Agreement
of Merger and Plan of Reorganization, dated as of May 26, 2015 (the &ldquo;2015 Merger Agreement&rdquo;), and in connection with
the 2015 Merger, Ameri changed its name to AMERI Holdings, Inc. Ameri does business under the brand name &ldquo;Ameri100&rdquo;.
Ameri Holdings, Inc., along with its eleven operating subsidiaries, provides SAP cloud, digital and enterprise services to clients
worldwide. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 30, 2020, we completed
the Offer and changed our name to &ldquo;Enveric Biosciences, Inc.&rdquo; Our principal corporate office is located at Enveric
Biosciences, Inc., 4851 Tamiami Trail N, Suite 200, telephone (239) 302-1707. Our internet address is <U>https://www.enveric.com/</U>,
and the information included in, or linked to our website is not part of this prospectus. We have included our website address
in this prospectus solely as a textual reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: center">&nbsp;</P>

<DIV STYLE="padding-right: 10pt; padding-left: 10pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="g_004"></A>THE
OFFERING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 38%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuer
    </FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
    Biosciences, Inc. </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock offered by us </FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,610,679
    shares </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-funded
warrants offered by us</FONT></P></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>We
are also offering the Pre-funded Warrants to purchase up to an aggregate of 610,679 shares of common stock to purchasers whose
purchase of shares of common stock in this offering would otherwise result in the purchaser, together with its affiliates, beneficially
owning more than 4.99% of our outstanding common stock immediately following the consummation of this offering, in lieu of shares
of common stock that would otherwise result in any such purchaser&rsquo;s beneficial ownership exceeding 4.99% (or, at the election
of the purchaser, 9.99%) of our outstanding common stock. Each Pre-funded Warrant will be exercisable for one share of our common
stock. The purchase price of each Pre-funded Warrant will equal the price per share at which the shares of common stock are being
sold to the public in this offering, minus $0.01, and the exercise price of each Pre-funded Warrant will be $0.01 per share. The
Pre-funded Warrants will be exercisable immediately and may be exercised at any time until all of the Pre-funded Warrants are
exercised in full. This offering also relates to the shares of common stock issuable upon the exercise of any Pre-funded Warrants
sold in this offering.</P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    of common stock to be outstanding after this offering </FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">13,816,467  <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
    (assuming all of the Pre-funded Warrants issued in this offering are exercised). </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offering
    price per share </FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$4.5018
    per share of common stock and $4.4918 per Pre-funded Warrant.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use
    of proceeds </FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
        intend to use the net proceeds from this offering for working capital purposes. See &ldquo;Use of Proceeds&rdquo; on page
        S-10.</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrent
    private placement of Warrants</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    a concurrent private placement, we are selling to investors in this offering Warrants to purchase up to an additional 1,666,019
    shares of our common stock. Each Warrant will be exercisable for one share of our common stock at an exercise price of $4.9519
    per share, will be exercisable immediately upon issuance and will have a term of five years from the date of issuance. The
    Warrants and the Warrant Shares are being offered pursuant to the exemptions provided in Section 4(a)(2) under the Securities
    Act and Rule 506(b) promulgated thereunder, and they are not being offered pursuant to this prospectus supplement and the
    accompanying prospectus. There is no established public trading market for the Warrants and we do not expect a market to develop.
    In addition, we do not intend to list the Warrants on the Nasdaq Capital Market, any other national securities exchange or
    any other nationally recognized trading system.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    factors </FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
    the &ldquo;Risk Factors&rdquo; section of this prospectus supplement, the Form S-8 and in the other documents
    incorporated by reference in this prospectus supplement for a discussion of factors to consider before deciding to invest
    in our securities. </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq
    Capital Market symbol </FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;ENVB&rdquo;
    </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 8.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The number of shares of our common stock that
will be outstanding immediately after this offering as shown above is based on 11,595,109 shares outstanding as of January
12, 2021. The number of shares outstanding as of January 12, 2021, as used throughout this prospectus supplement,
unless otherwise indicated, excludes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 8.7pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 8.7pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 8.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1,512,907
                                         shares of common stock issuable upon the conversion of outstanding shares of Series
                                         B Convertible Preferred Stock;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">610,657
                                         shares of common stock issuable upon the exercise of Series B Warrants;</P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">806,563
                                         shares of common stock issuable upon the exercise of stock options outstanding at
                                         a weighted average exercise price of $1.37 per share;</P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">547,805
    </FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">shares of common stock issuable upon the exercise of warrants
    outstanding at a weighted average exercise price of $35.33 per share;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">2,695,893
                                         shares of common stock reserved for future issuance under our Long-Term Incentive
                                         Plan; and</P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,666,019
    shares of common stock issuable upon the exercise of the Warrants to be issued to the purchasers in a concurrent private placement
    with this offering at an exercise price of $4.9519 per share.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 44.7pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise indicated, the information in this prospectus supplement is as of January 12, 2021 and assumes (i) the exercise
of all of the Pre-funded Warrants sold in this offering and (ii) no exercise of options, vesting of restricted stock units or
exercise of warrants described above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.7pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="g_005"></A>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Investing
in our securities involves a high degree of risk. In addition to the other information contained in this prospectus supplement
to the accompanying prospectus and in the documents we incorporate by reference, you should carefully consider the risks discussed
below and under the heading &ldquo;Risk Factors&rdquo; in the Form S-4 before making a decision about investing in our securities.
The risks and uncertainties discussed below and in the Form S-4 are not the only ones facing us. Additional risks and uncertainties
not presently known to us, or that we currently see as immaterial, may also harm our business. If any of these risks occur, our
business, financial condition and operating results could be harmed, the trading price of our common stock could decline and you
could lose part or all of your investment.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
you purchase securities in this offering, you will suffer immediate dilution of your investment.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
offering price of our common stock in this offering is substantially higher than the net tangible book value per share of our
common stock. Therefore, if you purchase securities in this offering, you will pay a price per share of our common stock that
substantially exceeds our net tangible book value per share after giving effect to this offering. Based on an offering price of
$4.5018 per share of our common stock, if you purchase securities in this offering, you will experience immediate dilution of
$3.4218 per share&nbsp;, representing the difference between the offering price per share of our common stock and our pro
forma as adjusted net tangible book value per share after giving effect to this offering, assuming exercise of all Pre-funded
Warrants sold in this offering. Furthermore, if any of our outstanding options or warrants are exercised at prices below the offering
price, or if we grant additional options or other awards under our equity incentive plans or issue additional warrants, you may
experience further dilution of your investment. See the section entitled &ldquo;Dilution&rdquo; below for a more detailed illustration
of the dilution you would incur if you participate in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Because
we will have broad discretion and flexibility in how the net proceeds from this offering are used, we may use the net proceeds
in ways in which you disagree.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to use the net proceeds from this offering for working capital purposes. See &ldquo;Use of Proceeds&rdquo; on page S-10.
We have not allocated specific amounts of the net proceeds from this offering for any of the foregoing purposes. Accordingly,
our management will have significant discretion and flexibility in applying the net proceeds of this offering. You will be relying
on the judgment of our management with regard to the use of these net proceeds, and you will not have the opportunity, as part
of your investment decision, to assess whether the net proceeds are being used appropriately. It is possible that the net proceeds
will be invested in a way that does not yield a favorable, or any, return for us. The failure of our management to use such funds
effectively could have a material adverse effect on our business, financial condition, operating results and cash flow.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>You
may experience future dilution as a result of future equity offerings and other issuances of our securities. In addition, this
offering and future equity offerings and other issuances of our common stock or other securities may adversely affect the price
of our common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to raise additional capital, we may in the future offer additional shares of common stock or other securities convertible
into or exchangeable for our common stock prices that may not be the same as the price per share in this offering. We may not
be able to sell shares or other securities in any other offering at a price per share that is equal to or greater than the price
per share paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights
superior to existing stockholders. The price per share at which we sell additional shares of common stock or securities convertible
into shares of common stock in future transactions may be higher or lower than the price per share in this offering. You will
incur dilution upon exercise of any outstanding stock options, warrants or upon the issuance of shares of common stock under our
stock incentive programs. In addition, the sale of shares of common stock in this offering and any future sales of a substantial
number of shares of common stock in the public market, or the perception that such sales may occur, could adversely affect the
price of our common stock. We cannot predict the effect, if any, that market sales of those shares of common stock or the availability
of those shares for sale will have on the market price of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to require additional capital in the future in order to develop our product candidates, which are in early stages of development.
If we do not obtain any such additional financing, it may be difficult to effectively realize our long-term strategic goals and
objectives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75pt; text-align: justify">Our current cash resources will
not be sufficient to fund the development of our product candidates through all of the required clinical trials to receive regulatory
approval and commercialization. If we cannot secure this additional funding when such funds are required, we may fail to develop
our product candidates or be forced to forego certain strategic opportunities.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
additional capital raised through the sale of equity or equity-backed securities may dilute our stockholders&rsquo; ownership
percentages and could also result in a decrease in the market value of our equity securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
terms of any securities issued by us in future capital transactions may be more favorable to new investors, and may include preferences,
superior voting rights and the issuance of warrants or other derivative securities, which may have a further dilutive effect on
the holders of any of our securities then outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we may incur substantial costs in pursuing future capital financing, including investment banking fees, legal fees,
accounting fees, securities law compliance fees, printing and distribution expenses and other costs. We may also be required to
recognize non-cash expenses in connection with certain securities we issue, such as convertible notes and warrants, which may
adversely impact our financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>There
is no established public trading market for the Pre-funded Warrants being offered in this offering.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no established public trading market for the Pre-funded Warrants being offered in this offering, and we do not expect a market
to develop. In addition, we do not intend to apply to list the Pre-funded Warrants on any national securities exchange or other
nationally recognized trading system, including Nasdaq Capital Market. Without an active market, the liquidity of the Pre-funded
Warrants will be limited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Except
as otherwise provided in the Pre-funded Warrants, holders of Pre-funded Warrants purchased in this offering will have no rights
as stockholders of common stock until such holders exercise their Pre-funded Warrants and acquire our common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise provided in the Pre-funded Warrants, until holders of Pre-funded Warrants acquire our common stock upon exercise
of the Pre-funded Warrants, holders of Pre-funded Warrants will have no rights with respect to our common stock underlying such
Pre-funded Warrants. Upon exercise of the Pre-funded Warrants, the holders will be entitled to exercise the rights of a stockholder
of our common stock only as to matters for which the record date occurs after the exercise date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="g_006"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate that the net proceeds from the sale of the securities offered under this prospectus supplement, after deducting
estimated offering expenses payable by us, will be approximately $9 million, excluding the proceeds we may receive form the
exercise of the Pre-funded Warrants issued in this offering and Warrants issued in the concurrent private
placement.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to use the net proceeds from the sale of the shares for working capital purposes. The amounts and timing of our use of
proceeds will vary depending on a number of factors, including the amount of cash generated or used by our operations. As a result,
we will retain broad discretion in the allocation of the net proceeds of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75pt; text-align: center"><A NAME="g_007"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DIVIDEND
POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and any
future earnings, if any, to fund the development and expansion of our business and we do not anticipate paying any cash dividends
in the foreseeable future. Any future determination to pay dividends will be made at the discretion of our board of directors.
Investors should not purchase our common stock with the expectation of receiving cash dividends.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75pt; text-align: center"><A NAME="g_008"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DILUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If you invest in our common stock (and/or
pre-funded warrants) in this offering, your ownership interest will be diluted by the difference between the price per share you
pay and the net tangible book value per share of our common stock immediately after this offering.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our net tangible book value as of September
30, 2020, was approximately $(3,589,158), or $(0.63) per share of our common stock, based upon 5,737,001 shares of our common
stock outstanding as of that date. Net tangible book value per share is determined by dividing our total tangible assets, less
total liabilities, by the number of shares of our common stock outstanding as of September 30, 2020. Dilution in net tangible
book value per share represents the difference between the amount per share paid by purchasers of shares of common stock in this
offering and the net tangible book value per share of our common stock immediately after this offering.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our pro forma net tangible book value as
of September 30, 2020, was approximately $5,884,217, or $0.51 per share, after giving effect to (i) the Spin-Off; (ii) the Offer,
whereby the Company issued 7,621,052 shares of common stock and 262,500 shares of Series B Preferred Stock that are convertible
into 262,500 shares of common stock in exchange for 35,635,807 common shares of Jay Pharma (excluding the issuance of an aggregate
of 3,262,907 shares of Series B Preferred Stock that are convertible into 3,262,907 shares of common stock issued in transactions
related to the Offer); (iii) the conversion of indebtedness and the securities issued upon closing of a private placement made
in connection with the Offer; (iv) the acquisition of intellectual property by Jay Pharma in exchange for 10,360,007 common shares
of Jay Pharma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">After giving effect to the sale of 1,610,679
shares of our common stock in this offering at the price of $4.5018 per share and Pre-funded Warrants to purchase up to 610,679
shares of common stock, and after deducting the estimated offering expenses payable by us and assuming exercise of all Pre-funded
Warrants in this offering, our pro forma as adjusted net tangible book value as of September 30, 2020, would have been approximately
$14,884,217, or $1.08 per share. This represents an immediate increase in net tangible book value of $0.57 per share to existing
stockholders and immediate dilution in net tangible book value of $3.4218 per share to new investors. The following table illustrates
this dilution on a per share basis:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%">Offering price per share</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">4.5018</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Historical net tangible book value per share as of September 30, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.63</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Pro forma increase in net tangible book value per share</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1.14</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Pro forma net tangible book value per share as of September 30, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.51</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Increase in net tangible book value per share attributable to this offering</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.57</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Pro forma as adjusted net tangible book value per share as of September 30, 2020, after giving effect to this offering</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1.08</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Dilution in net tangible book value per share to new investors</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.4218</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The foregoing discussion and table assumes
(i) the exercise of all Pre-funded Warrants sold in this offering and (ii) no exercise of the Warrants to be issued in a concurrent
private placement. To the extent that outstanding options or warrants are exercised, you may experience further dilution. In addition,
we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient
funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or
convertible debt securities, the issuance of these securities could result in further dilution to our stockholders.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The above discussion and table as of September
30, 2020 are based upon, after giving effect to the adjustments set forth above, and excludes, as of that date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,512,907 shares
    of common stock issuable upon the conversion of outstanding shares of Series B Convertible Preferred Stock;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">610,657 shares
    of common stock issuable upon the exercise of Series B Warrants;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">806,563 shares
    of common stock issuable upon the exercise of stock options outstanding at a weighted average exercise price of $1.37 per
    share;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">547,805 shares
    of common stock issuable upon the exercise of warrants outstanding at a weighted average exercise price of $35.33 per share;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,695,893 shares
    of common stock reserved for future issuance under our Long-Term Incentive Plan; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,666,019 shares
    of common stock issuable upon the exercise of the Warrants to be issued to the purchasers in a concurrent private placement
    with this offering at an exercise price of $4.9519 per share.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="g_009"></A>Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 15.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>You
should read the following discussion and analysis of our financial condition and operating results together with our financial
statements and related notes incorporated by reference into this prospectus. This discussion and analysis and other parts of this
prospectus contain forward-looking statements based upon current beliefs, plans and expectations that involve risks, uncertainties
and assumptions. See &ldquo;Special Note Regarding Forward-Looking Statements.&rdquo; Our actual results may differ materially
from those anticipated in these forward-looking statements as a result of various factors, including those set forth under &ldquo;Risk
Factors&rdquo; or in other parts of this prospectus or the documents incorporated by reference into this prospectus. Unless stated
otherwise, references in this discussion and analysis to &ldquo;us,&rdquo; &ldquo;we,&rdquo; &ldquo;our,&rdquo; &ldquo;Enveric&rdquo;
or our &ldquo;Company&rdquo; and similar terms refer to Enveric Biosciences, Inc., a Delaware corporation. References to &ldquo;Ameri&rdquo;
refer to our Company prior to the Offer.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Merger</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 30, 2020, pursuant to the previously announced the Tender Agreement, we completed the Offer to purchase all of the outstanding
common shares of Jay Pharma for the number of shares of common stock of the Company, par value $0.01 per share or Series B Preferred
Stock, as applicable, equal to the exchange ratio of 0.8849, and Jay Pharma became a wholly-owned subsidiary of the Company, on
the terms and conditions set forth in the Tender Agreement. Following the effective time of the Offer, the Company changed the
name of the Company from AMERI Holdings, Inc. to Enveric Biosciences, Inc. and effected a 1-for-4 reverse stock split of the issued
and outstanding common stock. Immediately following completion of the Offer and the transactions contemplated in the Tender Agreement,
but without giving effect to the issuance of the Series B Warrants to purchase 1,791,923 shares of common stock, (i) the former
Jay Pharma equity holders (including certain investors in private placements that closed prior to the completion of the Offer)
own approximately 82.3% of the Company; (ii) former Ameri equity holders own approximately 14.5% of the Company; and (iii) a financial
advisor to Jay Pharma and Ameri owns approximately 3.2% of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 30, 2020, pursuant to the Ameri Share Purchase Agreement, Ameri consummated the Spin-Off and all of the issued and outstanding
shares of Series A Preferred Stock were redeemed for an equal number of shares of Private Ameri Preferred Stock. Ameri contributed,
transferred and conveyed to Private Ameri all of the issued and outstanding equity interests of the existing subsidiaries of Ameri,
constituting the entire business and operations of Ameri and its subsidiaries, and Private Ameri assumed the liabilities of such
subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Offer has been accounted for as a &ldquo;reverse merger&rdquo; under the acquisition method of accounting for business combinations
with Jay Pharma treated as the accounting acquirer of Ameri. As such, the historical financial statements of Jay Pharma have become
the historical financial statements of Ameri, or the combined company, and are incorporated into this report labeled &ldquo;Jay
Pharma, Inc.&rdquo; <B>No historical common stock, stock options and additional paid-in capital, including share and per share
amounts presented in this Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations has been
adjusted to reflect the equity structure of the resulting issuer as a result of the Offer and the related transactions, including
the effect of the Exchange Ratio and the common stock.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reverse
Stock Split</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">December 30, 2020, we affected a 1-for-4 reverse stock
split. We made proportionate adjustments to the per share exercise price and/or the number of shares issuable upon the exercise
or vesting of all stock options, restricted stock units (if any) and warrants outstanding as of the effective times of the reverse
stock split in accordance with the terms of each security based on the split ratio. Also, we reduced the number of shares reserved
for issuance under our equity compensation plans proportionately based on the split ratios. Except for adjustments that resulted
from the rounding up of fractional shares to the next whole share, the reverse stock split affected all stockholders uniformly
and did not change any stockholder&rsquo;s percentage ownership interest in our company. All share and related option and warrant
information presented in this prospectus supplement (other than this Management&rsquo;s Discussion and Analysis of Financial
Condition and Results of Operations as noted below) have been retroactively adjusted to reflect the reduced number of shares
outstanding and the increase in share price which resulted from these actions; however, common stock share and per share amounts
in the accompanying prospectus and certain of the documents incorporated by reference herein have not been adjusted to give effect
to the reverse stock split. <B>No share or related option or warrant information presented in this Management&rsquo;s Discussion
and Analysis of Financial Condition and Results of Operations has been adjusted to reflect the reduced number of shares outstanding,
the increase in share price which resulted from these actions or otherwise give effect to the reverse stock split.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Business
Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a biopharmaceutical and wellness company that is seeking to develop innovative, evidence-based cannabinoid product candidates
and combination therapies to address unmet needs in cancer care. We seek to improve the lives of persons suffering from cancer,
initially by developing over-the-counter palliative cancer care and wellness cosmetic product candidates for persons suffering
from the side effects of cancer and cancer treatment. We are also aiming to advance a pipeline of novel cannabinoid combination
therapies for hard-to-treat cancers, including glioblastoma multiforme (GBM). We are to bring leading oncology clinicians and
researchers, academic and industry partners, proprietary products and data, and eventually a robust pipeline of product candidates,
to improve quality of life and provide symptomatic relief to cancer patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Key
Components of Our Results of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Operating
Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operating expenses include financial statement preparation services, tax compliance, various consulting and director fees, legal
services, auditing fees, and stock-based compensation. These expenses have increased in connection with the Company&rsquo;s product
development and the Company&rsquo;s management expects these expenses to continue to increase as the Company continues to develop
its potential product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results
of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Comparison
of the Nine Months Ended September 30, 2020 and 2019</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The following table
sets forth information comparing the components of net loss for the nine months ended September 30, 2020 and the comparable period
in 2019:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid">Nine Months Ended September
    30,</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold">Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 64%; font-size: 10pt; text-align: left">Operating expenses</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 14%; border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">2,094,044</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 14%; border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">1,895,355</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Loss from operations</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(2,094,044</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(1,895,355</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Other expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-align: left">Extinguishment of notes payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">32,257</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-align: left">Interest expense</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">388,143</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">47,858</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; font-size: 10pt; text-align: left">Total other expense</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">312,642</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">80,115</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Net Loss</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(2,482,187</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(1,975,470</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Other comprehensive income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-align: left">Foreign exchange (loss) gain</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(30,077</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(5,204</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Comprehensive loss</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(2,512,264</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(1,970,266</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Net loss per share - basic and diluted</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.10</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.08</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold">Weighted average shares outstanding, basic and diluted</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">25,916,419</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">25,060,193</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Operating Expenses</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our operating expenses
increased to $2,094,044, for the nine months ended September 30, 2020 from $1,895,355 for the nine months ended September 30,
2019, for an increase of $198,689, or 10.5%. This change was primarily driven by an increase in legal fees of $677,646 and consulting
fees of $259,773, offset by a decrease in stock-based compensation of $535,587, marketing costs of $180,354, and research and
development of $156,911.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Interest Expense </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our interest expense
for the nine months ended September 30, 2020 was $388,143 compared to $47,858 for the nine months ended September 30, 2019. This
increase was primarily driven by the Company&rsquo;s promissory notes that were entered into during 2019, with an aggregate principal
amount of $2,077,925, which it did not have during the nine months ended September 30, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Foreign Exchange</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our foreign exchange
(loss) gain was $(30,077) for the nine months ended September 30, 2020 as compared to $5,204 for the nine months ended September
30, 2019. The increase in foreign exchange loss is primarily due to the U.S. Dollar weakening against the Canadian Dollar and
the conversion of the Canadian Dollars into United States Dollars for payment of United States Dollar denominated expenses.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Comparison
of the Year Ended December 30, 2019 and 2018</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information comparing the components of net loss for the year ended December 31, 2019 and the comparable
year in 2018:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Year Ended December 31,</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 68%; text-align: left; padding-bottom: 1.5pt">Operating expenses</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 12%; border-bottom: Black 1.5pt solid; text-align: right">2,296,534</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 12%; border-bottom: Black 1.5pt solid; text-align: right">1,919,577</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Operating loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,296,534</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,919,577</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Other expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Extinguishment of notes payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,316</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Accretion and interest</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">81,823</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total other expense</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">114,139</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net Loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2,410,673</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,919,577</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Other comprehensive loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Foreign exchange loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(6,667</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,877</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Comprehensive loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2,417,340</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,923,454</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Loss per share - basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.10</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.08</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Weighted average shares outstanding, basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">25,085,980</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">22,607,147</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Operating
Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operating expenses increased to $2,296,534, for the year ended December 31, 2019 from $1,919,577 for the year ended December 31,
2018, for an increase of $376,957, or 19.6%. This change was primarily driven by an increase in payroll and consulting fees of
approximately $409,000, an increase in stock-based compensation of $117,896, offset by a decrease in patent costs of $652,624.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Extinguishment
of Notes Payable</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
loss on extinguishment of notes payable increased to $32,316, for year ended December 31, 2019 was due to the Company entering
into an amendment to the July 2019 Note on September 20, 2019, which extended the maturity date for such note to until the earlier
of (a) the completion of a bridge financing of greater than or equal to $1.5 million, or (b) November 7, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Accretion
and Interest</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
accretion and interest expense for the year ended December 31, 2019 was $81,823 compared to $0 for the year ended December 31,
2018. This increase was primarily driven by the Company&rsquo;s promissory notes that were entered into during 2019, with an aggregate
principal amount of $740,336, which it did not have during the year ended December 31, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Foreign
Exchange</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
foreign exchange loss was $6,667 for the year ended December 31, 2019 as compared to $3,877 for the year ended December 31, 2018,
for an increase of $2,790. The increase in foreign exchange loss is primarily due to the U.S. Dollar strengthening against the
Canadian Dollar and the conversion of the Canadian Dollars into United States Dollars for payment of United States Dollar denominated
expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity
and Capital Resources</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has incurred continuing losses
from its operations and as of September 30, 2020, the Company had an accumulated deficit of $7,377,068 and working capital
deficiency of $3,589,158.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
inception, the Company has met its liquidity requirements principally through the issuance of notes payable and the sale of its
shares of common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has no present revenue and the Company&rsquo;s ability to continue its operations and to pay its obligations when they
become due is contingent upon the Company obtaining additional financing. Management&rsquo;s plans include seeking to procure
additional funds through debt and equity financings and to continue to develop its technologies under its sublicense agreement
(see Note 4 to the financial statements for the year ended December 31, 2019). Without further funding, the sublicense agreement
will have no commercial value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no assurances that the Company will be able to raise capital on terms acceptable to the Company or at all, or that cash flows
generated from its operations will be sufficient to meet its current operating costs and required debt service. Our ability to
obtain additional capital may depend on prevailing economic conditions and financial, business and other factors beyond our control.
The COVID-19 pandemic has caused an unstable economic environment globally. Disruptions in the global financial markets may adversely
impact the availability and cost of credit, as well as our ability to raise money in the capital markets. Current economic conditions
have been and continue to be volatile. Continued instability in these market conditions may limit our ability to access the capital
necessary to fund and grow our business. If the Company is unable to obtain sufficient amounts of additional capital, it may be
required to reduce the scope of its planned product development, which could harm its financial condition and operating results,
or it may not be able to continue to fund its ongoing operations. These conditions raise substantial doubt about the Company&rsquo;s
ability to continue as a going concern to sustain operations for at least one year from the issuance date of these financial statements.
The accompanying financial statements do not include any adjustments that might result from the outcome of these uncertainties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 12, 2018, the Company entered into a sublicense agreement (which formalized the sublicense terms as agreed to in 2017)
with TO Pharmaceuticals USA LLC (&ldquo;TOP&rdquo;). This agreement requires TOP to sublicense to the Company certain patent and
other intellectual property rights for the exclusive use by the Company in cancer-related applications. These rights include intellectual
property consisting of patents regarding cannabis pharmaceutical products. The sublicense does not provide for any ability for
the Company to sublicense these rights to third parties without the express written consent of TOP. In exchange for the sublicensed
patents, the Company issued to TOP 7,280,000 shares of its common stock along with an obligation to issue to TOP 40% of shares
of common stock issued to investors during future financings up to $1.25 million. In connection with the additional rounds of
financing, the Company issued to TOP an additional 2,157,162 common shares during the year ended December 31, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2018, the Company closed a private placement for 1,900,000 shares of common stock for CAD $0.25 (USD $0.20) per common
share for gross proceeds of CAD $475,000 (USD $376,203).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2018, the Company closed a private placement for 992,244 shares of common stock and warrants to purchase 992,244 shares
of common stock for CAD $0.87 (USD $0.68) per common share for gross proceeds of CAD $579,044 (USD $446,462). The warrants are
exercisable immediately and expire on October 31, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 7, 2019, the Company received
$60,000 in exchange for a promissory note to David Stefansky with an aggregate face value of $66,000, including an original issue
discount of $6,000 (the &ldquo;February 2019 Note&rdquo;). The February 2019 Note bears no stated interest rate and was due on
May 8, 2019. Given that the Company was unable to pay its obligation under the note, the February 2019 Note is currently in default.
The Company amortized the full $6,000 original issue discount in the statement of operations and comprehensive loss through December
31, 2019. On December 30, 2020, the February 2019 Note was converted into the Company&rsquo;s common stock in connection with
the consummation of the Offer.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 1, 2019, the Company entered into a consulting agreement with David Stefansky. In connection with the consulting agreement,
on March 5, 2019, the Company issued a note payable to its executive director for $150,000 (the &ldquo;March 2019 Note&rdquo;).
The note bears no interest and is due and payable on March 4, 2020. The agreement expired on February 1, 2020. On December
30, 2020, the March 2019 Note was converted into common stock of the Company in connection with the consummation of the Offer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
April 2019, the Company received $300,000 in exchange for convertible notes in an aggregate principal amount of $300,000 (the
&ldquo;April 2019 Convertible Notes&rdquo;) and warrants to purchase 250,000 shares of the Company&rsquo;s common stock. The April
2019 Convertible Notes payable bear interest at a rate of 6% per annum and are due and payable one year from the date of issuance.
The notes are convertible at any time by the holder into shares of the Company&rsquo;s common stock at a price of $0.60 per share.
If the Company sells or issues common stock at a price lower than the conversion price of the notes, the conversion price shall
be reduced to that price. The notes payable will automatically convert into shares of the Company&rsquo;s common stock in the
event that the Company consummates a reverse merger with a publicly traded company. </FONT><FONT STYLE="font-size: 10pt">On
December 30, 2020, the April 2019 Convertible Notes converted into shares of the Company&rsquo;s common stock in connection with
the consummation of the Offer.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 8, 2019, the Company entered into a note agreement (the &ldquo;July 2019 Note&rdquo;) with a limited liability company (the
&ldquo;Lender&rdquo;). The July 2019 Note&rsquo;s face value was $157,714.29 and the original issue discount was $19,714.29 for
total gross proceeds of $138,000. The maturity date of the July 2019 Note was September 8, 2019. As there remained an outstanding
balance on the July 2019 Note at its maturity date, the Company was in default. Per the July 2019 Note, the Lender may at its
option (a) declare the entire principal amount of the July 2019 Note, together with all accrued interest thereon and all other
amounts payable hereunder, immediately due and payable; and/or (b) exercise any or all of its rights, powers or remedies under
applicable law. In connection with the July 2019 Note, the Company issued warrants to purchase 131,429 shares of the Company&rsquo;s
common stock at an exercise price of $0.71 per share. The warrants are exercisable for a period of five years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 20, 2019, the Company entered into the first amendment to the July 2019 Note. The amendment extended the maturity date
for the July 2019 Note until the earlier of (a) the completion of a bridge financing of greater than or equal to $1,500,000, or
(b) November 7, 2019. In consideration for the amendment, the Company agreed to pay an extension fee of $18,926, which was added
to the outstanding balance of the July 2019 Note. In addition to the extension fee, the Company agreed to grant warrants to purchase
50,000 shares of the Company&rsquo;s common stock, subject to approval by the Company&rsquo;s board of directors. If the Company&rsquo;s
board of directors did not approve the grant of the warrants prior to October 18, 2019, the Company agreed to pay an additional
extension fee of $15,000 in lieu of issuing the warrants. On October 19, 2019, given that the Company did not grant the warrants,
$15,000 was added to the face value of the July 2019 Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 21, 2019, the Company entered into the second amendment to the July 2019 Note (the &ldquo;November 21 Amendment&rdquo;).
The November 21 Amendment extended the maturity date for the Note until the earlier of (a) the completion of a bridge financing
of greater than or equal to $1,500,000, or (b) December 9, 2019. In consideration for the November 21 Amendment, the Company agreed
to grant 25,440 shares of the Company&rsquo;s common stock, subject to approval by the Company&rsquo;s board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 9, 2019, the Company entered into the third amendment to the July 2019 Note (the &ldquo;December 9 Amendment&rdquo;).
The December 9 Amendment extended the maturity date for the Note until the earlier of (a) the completion of a bridge financing
of greater than or equal to $1,500,000, or (b) January 7, 2020. In consideration for the December 9 Amendment, the Company agreed
to pay the previously outstanding extension fees of $33,926 on or before March 1, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify">On January 8, 2020 the
Company entered into the fourth amendment to the July 2019 Note (the &ldquo;January 8 Amendment&rdquo;). The January 8 Amendment
extended the maturity date for the July 2019 Note until the (a) the completion of a bridge financing of greater than or equal
to $1,500,000, or (b) April 1, 2020. In consideration for the January 8 Amendment, the Company agreed to grant 50,000 shares of
the Company&rsquo;s common stock, subject to approval by the Company&rsquo;s board of directors. On December 30, 2020, the
July 2019 Notes were repaid in connection with the consummation of the Offer<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 10, 2020, the Company issued a convertible note payable for $1,500,000 to Alpha in exchange for cash. </FONT><FONT STYLE="font-size: 10pt">On
December 30, 2020, the convertible note issued to Alpha converted into shares of the Company&rsquo;s common stock and shares of
Series B Preferred Stock in connection with the consummation of the Offer.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has no present revenue and the Company&rsquo;s ability to continue its operations and to pay its obligations when they
become due is contingent upon the Company obtaining additional financing. Management&rsquo;s plans include seeking to procure
additional funds through debt and equity financings and to continue to develop the Company&rsquo;s technologies under the series
of assignment and assumption agreements with Tikkun.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the Company&rsquo;s current development plans, the Company believes that existing cash, the cash it received from the Alpha
Investment and this offering will be sufficient to satisfy its anticipated cash requirements for the next twelve months, but that
the Company will be required to seek additional equity or debt financing in the next twelve months. In the event that additional
financing is required from outside sources, the Company may not be able to raise monies on terms acceptable to it or at all. If
we are unable to obtain sufficient amounts of additional capital, it may be required to reduce the scope of its planned product
development, which could harm its financial condition and operating results, or it may not be able to continue to fund its ongoing
operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cash
Flows</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
inception, we have primarily used its available cash to fund its product development expenditures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Cash
Flows for the Nine Months Ended September 30, 2020 and 2019</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; color: #231F20">The
following table sets forth a summary of cash flows for the periods presented:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid">Nine Months Ended September 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; font-size: 10pt; text-align: left">Net cash used in operating activities</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">(1,638,798</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">(632,590</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Net cash provided by financing activities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,932,196</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">520,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.5pt">Effect of foreign exchange rate on cash</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">3,786</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">7,802</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Net (decrease) increase in cash</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">297,184</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(104,788</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #231F20"><I>Operating Activities</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; color: #231F20">Net
cash used in operating activities was $1,638,798 during the nine months ended September 30, 2020, which consisted primarily of
a net loss of $2,482,187, offset by amortization of note discount of $285,858, increases in prepaid expenses and other current
assets for $1,841, and increases in accounts payable and accrued liabilities of $522,162.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; color: #231F20">Net
cash used in operating activities was $632,590 during the nine months ended September 30, 2019, which consisted primarily of a
net loss of $1,975,470, offset by amortization of note discount of $38,985, increases in stock based compensation of $624,052,
decreases in prepaid expenses and other current assets of $67,591, an extinguishment of notes payable of $32,257, and increases
in accounts payable and accrued liabilities of $571,121.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #231F20"><I>Financing Activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; color: #231F20">Net
cash provided by financing activities was $1,932,196 during the nine months ended September 30, 2020, which consisted primarily
of $50,000 in proceeds from convertible notes payable, $1,812,410 in proceeds from note payable, $227,500 in proceeds from the
sale of common stock, and a decrease of $157,714 in repayment of note payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; color: #231F20">Net
cash provided by financing activities was $520,000 during the nine months ended September 30, 2019, which consisted of $300,000
in proceeds from convertible notes payable, $198,000 in proceeds from note payable, and $22,000 in advances from related parties.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Cash
Flows for the year ended December 31, 2019 and 2018</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth a summary of cash flows for the periods presented:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Year Ended December 31,</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; text-align: left">Net cash used in operating activities</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(647,860</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(711,165</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net cash provided by financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">560,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">822,665</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Effect of foreign exchange rate on cash</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">17,903</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,744</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net (decrease) increase in cash</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(69,957</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">107,756</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Operating
Activities</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was $647,860 during the year ended December 31, 2019, which consisted primarily of a net loss
of $2,410,673, offset by extinguishment of note payable of $32,316, amortization of note discount of 68,453, stock-based compensation
of $624,052, increases in prepaid expenses and other current assets for $104,340, and increases in accounts payable and accrued
liabilities of $933,652.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was $711,165 during the year ended December 31, 2018, which consisted primarily of a net loss
of $1,919,577, offset by stock-based compensation of $53,294, stock issued for sublicense in the amount of $644,006, decreases
in prepaid expenses and other current assets of $5,938, and increases in accounts payable and accrued liabilities of $151,668.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Financing
Activities</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was $560,000 during the year ended December 31, 2019, which consisted primarily of $238,000
in proceeds from notes payable, $300,000 in proceeds from convertible notes payable, and $22,000 in advances from related party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was $822,665 during the year ended December 31, 2018, which consisted of $822,665 in proceeds
from common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Off-Balance
Sheet Arrangements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company did not have any off-balance sheet financing arrangements or liabilities, guarantee contracts, retained or contingent
interests in transferred assets, or any obligation arising out of a material variable interest in an unconsolidated entity. Additionally, the Company
does not have interests in, nor relationships with, any special purpose entities.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Critical
Accounting Policies and Significant Judgments and Estimates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s accounting policies are fundamental to understanding its management&rsquo;s discussion and analysis. The Company&rsquo;s
significant accounting policies are presented in Note 3 to its financial statements for the year ended December 31, 2019, which
are incorporated by reference into this prospectus supplement. The Company&rsquo;s financial statements have been prepared in
accordance with accounting principles generally accepted in the United States of America (&ldquo;U.S. GAAP&rdquo;) for interim
financial information. Accordingly, they do not include all of the information and notes required by U.S. GAAP. However, in the
opinion of the management of the Company, all adjustments necessary for a fair presentation of the financial position and operating
results have been included in the Company&rsquo;s condensed financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
Accounting Standards</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
does not believe that any recently issued, but not yet effective accounting standards, when adopted, will have a material effect
on the accompanying financial statements, other than those disclosed below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 25, 2016, the Financial Accounting Standards Board (&ldquo;FASB&rdquo;) issued Accounting Standards Update (&ldquo;ASU&rdquo;)
2016-02, Leases (Topic 842). This update will require organizations that lease assets to recognize on the balance sheet the assets
and liabilities for the rights and obligations created by those leases. The new guidance will also require additional disclosures
about the amount, timing and uncertainty of cash flows arising from leases. The provisions of this update are effective for annual
and interim periods beginning after December 15, 2019. The Company has determined that the adoption of this ASU will not have
a material impact on the Company&rsquo;s financial position and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2018, the FASB issued ASU 2018-10, &ldquo;Codification Improvements to Topic, 842, Leases&rdquo;, which clarifies how to
apply certain aspects of the new leases standard, ASC 842. The amendments address the rate implicit in the lease, impairment of
the net investment in the lease, lessee reassessment of lease classification, lessor reassessment of lease term and purchase options,
variable payments that depend on an index or rate and certain transition adjustments, among other things.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2018, the FASB issued ASU 2018-11, &ldquo;Leases (Topic 842): Targeted Improvements&rdquo;, which provides entities with
relief from the costs of implementing certain aspects of the new leasing standard, ASC 842. Specifically, under the amendments
in ASU 2018-11, (1) entities may elect not to recast the comparative periods presented when transitioning to ASC 842 and (2) lessors
may elect not to separate lease and nonlease components when certain conditions are met.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Concentration
of Credit Risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution,
which at times, may exceed the Federal depository insurance coverage of $250,000. The Company has not experienced losses on these
accounts and management believes the Company is not exposed to significant risks on such accounts. As of September 30, 2020, the
Company did not have greater than $250,000 at any US or Canadian financial institutions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Foreign
Currency Risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
inception through September 30, 2020, the reporting currency of the Company is the United States dollar while the functional currency
of the Company is the Canadian dollar. As a result, the Company is subject to exposure from changes in the exchange rates of the
Canadian dollar and the U.S. dollar.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not entered into any financial derivative instruments that expose it to material market risk, including any instruments
designed to hedge the impact of foreign currency exposures. The Company may, however, hedge such exposure to foreign currency
exchange fluctuations in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="g_010"></A>DESCRIPTION
OF SECURITIES WE ARE OFFERING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are offering shares of our common stock and pre-funded warrants to purchase shares of our common stock. For each pre-funded warrant
we sell, the number of shares of common stock we are offering will be decreased on a one-for-one basis. We are also registering
the shares of common stock issuable from time to time upon exercise of the pre-funded warrants offered hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Authorized
Capital Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75pt; text-align: justify">We have authorized 120,000,000
shares of capital stock, of which 100,000,000 are shares of common stock, $0.01 par value per share and 20,000,000 are shares
of preferred stock, $0.01 par value per share. On January 12, 2021, there were 11,595,109 shares of common stock
and 1,775,407 shares of our Series B Preferred Stock issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of common stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. Holders of
common stock has no cumulative voting rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
holders of common stock have no preemptive or conversion rights or other subscription rights. Upon liquidation, dissolution or
winding- up, holders of common stock are entitled to share in all assets remaining after payment of all liabilities and the liquidation
preferences of any of the outstanding shares of preferred stock. Subject to preferences that may be applicable to any outstanding
shares of preferred stock, holders of common stock are entitled to receive dividends, if any, as may be declared from time to
time by the board of directors out of our assets which are legally available. Such dividends, if any, are payable in cash, in
property or in shares of capital stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of a majority of the shares of the capital stock, represented at the special meeting or by proxy, are necessary to constitute
a quorum for the transaction of business at any meeting. If a quorum is present, an action by stockholders entitled to vote on
a matter is approved if the number of votes cast in favor of the action exceeds the number of votes cast in opposition to the
action, with the exception of the election of directors, which requires a plurality of the votes cast.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on Nasdaq under the symbol &ldquo;ENVB.&rdquo; The transfer agent and registrar for our common stock Corporate
Stock Transfer, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pre-Funded
Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Duration
and Exercise Price</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pre-funded warrants offered hereby will have an exercise price of $0.01 per share. The pre-funded warrants will be immediately
exercisable and may be exercised at any time after their original issuance until such pre-funded warrants are exercised in full.
The exercise price and number of shares of common stock issuable upon exercise are subject to appropriate adjustment in the event
of share dividends, share splits, reorganizations or similar events affecting our shares of common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Exercisability</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pre-funded warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed
exercise notice accompanied by payment in full for the number of shares of our common stock purchased upon such exercise (except
in the case of a cashless exercise as discussed below). A holder (together with its affiliates) may not exercise any portion of
the pre-funded warrant to the extent that the holder would own more than 4.99% (or at the election of a holder prior to the date
of issuance, 9.99%) of the outstanding common stock immediately after exercise; provided, however, that upon notice to us, the
holder may increase or decrease the such beneficial ownership limitation, provided that in no event shall the beneficial ownership
limitation exceed 9.99% and any increase in the beneficial ownership limitation will not be effective until 61 days following
notice of such increase from the holder to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cashless
Exercise</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the time a holder exercises its pre-funded warrants, in lieu of making the cash payment otherwise contemplated to be made to us
upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either
in whole or in part) the net number of shares of common stock determined according to a formula set forth in the pre-funded warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Fundamental
Transactions</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a fundamental transaction, as described in the pre-funded warrants and generally including any reorganization, recapitalization
or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties
or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding common
stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding common stock,
the holders of the pre-funded warrants will be entitled to receive upon exercise of the pre-funded warrants the kind and amount
of securities, cash or other property that the holders would have received had they exercised the pre-funded warrants immediately
prior to such fundamental transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Transferability</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to applicable laws, a pre-funded warrant may be transferred at the option of the holder upon surrender of the pre-funded warrant
to us together with the appropriate instruments of transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Fractional
Shares</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
fractional shares of common stock will be issued upon the exercise of the pre-funded warrants. Rather, the number of shares of
common stock to be issued will, at our election, either be rounded up to the nearest whole number or we will pay a cash adjustment
in respect of such final fraction in an amount equal to such fraction multiplied by the exercise price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Trading
Market</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no established trading market for the pre-funded warrants, and we do not expect a market to develop. We do not intend to apply
for a listing for the pre-funded warrants on any securities exchange or other nationally recognized trading system. Without an
active trading market, the liquidity of the pre-funded warrants will be limited. The common stock issuable upon exercise of the
pre-funded warrants is currently listed on the Nasdaq Capital Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Rights
as a Stockholder</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise provided in the pre-funded warrants or by virtue of the holders&rsquo; ownership of shares of common stock, the holders
of pre-funded warrants do not have the rights or privileges of holders of our shares of common stock, including any voting rights,
until such pre-funded warrant holders exercise their warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="g_011"></A>PRIVATE
PLACEMENT OF WARRANTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a concurrent private placement, we are selling to each of the investors in this offering Warrants to purchase one share of common
stock for every one share of common stock purchased in the offering by each such investor. The aggregate number of Warrant Shares
is 1,666,019. The Warrants will be exercisable at an exercise price of $4.9519 per share. The exercise price and number of Warrant
Shares will be subject to adjustment in the event of any stock dividend and split, reverse stock split, recapitalization, reorganization
or similar transaction, as described in the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Warrant shall be exercisable immediately upon issuance and have a term of exercise equal to five years from the date of issuance.
A holder of Warrants will have the right to exercise the Warrants on a &ldquo;cashless&rdquo; basis if there is no effective registration
statement registering the resale of the Warrant Shares after the closing date of this offering. Subject to limited exceptions,
a holder of Warrants will not have the right to exercise any portion of its Warrants if the holder, together with its affiliates,
would beneficially own in excess of 4.99% (or 9.99% at the election of the holder prior to the date of issuance) of the number
of shares of our common stock outstanding immediately after giving effect to such exercise, provided that the holder may increase
or decrease the beneficial ownership limitation up to 9.99%. Any increase in the beneficial ownership limitation shall not be
effective until 61 days following notice of such change to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also entered into a registration rights agreement, dated January 12, 2021, with each of the investors, pursuant to which,
among other things, we agreed to prepare and file with the Securities and Exchange Commission a registration statement to register
for resale of all of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise provided in the Warrants or by virtue of such holder&rsquo;s ownership of shares of our common stock, the holders
of the Warrants do not have the rights or privileges of holders of our common stock, including any voting rights, until they exercise
their Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrants and the Warrant Shares are being offered pursuant to the exemptions provided in Section 4(a)(2) under the Securities
Act and Rule 506(b) promulgated thereunder, and they are not being offered pursuant to this prospectus supplement and the accompanying
prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no established public trading market for the Warrants and we do not expect a market to develop. In addition, we do not intend
to list the Warrants on the Nasdaq Capital Market, any other national securities exchange or any other nationally recognized trading
system. All purchasers are required to be &ldquo;accredited investors&rdquo; as such term is defined in Rule 501(a) under the
Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="g_012"></A>PLAN
OF DISTRIBUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are offering 1,610,679 shares of our common stock at an offering
price of $4.5018 per share and Pre-funded Warrants to purchase up to 610,679 shares of our common stock at an offering price of
$4.4918 in a registered direct offering to investors that are not affiliated with us. We established the price following negotiations
with prospective investors and with reference to the prevailing market price of our common stock, recent trends in such price and
other factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of our common stock offered hereby are being sold directly to purchasers and not through a placement agent, underwriter
or securities broker or dealer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; margin: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">We estimate
the total expenses of this offering paid or payable by us will be approximately $1 million, which includes an advisory
fee of $900,000 paid to Palladium Capital Advisors, LLC for its services as an advisor in connection with this offering. After
deducting our estimated expenses in connection with this offering, we expect the net proceeds from this offering will be approximately
$9 million.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We entered into a securities purchase agreement
with purchasers covering the sale of the shares and pre-funded warrants offered under this prospectus supplement. A copy
of the form of securities purchase agreement between us and the purchasers is included as Exhibit 10.1 to the Current Report on
Form 8-K filed with the SEC on January 11, 2021, as amended on January 13, 2021. We currently anticipate that closing of
this offering will take place on or about January 14, 2021.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer agent and registrar for our common stock is Corporate Stock Transfer, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
shares of common stock are listed on The Nasdaq Capital Market under the symbol &ldquo;ENVB.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="g_013"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity of the securities offered by this prospectus supplement will be passed upon for us by Haynes and Boone, LLP, New York,
New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="g_014"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of Ameri as of and for the years ended December 31, 2019 and 2018 incorporated by reference into this prospectus
supplement have been audited by RAM Associates, CPA, an independent registered public accounting firm, as stated in their report
appearing herein. Such financial statements are iincorporated by reference in reliance upon the report of such firm given upon
its authority as experts in accounting and auditing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of Jay Pharma as of December 31, 2019 and 2018 and for each of the two years in the period ended December
31, 2019 incorporated by reference into this prospectus supplement have been audited by Marcum LLP, independent registered public
accounting firm, as set forth in their report thereon, which report includes an explanatory paragraph relating to substantial
doubt about the ability of Jay Pharma, Inc. to continue as a going concern as described in Note 1 to the financial statements,
and which report appears herein and elsewhere in this joint proxy statement/ prospectus. Such financial statements are incorporated
by reference in reliance upon the report of such firm given upon its authority as experts in accounting and auditing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="g_015"></A>WHERE
YOU CAN FIND MORE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed with the SEC a registration statement on Form S-3 under the Securities Act with respect to the common stock offered
by this prospectus supplement and the accompanying prospectus. This prospectus supplement, filed as part of the registration statement,
does not contain all the information set forth in the registration statement and its exhibits and schedules, portions of which
have been omitted as permitted by the rules and regulations of the SEC. For further information about us, we refer you to the
registration statement and to its exhibits and schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
file annual, quarterly and current reports and other information with the SEC. The SEC maintains an internet website at <I>www.sec.gov
</I>that contains periodic and current reports, proxy and information statements, and other information regarding registrants
that are filed electronically with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
documents are also available, free of charge, through the Investors section of our website, which is located at <I>https://enveric.com/</I>.
Information contained on our website is not incorporated by reference into this prospectus supplement or the accompanying prospectus
and you should not consider information on our website to be part of this prospectus supplement or the accompanying prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="g_016"></A>INCORPORATION
BY REFERENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC allows us to &ldquo;incorporate by reference&rdquo; information that we file with it. Incorporation by reference allows us
to disclose important information to you by referring you to those other documents. The information incorporated by reference
is an important part of this prospectus supplement and the accompanying prospectus, and information that we file later with the
SEC will automatically update and supersede this information. We filed a registration statement on Form S-3 under the Securities
Act of 1933, as amended, with the SEC with respect to the securities being offered pursuant to this prospectus supplement and
the accompanying prospectus. This prospectus supplement and the accompanying prospectus omit certain information contained in
the registration statement, as permitted by the SEC. You should refer to the registration statement, including the exhibits thereto,
for further information about us and the securities being offered pursuant to this prospectus supplement and the accompanying
prospectus. Statements in this prospectus supplement and the accompanying prospectus regarding the provisions of certain documents
filed with, or incorporated by reference in, the registration statement are not necessarily complete and each statement is qualified
in all respects by that reference. Copies of all or any part of the registration statement, including the documents incorporated
by reference or the exhibits, may be obtained upon payment of the prescribed rates at the offices of the SEC listed above in &ldquo;Where
You Can Find More Information.&rdquo; The documents we are incorporating by reference are:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    Annual Report on <A HREF="https://www.sec.gov/Archives/edgar/data/890821/000114036120006825/form10k.htm" STYLE="-sec-extract: exhibit">Form 10-K</A> for the year ended December 31, 2019, filed with the SEC on March 25, 2020, as amended by our Annual
    Report on <A HREF="https://www.sec.gov/Archives/edgar/data/890821/000149315220015385/form10ka.htm" STYLE="-sec-extract: exhibit">Form 10-K/A</A>, filed with the SEC on August 12, 2020;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    Quarterly Reports on Form 10-Q for the quarters ended <A HREF="https://www.sec.gov/Archives/edgar/data/890821/000156761920010243/form10q.htm" STYLE="-sec-extract: exhibit">March 31, 2020</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/890821/000149315220015855/form10-q.htm" STYLE="-sec-extract: exhibit">June 30, 2020</A> and <A HREF="https://www.sec.gov/Archives/edgar/data/890821/000149315220021409/form10-q.htm" STYLE="-sec-extract: exhibit">September 30, 2020</A>, filed with the
    SEC on May 15, 2020, August 14, 2020 and November 16, 2020, respectively;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    Current Reports on Form 8-K filed with the SEC on <A HREF="https://www.sec.gov/Archives/edgar/data/890821/000114036120000667/form8k.htm" STYLE="-sec-extract: exhibit">January
    13, 2020</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/890821/000114036120004807/form8k.htm" STYLE="-sec-extract: exhibit">March
    4, 2020</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/890821/000114036120010802/form8k.htm" STYLE="-sec-extract: exhibit">May
    6, 2020</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/890821/000149315220010211/form8-k.htm" STYLE="-sec-extract: exhibit">June
    1, 2020</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/890821/000149315220010535/form8-k.htm" STYLE="-sec-extract: exhibit">June
    4, 2020</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/890821/000149315220014442/form8-k.htm" STYLE="-sec-extract: exhibit">August
    3, 2020</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/890821/000149315220015383/form8-k.htm" STYLE="-sec-extract: exhibit">August
    12, 2020</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/890821/000149315220017593/form8-k.htm">September 11, 2020</A>,
    as amended by Form 8-K/A filed with the SEC on <A HREF="https://www.sec.gov/Archives/edgar/data/890821/000149315220017871/form8-ka.htm" STYLE="-sec-extract: exhibit">September
    16, 2020</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/890821/000149315220023638/form8-k.htm" STYLE="-sec-extract: exhibit">December
    15, 2020</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/890821/000149315220023958/form8-k.htm" STYLE="-sec-extract: exhibit">December
    18, 2020</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/890821/000149315220024425/form8-k.htm" STYLE="-sec-extract: exhibit">December
    29, 2020</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/890821/000149315221000336/form8-k.htm" STYLE="-sec-extract: exhibit">January
    6, 2021</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/890821/000149315221000337/form8-k.htm" STYLE="-sec-extract: exhibit">January
    6, 2021</A>, as amended by Form 8-K/A filed with the SEC on <A HREF="https://www.sec.gov/Archives/edgar/data/890821/000149315221000698/form8ka.htm" STYLE="-sec-extract: exhibit">January
    11, 2021</A>, and <A HREF="https://www.sec.gov/Archives/edgar/data/890821/000149315221000824/form8-k.htm" STYLE="-sec-extract: exhibit">January
    12, 2021</A>, as amended by Form 8-K/A filed with the SEC on January 13, 2021 respectively;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    following sections from the Form S-4: &ldquo;Risk Factors,&rdquo; &ldquo;Management of the Resulting Issuer,&rdquo; &ldquo;Information
    About Jay Pharma,&rdquo; &ldquo;Information About Ameri&mdash;Legal Proceedings,&rdquo; &ldquo;Principal Stockholders of Jay
    Pharma and the Resulting Issuer,&rdquo; &ldquo;Principal Stockholders of Ameri and the Resulting Issuer&rdquo;, &ldquo;Related
    Party Transactions&rdquo; and &ldquo;Description of Ameri Capital Stock;&rdquo; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    description of our common stock contained in the &ldquo;Description of Ameri Capital Stock&rdquo; in the <A HREF="https://www.sec.gov/Archives/edgar/data/890821/000149315220009947/forms-4.htm" STYLE="-sec-extract: exhibit">Form S-4</A>.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, all documents (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed in such
forms that are related to such items unless such Form 8-K expressly provides to the contrary) subsequently filed by us pursuant
to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, before the date our offering is terminated
or completed are deemed to be incorporated by reference into, and to be a part of, this prospectus supplement and the accompanying
prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
statement contained in this prospectus supplement and the accompanying prospectus, or any free writing prospectus provided in
connection with this offering or in a document incorporated or deemed to be incorporated by reference into this prospectus supplement
and the accompanying prospectus will be deemed to be modified or superseded for purposes of this prospectus supplement and the
accompanying prospectus to the extent that a statement contained in this prospectus supplement and the accompanying prospectus,
or any free writing prospectus provided in connection with this offering or any other subsequently filed document that is deemed
to be incorporated by reference into this prospectus supplement and the accompanying prospectus modifies or supersedes the statement.
Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this
prospectus supplement and the accompanying prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
written or oral request, we will provide you without charge, a copy of any or all of the documents incorporated by reference,
other than exhibits to those documents unless the exhibits are specifically incorporated by reference in the documents. Please
send requests to Enveric Biosciences, Inc., 4851 Tamiami Trail N, Suite 200, Naples, Florida 34103, Attention: John Van Buiten.
You should rely only on information contained in, or incorporated by reference into, this prospectus supplement and the accompanying
prospectus or any free writing prospectus provided in connection with this offering. We have not authorized anyone to provide
you with information different from that contained in this prospectus supplement and the accompanying prospectus or any free writing
prospectus provided in connection with this offering or incorporated by reference in this prospectus supplement and the accompanying
prospectus. We are not making offers to sell the securities in any jurisdiction in which such an offer or solicitation is not
authorized or to anyone to whom it is unlawful to make such offer or solicitation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>
  <div style="color: #FF4040; font-weight: bold;"></div>
  <div><font style="color: #FF4040;"> </font><br>
  </div>
  <div style="text-align: center; color: #FF4040; font-weight: bold;"></div>
  <DIV STYLE="text-align: center; background-color: #FFFFFF">
    <IMG SRC="form424b5_002.jpg" ALT="" STYLE="height: 47; width: 195"><div style="text-align: center;"></div>
    <div style="text-align: center; color: #000000; font-weight: bold;">AMERI Holdings, Inc.</div>
  </div>
  <div><br>
  </div>
  <div> <br>
  </div>
  <div style="text-align: center; font-weight: bold;">Common Stock</div>
  <div style="text-align: center; font-weight: bold;">Preferred Stock</div>
  <div style="text-align: center; font-weight: bold;">Debt Securities</div>
  <div style="text-align: center; font-weight: bold;">Warrants</div>
  <div style="text-align: center; font-weight: bold;">Units</div>
  <div> <br>
  </div>
  <div style="text-indent: 36pt;">We may offer and sell, from time to time in one or more offerings, any combination of common stock, preferred stock, debt securities, warrants to purchase common stock, preferred stock or debt securities, or any
    combination of the foregoing, either individually or as units comprised of one or more of the other securities, having an aggregate initial offering price not exceeding $25,000,000.</div>
  <div> <br>
  </div>
  <div style="text-indent: 36pt;">This prospectus provides a general description of the securities we may offer.&#160; Each time we sell a particular class or series of securities, we will provide specific terms of the securities offered in a supplement to this
    prospectus.&#160; The prospectus supplement and any related free writing prospectus may also add, update or change information contained in this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with
    these offerings. You should read carefully this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as any documents incorporated by reference herein or therein before you invest in any of our securities.</div>
  <div> <br>
  </div>
  <div style="text-indent: 36pt;">The specific terms of any securities to be offered, and the specific manner in which they may be offered, will be described in one or more supplements to this prospectus. This prospectus may not be used to consummate sales
    of any of these securities unless it is accompanied by a prospectus supplement. Before investing, you should carefully read this prospectus and any related prospectus supplement.</div>
  <div> <br>
  </div>
  <div style="text-indent: 36pt;">Our common stock is presently listed on The Nasdaq Capital Market under the symbol &#8220;AMRH.&#8221;&#160; On August 12, 2019, the last reported sale price of our common stock was $0.3234 per share.&#160; The applicable prospectus supplement
    will contain information, where applicable, as to any other listing on The Nasdaq Capital Market or any securities market or other exchange of the securities, if any, covered by the prospectus supplement.&#160; Prospective purchasers of our securities are
    urged to obtain current information as to the market prices of our securities, where applicable.</div>
  <div> <br>
  </div>
  <div style="text-indent: 36pt;">These securities may be sold directly by us, through dealers or agents designated from time to time, to or through underwriters, dealers, or through a combination of these methods on a continuous or delayed basis.&#160; See &#8220;<font style="font-style: italic;">Plan of Distribution</font>&#8221; in this prospectus. We may also describe the plan of distribution for any particular offering of our securities in a prospectus supplement. If any agents, underwriters or dealers are involved
    in the sale of any securities in respect of which this prospectus is being delivered, we will disclose their names and the nature of our arrangements with them in a prospectus supplement. The price to the public of such securities and the net proceeds
    we expect to receive from any such sale will also be included in a prospectus supplement.</div>
  <div> <br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
    <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">- 3 -</font></div>
    <div style="page-break-after: always;" id="DSPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <div style="text-indent: 36pt;">The aggregate market value of our outstanding common stock held by non-affiliates was approximately $17,887,017 which was calculated based on 45,982,047 shares of outstanding common stock held by non-affiliates as of
    August 9, 2019, and a price per share of $0.389, the closing price of our common stock on June 17, 2019. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities pursuant to this registration statement with a value more
    than one-third of the aggregate market value of our common stock held by non-affiliates in any 12-month period, so long as the aggregate market value of our common stock held by non-affiliates is less than $75.0 million. In the event that subsequent to
    the effective date of this registration statement, the aggregate market value of our outstanding common stock held by non-affiliates equals or exceeds $75.0 million, then the one-third limitation on sales shall not apply to additional sales made
    pursuant to this registration statement. We have sold no securities pursuant to General Instruction I.B.6 of Form S-3 during the 12 calendar months prior to, and including, the date of this registration statement.</div>
  <div> <br>
  </div>
  <div style="text-indent: 36pt; font-weight: bold;">Investing in our securities involves various risks.&#160; See &#8220;<font style="font-style: italic;">Risk Factors</font>&#8221; contained herein for more information on these risks. Additional risks will be described
    in the related prospectus supplements under the heading &#8220;<font style="font-style: italic;">Risk Factors</font>.&#8221; You should review that section of the related prospectus supplements for a discussion of matters that investors in our securities should
    consider.</div>
  <div> <br>
  </div>
  <div style="text-indent: 36pt; font-weight: bold;">Neither the U.S. Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or passed upon the adequacy or accuracy of this prospectus or any
    accompanying prospectus supplement.&#160; Any representation to the contrary is a criminal offense.</div>
  <div> <br>
  </div>
  <div style="text-align: center;">The date of this prospectus is November 19, 2019.</div>
  <div> <br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
    <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">- 4 -</font></div>
    <div style="page-break-after:always;" id="DSPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div style="text-align: center; font-weight: bold;"><a name="TABLEOFCONTENTS"><!--Anchor--></a>TABLE OF CONTENTS</div>
  <div> <br>
  </div>
  <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="z18712f81671148cfb2bcf18c59d12d0e">

      <tr>
        <td style="width: 92%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
        <td style="width: 8%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
          <div style="text-align: center; font-weight: bold;">Page</div>
        </td>
      </tr>
      <tr>
        <td style="width: 92%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="color: rgb(0, 0, 0);"><a href="#ABOUTTHISPROSPECTUS">ABOUT THIS PROSPECTUS</a></div>
        </td>
        <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;">6<br>
        </td>
      </tr>
      <tr>
        <td style="width: 92%; vertical-align: top; background-color: rgb(255, 255, 255);">
          <div style="color: rgb(0, 0, 0);"><a href="#RISKFACTORS">RISK FACTORS</a></div>
        </td>
        <td style="width: 8%; vertical-align: top; background-color: rgb(255, 255, 255); text-align: center;">16<br>
        </td>
      </tr>
      <tr>
        <td style="width: 92%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="color: rgb(0, 0, 0);"><a href="#FORWARD-LOOKINGSTATEMENTS">DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS</a></div>
        </td>
        <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;">17</td>
      </tr>
      <tr>
        <td style="width: 92%; vertical-align: top; background-color: rgb(255, 255, 255);">
          <div style="color: rgb(0, 0, 0);"><a href="#USEOFPROCEEDS">USE OF PROCEEDS</a></div>
        </td>
        <td style="width: 8%; vertical-align: top; background-color: rgb(255, 255, 255); text-align: center;">18</td>
      </tr>
      <tr>
        <td style="width: 92%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="color: rgb(0, 0, 0);"><a href="#DESCRIPTIONOFCAPITALSTOCK">DESCRIPTION OF CAPITAL STOCK</a></div>
        </td>
        <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;">19<br>
        </td>
      </tr>
      <tr>
        <td style="width: 92%; vertical-align: top; background-color: rgb(255, 255, 255);">
          <div style="color: rgb(0, 0, 0);"><a href="#DESCRIPTIONOFDEBTSECURITI">DESCRIPTION OF DEBT SECURITIES</a></div>
        </td>
        <td style="width: 8%; vertical-align: top; background-color: rgb(255, 255, 255); text-align: center;">21</td>
      </tr>
      <tr>
        <td style="width: 92%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="color: rgb(0, 0, 0);"><a href="#OF">DESCRIPTION OF WARRANTS</a></div>
        </td>
        <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;">29</td>
      </tr>
      <tr>
        <td style="width: 92%; vertical-align: top; background-color: rgb(255, 255, 255);">
          <div style="color: rgb(0, 0, 0);"><a href="#DESCRIPTION">DESCRIPTION OF UNITS</a></div>
        </td>
        <td style="width: 8%; vertical-align: top; background-color: rgb(255, 255, 255); text-align: center;">31</td>
      </tr>
      <tr>
        <td style="width: 92%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="color: rgb(0, 0, 0);"><a href="#LEGAL">LEGAL OWNERSHIP OF SECURITIES</a></div>
        </td>
        <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;">32</td>
      </tr>
      <tr>
        <td style="width: 92%; vertical-align: top; background-color: rgb(255, 255, 255);">
          <div style="color: rgb(0, 0, 0);"><a href="#PLAN">PLAN OF DISTRIBUTION</a></div>
        </td>
        <td style="width: 8%; vertical-align: top; background-color: rgb(255, 255, 255); text-align: center;">36</td>
      </tr>
      <tr>
        <td style="width: 92%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="color: rgb(0, 0, 0);"><a href="#LEGALM">LEGAL MATTERS</a></div>
        </td>
        <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;">38</td>
      </tr>
      <tr>
        <td style="width: 92%; vertical-align: top; background-color: rgb(255, 255, 255);">
          <div style="color: rgb(0, 0, 0);"><a href="#EXP">EXPERTS</a></div>
        </td>
        <td style="width: 8%; vertical-align: top; background-color: rgb(255, 255, 255); text-align: center;">38</td>
      </tr>
      <tr>
        <td style="width: 92%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="color: rgb(0, 0, 0);"><a href="#CAN">WHERE YOU CAN FIND MORE INFORMATION</a></div>
        </td>
        <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;">39</td>
      </tr>
      <tr>
        <td style="width: 92%; vertical-align: top; background-color: rgb(255, 255, 255);">
          <div style="color: rgb(0, 0, 0);"><a href="#DOCUMENTS">INCORPORATION OF DOCUMENTS BY REFERENCE</a></div>
        </td>
        <td style="width: 8%; vertical-align: top; background-color: rgb(255, 255, 255); text-align: center;">39</td>
      </tr>

  </table>
  <div> <br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
    <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">- 5 -</font></div>
    <div style="page-break-after:always;" id="DSPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div style="width: 100%;" id="DSPFPageHeader"><a href="#TABLEOFCONTENTS"><font style="font-size: 8pt; font-style: italic;"> Table of Contents</font></a></div>
  </div>
  <div style="text-align: center; font-weight: bold;"><a name="ABOUTTHISPROSPECTUS"><!--Anchor--></a>ABOUT THIS PROSPECTUS</div>
  <div> <br>
  </div>
  <div style="text-indent: 36pt;">This prospectus is part of a registration statement that we filed with the U.S. Securities and Exchange Commission, or SEC, using a &#8220;shelf&#8221; registration process. Under this shelf registration statement, we may sell from
    time to time in one or more offerings of common stock and preferred stock, various series of debt securities and/or warrants to purchase any of such securities, either individually or as units comprised of a combination of one or more of the other
    securities in one or more offerings up to a total dollar amount of $25,000,000. This prospectus provides you with a general description of the securities we may offer. Each time we sell any type or series of securities under this prospectus, we will
    provide a prospectus supplement that will contain more specific information about the terms of that offering.</div>
  <div> <br>
  </div>
  <div style="text-indent: 36pt;">This prospectus does not contain all of the information included in the registration statement. For a more complete understanding of the offering of the securities, you should refer to the registration statement, including
    its exhibits.&#160; We may add, update or change in a prospectus supplement or free writing prospectus any of the information contained in this prospectus or in the documents we have incorporated by reference into this prospectus. We may also authorize one
    or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. This prospectus, together with the applicable prospectus supplement, any related free writing prospectus and the documents
    incorporated by reference into this prospectus and the applicable prospectus supplement, will include all material information relating to the applicable offering. You should carefully read both this prospectus and the applicable prospectus supplement
    and any related free writing prospectus, together with the additional information described under &#8220;<font style="font-style: italic;">Where You Can Find More Information</font>,&#8221; before buying any of the securities being offered.</div>
  <div> <br>
  </div>
  <div style="text-indent: 36pt;">We have not authorized any dealer, agent or other person to give any information or to make any representation other than those contained or incorporated by reference in this prospectus, any accompanying prospectus
    supplement or any related free writing prospectus that we may authorize to be provided to you. You must not rely upon any information or representation not contained or incorporated by reference in this prospectus or an accompanying prospectus
    supplement, or any related free writing prospectus that we may authorize to be provided to you. This prospectus, the accompanying prospectus supplement and any related free writing prospectus, if any, do not constitute an offer to sell or the
    solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus, the accompanying prospectus supplement or any related free writing prospectus, if any, constitute an offer to sell or the
    solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. You should not assume that the information contained in this prospectus, any applicable
    prospectus supplement or any related free writing prospectus is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the date
    of the document incorporated by reference (as our business, financial condition, results of operations and prospects may have changed since that date), even though this prospectus, any applicable prospectus supplement or any related free writing
    prospectus is delivered or securities are sold on a later date.</div>
  <div> <br>
  </div>
  <div style="text-indent: 36pt;">We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference in this prospectus were made solely for the
    benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations,
    warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.</div>
  <div> <br>
  </div>
  <div style="text-indent: 36pt;">This prospectus may not be used to consummate sales of our securities, unless it is accompanied by a prospectus supplement. To the extent there are inconsistencies between any prospectus supplement, this prospectus and any
    documents incorporated by reference, the document with the most recent date will control.</div>
  <div> <br>
  </div>
  <div style="text-indent: 36pt;">As permitted by the rules and regulations of the SEC, the registration statement, of which this prospectus forms a part, includes additional information not contained in this prospectus. You may read the registration
    statement and the other reports we file with the SEC at the SEC&#8217;s web site or at the SEC&#8217;s offices described below under the heading &#8220;<font style="font-style: italic;">Where You Can Find Additional Information.&#8221;</font></div>
  <div> <br>
  </div>
  <div style="font-weight: bold;">Company References</div>
  <div> <br>
  </div>
  <div style="text-indent: 36pt;">In this prospectus &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to AMERI Holdings Inc., and its subsidiaries together, unless the context indicates otherwise.</div>
  <br>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
    <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">- 6 -</font></div>
    <div style="page-break-after:always;" id="DSPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div style="width: 100%;" id="DSPFPageHeader"><a href="#TABLEOFCONTENTS"><font style="font-size: 8pt; font-style: italic;"> Table of Contents</font></a></div>
  </div>
  <div></div>
  <div style="text-align: center; font-weight: bold;">SUMMARY</div>
  <div> <br>
  </div>
  <div style="background-color: #FFFFFF;">
    <div style="color: rgb(0, 0, 0); font-weight: bold;">Our Company</div>
    <div><br>
    </div>
  </div>
  <div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt;">We specialize in delivering SAP cloud, digital and enterprise services to clients worldwide.&#160; SAP is a leader in providing enterprise resource planning (&#8220;ERP&#8221;) software and
    technologies to enterprise customers worldwide. We deliver a wide range of solutions and services across multiple domains and industries. Our services center around SAP and include technology consulting, business intelligence, cloud services,
    application development/integration and maintenance, implementation services, infrastructure services, and independent validation services, all of which can be delivered as a set of managed services or on an on-demand service basis, or a combination of
    both.</div>
  <div><br>
  </div>
  <div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt;">Our SAP focus allows us to provide technological solutions to a broad base of clients. We are headquartered in Suwanee, Georgia, and have offices across the United States, which
    are supported by offices in India and Canada. Our model inverts the conventional global delivery model wherein offshore information technology (&#8220;IT&#8221;) service providers are based abroad and maintain a minimal presence in the United States. With a strong
    SAP focus, our client partnerships anchor around SAP cloud and digital services. In 2018, we signed a strategic partnership agreement with Google Cloud to offer SAP S/4 HANA (a next generation enterprise system) migration services. This partnership
    will allow us to offer our clients a broader spectrum of services.</div>
  <div><br>
  </div>
  <div style="text-align: justify; text-indent: 36pt; color: #000000;">Our primary business objective is to provide our clients with a competitive advantage by enhancing their business capabilities and technologies with our expanding consulting services
    portfolio. Our strategic acquisitions allow us to bring global service delivery, SAP S/4 HANA, SAP Business Intelligence, SAP Success Factors, SAP Hybris and high-end SAP consulting capabilities to a broader geographic market and customer base. We
    continue to leverage our growing geographical footprint and technical expertise to simultaneously expand our service and product offering. Our goal is to identify business synergies that will allow us to bring new services and products from one
    subsidiary to customers at our other subsidiaries. While we generate revenues from the consulting businesses of each of our acquired subsidiaries, we believe that additional revenues will be generated through new business relationships and services
    developed through our business combinations.</div>
  <div style="background-color: #FFFFFF;">
    <div><br>
    </div>
  </div>
  <div style="background-color: #FFFFFF;">
    <div style="color: #000000; font-weight: bold;">Background</div>
    <div><br>
    </div>
  </div>
  <div style="background-color: #FFFFFF;">
    <div style="text-align: justify; text-indent: 36pt; color: #000000;">We were incorporated under the laws of the State of Delaware in February 1994 as Spatializer Audio Laboratories, Inc., which was a shell company immediately prior to our completion of
      a &#8220;reverse merger&#8221; transaction on May 26, 2015, in which we caused Ameri100 Acquisition, Inc., a Delaware corporation and our newly created, wholly owned subsidiary, to be merged with and into Ameri and Partners Inc. (&#8220;Ameri and Partners&#8221;), a
      Delaware corporation (the &#8220;Merger&#8221;). As a result of the Merger, Ameri and Partners became our wholly owned subsidiary with Ameri and Partners&#8217; former stockholders acquiring a majority of the outstanding shares of our common stock. The Merger was
      consummated under Delaware law, pursuant to an Agreement of Merger and Plan of Reorganization, dated as of May 26, 2015 (the &#8220;Merger Agreement&#8221;), and in connection with the Merger we changed our name to AMERI Holdings, Inc. and do business under the
      brand name &#8220;Ameri100&#8221;.</div>
  </div>
  <div style="background-color: #FFFFFF;">
    <div><br>
    </div>
  </div>
  <div style="background-color: #FFFFFF;">
    <div></div>
    <div style="text-align: justify; text-indent: 36pt; color: #000000;">Ameri Holdings, Inc., along with its eleven subsidiaries, Ameri and Partners, Ameri Consulting Service Private Ltd., Ameri100 Georgia Inc. (&#8220;Ameri Georgia&#8221;), Bellsoft India Solutions
      Private Ltd., Ameri100 Canada Inc. (formerly BSI Global IT Solutions Inc.), Linear Logics, Corp., Ameri100 Virtuoso Inc. (&#8220;Virtuoso&#8221;), Ameri100 Arizona LLC (&#8220;Ameri Arizona&#8221;), Bigtech Software Private Limited (&#8220;Bigtech&#8221;), Ameri100 California Inc.
      (&#8220;Ameri California) and Ameritas Technologies India Private Limited, provides SAP cloud, digital and enterprise services to clients worldwide.</div>
    <div style="text-align: justify; text-indent: 36pt; color: #000000;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">- 7 -</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      <div style="width: 100%;" id="DSPFPageHeader"><a href="#TABLEOFCONTENTS"><font style="font-size: 8pt; font-style: italic;"> Table of Contents</font></a></div>
    </div>
    <div style="background-color: #FFFFFF;">
      <div></div>
      <div style="color: rgb(0, 0, 0); font-weight: bold;">Organizational Chart</div>
      <div>&#160;</div>
      <div style="text-align: center;"><IMG SRC="form424b5_001.jpg" ALT="" STYLE="height: 203; width: 624">&#160;</div>
    </div>
  </div>
  <div style="background-color: #FFFFFF;">
    <div>&#160;</div>
    <div style="color: rgb(0, 0, 0); font-weight: bold;">Our Industry</div>
    <div>&#160;</div>
    <div style="text-align: justify; color: #000000; font-style: italic; font-weight: bold;">Background</div>
    <div><br>
    </div>
  </div>
  <div style="background-color: #FFFFFF;">
    <div style="text-align: justify; text-indent: 36pt; color: #000000;">We operate in an intensely competitive IT outsourcing services industry, which competes on quality, service and costs.&#160; Though we are able to differentiate our company on all of these
      axes, our India-based capabilities ensure that labor arbitrage is our fundamental differentiator. Most offshore IT services providers have undertaken a &#8220;forward integration&#8221; to boost their capabilities and presence in their client geographies (large
      offshore presence with a small local presence). Conversely, large U.S. system integrators focus on &#8220;backward integration&#8221; to scale and boost their offshore narrative (offshore being the &#8220;back office&#8221; for the local operations).&#160; Today, the IT services
      industry is marked by the following characteristics:</div>
    <div>&#160;</div>
  </div>
  <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zeb319db25e9c45bbb2314a386a2da169">

      <tr>
        <td style="width: 10%; vertical-align: top; background-color: rgb(174, 170, 170); border-left: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
          <div style="text-align: center; font-weight: bold;">Characteristic</div>
        </td>
        <td style="width: 6%; vertical-align: top; background-color: rgb(174, 170, 170); border-left: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); text-align: center;">&#160;</td>
        <td style="width: 84%; vertical-align: top; background-color: rgb(174, 170, 170); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
          <div style="text-align: center; font-weight: bold;">Description</div>
        </td>
      </tr>
      <tr>
        <td style="width: 10%; vertical-align: middle; border-left: 2px solid rgb(0, 0, 0);">
          <div>Mature Market</div>
        </td>
        <td style="width: 6%; vertical-align: middle; border-left: 2px solid rgb(0, 0, 0);">
          <div style="text-align: center;">&#8226;</div>
        </td>
        <td style="width: 84%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0);">
          <div>Most large global companies have already outsourced what they wanted to outsource.</div>
        </td>
      </tr>
      <tr>
        <td style="width: 10%; vertical-align: middle; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
        <td style="width: 6%; vertical-align: middle; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); text-align: center;">&#160;</td>
        <td style="width: 84%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
      </tr>
      <tr>
        <td style="width: 10%; vertical-align: middle; background-color: rgb(255, 255, 255); border-left: 2px solid rgb(0, 0, 0);">
          <div>Commoditized Business Model</div>
        </td>
        <td style="width: 6%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0);">
          <div style="text-align: center;">&#8226;</div>
        </td>
        <td style="width: 84%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0);">
          <div>North America and Europe continue to be the markets with attractive spending potential. However, increased regulations and visa dependencies prove to be a major drawback of the model.</div>
        </td>
      </tr>
      <tr>
        <td style="width: 10%; vertical-align: middle; background-color: rgb(255, 255, 255); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
        <td style="width: 6%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); text-align: center;">&#160;</td>
        <td style="width: 84%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
      </tr>
      <tr>
        <td style="width: 10%; vertical-align: middle; background-color: rgb(255, 255, 255); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
        <td style="width: 6%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0);">
          <div style="text-align: center;">&#8226;</div>
        </td>
        <td style="width: 84%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0);">
          <div>The benefits realized from the business model are largely based on labor arbitrage, productivity benefits and portfolio restructuring. These contours have changed due to commoditization.</div>
        </td>
      </tr>
      <tr>
        <td style="width: 10%; vertical-align: middle; background-color: rgb(255, 255, 255); border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
        <td style="width: 6%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); text-align: center;">&#160;</td>
        <td style="width: 84%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
      </tr>
      <tr>
        <td style="width: 10%; vertical-align: middle; border-left: 2px solid rgb(0, 0, 0);">
          <div>Insourcing</div>
        </td>
        <td style="width: 6%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); text-align: center;">
          <div>&#8226;</div>
        </td>
        <td style="width: 84%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0);">
          <div>Extremely rapid changes in technology are forcing IT services&#8211;traditionally an outsourcing business&#8212;to adopt an insourcing model.</div>
        </td>
      </tr>
      <tr>
        <td style="width: 10%; vertical-align: middle; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
        <td style="width: 6%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); text-align: center;">&#160;</td>
        <td style="width: 84%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
      </tr>
      <tr>
        <td style="width: 10%; vertical-align: middle; background-color: rgb(255, 255, 255); border-left: 2px solid rgb(0, 0, 0);">
          <div>Rapid Technology Shifts</div>
        </td>
        <td style="width: 6%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); text-align: center;">
          <div>&#8226;</div>
        </td>
        <td style="width: 84%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0);">
          <div>Cloud services, robotic process automation, artificial intelligence and internet of things are increasingly in demand as part of outsourcing engagements. Smart robots increasingly operate in the cloud, and a &#8216;labor-as-a-service&#8217; approach has
            emerged, as clients and providers find that intelligent tools and virtual agents can be easily and flexibly hosted on cloud platforms.</div>
        </td>
      </tr>
      <tr>
        <td style="width: 10%; vertical-align: middle; background-color: rgb(255, 255, 255); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
        <td style="width: 6%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); text-align: center;">&#160;</td>
        <td style="width: 84%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
      </tr>
      <tr>
        <td style="width: 10%; vertical-align: middle; background-color: rgb(255, 255, 255); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
        <td style="width: 6%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); text-align: center;">
          <div>&#8226;</div>
        </td>
        <td style="width: 84%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0);">
          <div>Social media, cloud computing, mobility and big data will continue to be mainstays for any IT ecosystem.</div>
        </td>
      </tr>
      <tr>
        <td style="width: 10%; vertical-align: middle; background-color: rgb(255, 255, 255); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
        <td style="width: 6%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); text-align: center;">&#160;</td>
        <td style="width: 84%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
      </tr>
      <tr>
        <td style="width: 10%; vertical-align: middle; background-color: rgb(255, 255, 255); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
        <td style="width: 6%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); text-align: center;">
          <div>&#8226;</div>
        </td>
        <td style="width: 84%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0);">
          <div>The convergence of cloud computing, virtualization (applications and infrastructure) and utility computing is around the corner. The ability of a vendor to offer an integrated basket of services on a SaaS model, will be a key differentiator.</div>
        </td>
      </tr>
      <tr>
        <td style="width: 10%; vertical-align: middle; background-color: rgb(255, 255, 255); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
        <td style="width: 6%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); text-align: center;">&#160;</td>
        <td style="width: 84%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
      </tr>
      <tr>
        <td style="width: 10%; vertical-align: middle; background-color: rgb(255, 255, 255); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
        <td style="width: 6%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); text-align: center;">
          <div>&#8226;</div>
        </td>
        <td style="width: 84%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0);">
          <div>Enterprises are becoming more digital. There is a strong convergence of human and machine intelligence thanks to drivers like advanced sensors and machine learning. Operations and technology are converging.</div>
        </td>
      </tr>
      <tr>
        <td style="width: 10%; vertical-align: middle; background-color: rgb(255, 255, 255); border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
        <td style="width: 6%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); text-align: center;">&#160;</td>
        <td style="width: 84%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
      </tr>
      <tr>
        <td style="width: 10%; vertical-align: middle; background-color: rgb(255, 255, 255); border-left: 2px solid rgb(0, 0, 0);">
          <div>Contracts &amp; Decision Making</div>
        </td>
        <td style="width: 6%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); text-align: center;">
          <div>&#8226;</div>
        </td>
        <td style="width: 84%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0);">
          <div>Large multi-year contracts will be renegotiated and broken down into shorter duration contracts and will involve multiple vendors rather than sole sourcing.</div>
        </td>
      </tr>
      <tr>
        <td style="width: 10%; vertical-align: middle; background-color: rgb(255, 255, 255); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
        <td style="width: 6%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); text-align: center;">&#160;</td>
        <td style="width: 84%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
      </tr>
      <tr>
        <td style="width: 10%; vertical-align: middle; background-color: rgb(255, 255, 255); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
        <td style="width: 6%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0);">
          <div style="text-align: center;">
            <div>
              <div>&#8226;</div>
            </div>
          </div>
        </td>
        <td style="width: 84%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0);">
          <div>The ability to demonstrate value through Proof of Concepts (POCs) and willingness to offer outcome based pricing are becoming critical considerations for decision making, Requests for Proposal (RFP)-driven decisions are increasingly rare.</div>
        </td>
      </tr>
      <tr>
        <td style="width: 10%; vertical-align: middle; background-color: rgb(255, 255, 255); border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
        <td style="width: 6%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
        <td style="width: 84%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
      </tr>

  </table>
  <div style="background-color: #FFFFFF;">
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">- 8 -</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      <div style="width: 100%;" id="DSPFPageHeader"><a href="#TABLEOFCONTENTS"><font style="font-size: 8pt; font-style: italic;"> Table of Contents</font></a></div>
    </div>
    <div style="background-color: #FFFFFF;">
      <div style="color: #000000; font-style: italic; font-weight: bold;">The SAP Industry</div>
      <div>&#160;</div>
      <div style="background-color: #FFFFFF;">
        <div style="text-align: justify; text-indent: 36pt; color: #000000;">SAP as an ERP and Cloud product has become an industry by itself. The core SAP enterprise offering has been reinforced with cloud-based products that make the entire SAP ecosystem
          extremely attractive from our perspective due to the following attributes:</div>
        <div>&#160;</div>
        <div>
          <div>
            <div>
              <table cellspacing="0" cellpadding="0" id="z3f40a7bc907843d6b41f4e1325a51029" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                  <tr>
                    <td style="width: 36pt;">&#160;</td>
                    <td style="width: 18pt; vertical-align: top;">
                      <div>&#8226;</div>
                    </td>
                    <td style="vertical-align: top;">
                      <div>The alignment of SAP to enterprises is extremely strong.&#160; Given the reliance of enterprises on applications, clients tend to make long-term bets on SAP as an enterprise solution.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
          <div style="background-color: #FFFFFF;">
            <div><br>
            </div>
            <div>
              <div>
                <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zbd070d23e7f946308f95e846f9359bf6" class="DSPFListTable">

                    <tr style="vertical-align: top;">
                      <td style="width: 36pt;">&#160;</td>
                      <td style="vertical-align: top; width: 18pt;">
                        <div style="text-align: left;">
                          <div>&#8226;</div>
                        </div>
                      </td>
                      <td style="vertical-align: top;">
                        <div style="text-align: left;">According to the September 2014 &#8220;HfS Blueprint Report&#8221; from by HfS Research Ltd., the SAP market is a multi-billion-dollar market that is very fragmented (there are over 5,000 consulting firms), with
                          the three largest service providers capturing an increasing share of the market.</div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="background-color: #FFFFFF;">
                <div><br>
                </div>
              </div>
              <div>
                <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z2b39a669222a46b7aa4d24fff117550f" class="DSPFListTable">

                    <tr style="vertical-align: top;">
                      <td style="width: 36pt;">&#160;</td>
                      <td style="vertical-align: top; width: 18pt;">
                        <div style="text-align: left;">
                          <div>&#8226;</div>
                        </div>
                      </td>
                      <td style="vertical-align: top;">
                        <div style="text-align: left;">A significant number of SAP customers must move to S/4 HANA by 2025.</div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="background-color: #FFFFFF;">
                <div><br>
                </div>
                <div style="background-color: #FFFFFF;">
                  <div style="color: #000000; font-weight: bold;">Our Approach</div>
                  <div>&#160;</div>
                  <div style="text-indent: 36pt;">Our solutions deliver significant business efficiency outcomes through turnkey projects, consulting and offshore services. We believe that our strategic service portfolio, deep industry experience and
                    strong global talent pool offer a compelling proposition to clients. In 2017 we acquired ATCG Technology Solutions, Inc., which has become our wholly-owned subsidiary Ameri California.&#160; In 2016, we acquired three companies: <font style="background-color: rgb(255, 255, 255);">Virtuoso, L.L.C. </font>and DC&amp;M Partners, L.L.C.in the U.S. (now Virtuoso and Ameri Arizona, respectively) and Bigtech in India. These strategic acquisitions have brought offshore
                    delivery, SAP S/4 HANA, SAP SuccessFactors, SAP Hybris and high-end SAP consulting capabilities to our service portfolio. </div>
                  <div>&#160;</div>
                  <div style="color: #000000; font-weight: bold;">Our Portfolio of Service Offerings</div>
                  <div>&#160;</div>
                  <div style="text-align: justify; text-indent: 36pt; color: #000000;">
                    <div>Our portfolio of service offerings expanded significantly since 2016 with our acquisitions of Ameri Georgia, Ameri Arizona, Ameri California, Virtuoso and Bigtech.</div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
  </div>
  <div style="background-color: #FFFFFF;">
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; color: #000000;">Our current portfolio of services is divided into three categories:</div>
    <div style="background-color: #FFFFFF;">&#160;
      <div style="text-align: justify; color: #000000; font-style: italic; font-weight: bold;">Cloud Services</div>
      <div style="background-color: #FFFFFF;">&#160;
        <div style="text-align: justify; text-indent: 36pt; color: #000000;">An increasing trend in the IT services market is the adoption of cloud services. Historically, clients have resorted to on-premise software solutions, which required capital
          investments in infrastructure and data centers. Cloud services enable clients to build and host their applications at much lower costs.&#160; Our services offerings leverage the low cost and flexibility of cloud computing.</div>
        <div>&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">- 9 -</font></div>
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          <div style="width: 100%;" id="DSPFPageHeader"><a href="#TABLEOFCONTENTS"><font style="font-size: 8pt; font-style: italic;"> Table of Contents</font></a></div>
        </div>
        <div style="text-align: justify; text-indent: 36pt; color: #000000;">We have expertise in deploying SAP&#8217;s public, private and hybrid cloud services, as well as SAP S/4 HANA, SAP SuccessFactors and SAP Hybris cloud migration services. Our teams are
          experienced in the rapid delivery of cloud services. We perform SAP application and cloud support and SAP cloud development. Additionally, we provide cloud automation solutions that focus on business objectives and organizational growth.</div>
        <div style="background-color: #FFFFFF;">&#160;
          <div style="text-align: justify; color: #000000; font-style: italic; font-weight: bold;">Digital Services</div>
          <div style="background-color: #FFFFFF;">&#160;
            <div style="text-align: justify; text-indent: 36pt; color: #000000;">We have developed several cutting-edge mobile solutions, including Simple Advance Planning and Optimization (&#8220;APO&#8221;) and SAP IBP/S&amp;OP Mobile Analytics App. The Simple APO
              mobile application (app) provides sales professionals with real-time collaboration capabilities and customer data, on their mobile devices. It increases the efficiency of the sales process and the accuracy of customer needs forecasting. The
              SAP IBP mobile app enables the real-time management and analysis of sales and operations planning (S&amp;OP) related data from mobile devices. SAP is an implementation partner for this app. SAP has recognized the app&#8217;s value to the ecosystem,
              as S&amp;OP apps are complex and difficult to design.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt; color: #000000;">We are also active in robotic process automation (&#8220;RPA&#8221;), which leverages the capability of artificially intelligent software agents for business process automation.&#160; We have
              expertise in automating disparate and redundant data entry tasks by configuring software robots that seamlessly integrate with existing software systems. We also provide RPA solutions for reporting and analysis and deliver insights into
              business functions by translating large data into structured reports. Lastly, we have a working partnership with Blue Prism, a leading RPA solutions provider, which makes it possible for us to automate up to one-third of all standard
              back-office operations.</div>
            <div style="background-color: #FFFFFF;">&#160;
              <div style="text-align: justify; color: #000000; font-style: italic; font-weight: bold;">Enterprise Services</div>
              <div style="background-color: #FFFFFF;">&#160;
                <div style="text-align: justify; text-indent: 36pt; color: #000000;">We design, implement and manage Business Intelligence (&#8220;BI&#8221;) and analytics solutions. BI helps our clients navigate the market better by identifying new trends and by
                  targeting top-selling products. We also enable clients to use BI for generating instant financial reports and analytics of customer, product and cost information over time.&#160; In addition, we provide solutions for metadata repository,
                  master data management and data quality. Finally, we determine BI demands across various platforms.</div>
                <div>&#160;</div>
                <div style="text-align: justify; text-indent: 36pt; color: #000000;">Other key enterprise services that we offer include consulting services for global and regional SAP implementations, SAP/IT solution advisory and architectural services,
                  project management services, IT/ERP strategy and vendor selection services.&#160; Often clients have relied on us to deliver services in non-SAP packages, as well.</div>
                <div style="background-color: #FFFFFF;">&#160;
                  <div style="color: #000000; font-weight: bold;">Strategy</div>
                  <div>&#160;</div>
                  <div style="background-color: #FFFFFF;">
                    <div style="text-align: justify; text-indent: 36pt; color: #000000;">The integration of each of our acquisitions into our business enterprise requires establishing our company&#8217;s standard operating procedures at each acquired entity,
                      seamlessly transitioning each acquired entity&#8217;s branding to the &#8220;Ameri100&#8221; brand and assessing any necessity to transition account management. The integration process also requires us to evaluate any product-line expansions made
                      possible by the acquired entity and how to bring new product lines to the broader customer base of the entire Company. With the integration of each acquisition, we face challenges of maintaining cross-company visibility and
                      cooperation, creating a cohesive corporate culture, handling unexpected customer reactions and changes and aligning the interests of the acquired entity&#8217;s leadership with the interests of the Company.</div>
                    <div style="background-color: #FFFFFF;">&#160;
                      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
                        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">- 10 -</font></div>
                        <div style="page-break-after: always;" id="DSPFPageBreak">
                          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                        <div style="width: 100%;" id="DSPFPageHeader"><a href="#TABLEOFCONTENTS"><font style="font-size: 8pt; font-style: italic;"> Table of Contents</font></a></div>
                      </div>
                      <div style="text-align: justify; color: #000000; font-weight: bold;">Sales and Marketing</div>
                      <div style="background-color: #FFFFFF;">&#160;
                        <div style="text-align: justify; text-indent: 36pt; color: #000000;">We combine traditional sales with our strength in industries and technology. Our sales function is composed of direct sales and inside sales professionals. Both
                          work closely with our solutions directors to identify potential opportunities within each account. We currently have over 100+ active clients. Using a consultative selling methodology (working with clients to prescribe a solution
                          that suits their need in terms of efficiency, cost and timelines), target prospects are identified and a pursuit plan is developed for each key account. We utilize a blended sales model that combines consultative selling with
                          traditional sales methods. Once the customer has engaged us, the sales, solutions and marketing teams monitor and manage the relationship with the help of customer relationship management software.</div>
                        <div>&#160;</div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
  </div>
  <div style="background-color: #FFFFFF;">
    <div></div>
    <div style="text-align: justify; text-indent: 36pt; color: #000000;">Our marketing strategy is to build a strong, sustainable brand image for our company, position us in the SAP arena and facilitate business opportunities. We use a variety of marketing
      programs across traditional and social channels to target our prospective and current customers, including webinars, targeted email campaigns, co-sponsoring customer events with SAP to create customer and prospect awareness, search engine marketing
      and advertising to drive traffic to our web properties, and website development to engage and educate prospects and generate interest through white papers, case studies and marketing collateral.</div>
    <div style="background-color: #FFFFFF;">&#160;
      <div style="text-align: justify; color: #000000; font-weight: bold;">Revenues and Customers</div>
      <div>&#160;</div>
      <div style="background-color: #FFFFFF;">
        <div style="text-align: justify; text-indent: 36pt; color: #000000;">We generate revenue primarily through consulting services performed in the fulfillment of written service contracts. The service contracts we enter into generally fall into two
          categories: (1) time-and-materials contracts and (2) fixed-price contracts.</div>
        <div>&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; color: #000000;">When a customer enters into a time-and-materials or fixed-price, (or a periodic retainer-based) contract, we recognize revenue in accordance with an evaluation of the deliverables
          in each contract. If the deliverables represent separate units of accounting, we then measure and allocate the consideration from the arrangement to the separate units, based on vendor-specific objective evidence of the value for each
          deliverable.</div>
        <div>&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; color: #000000;">The revenue under time-and-materials contracts is recognized as services are rendered and performed at contractually agreed upon rates. Revenue pursuant to fixed-price contracts
          is recognized under the proportional performance method of accounting. We routinely evaluate whether revenue and profitability should be recognized in the current period. We estimate the proportional performance on our fixed-price contracts on a
          monthly basis utilizing hours incurred to date as a percentage of total estimated hours to complete the project.</div>
        <div>&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; color: #000000;">For the twelve months ended December 31, 2018 and December 31, 2017, sales to five major customers accounted for approximately 39% and 43% of our total revenue, respectively.</div>
        <div>&#160;</div>
        <div style="color: #000000; font-weight: bold;">Technology Research and Development</div>
        <div style="background-color: #FFFFFF;">&#160;
          <div style="text-align: justify; text-indent: 36pt; color: #000000;">We regard our services and solutions and related software products as proprietary. We rely primarily on a combination of copyright, trademark and trade secret laws of general
            applicability, employee confidentiality and invention assignment agreements, distribution and software protection agreements and other intellectual property protection methods to safeguard our technology and software products. We have not
            applied for patents on any of our technology. We also rely upon our efforts to design and produce new applications and upon improvements to existing software products to maintain a competitive position in the marketplace.</div>
          <div style="background-color: #FFFFFF;">&#160;
            <div style="text-align: justify; text-indent: 36pt; color: #000000;">We did not make any material expenditures on research or development activities for the twelve months ended December 31, 2018 and December 31, 2017.</div>
            <div>&#160;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
              <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">- 11 -</font></div>
              <div style="page-break-after: always;" id="DSPFPageBreak">
                <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
              <div style="width: 100%;" id="DSPFPageHeader"><a href="#TABLEOFCONTENTS"><font style="font-size: 8pt; font-style: italic;"> Table of Contents</font></a></div>
            </div>
            <div style="text-align: justify; color: #000000; font-weight: bold;">Strategic Alliances</div>
            <div style="background-color: #FFFFFF;">&#160;
              <div style="text-align: justify; text-indent: 36pt; color: #000000;">Through our Lean Enterprise Architecture Partnership (&#8220;LEAP&#8221;) methodology, we have strategic alliances with technology specialists who perform services on an as-needed basis
                for clients. We partner with niche specialty firms globally to obtain specialized resources to meet client needs. Our business partners include executive recruiters, staffing firms and niche technology companies. The terms of each strategic
                alliance arrangement depend on the nature of the particular partnership. Such alliance arrangements typically set forth deliverables, scope of the services to be delivered, costs of services and terms and conditions of payment (generally 45
                to 90 days for payment to be made). Each alliance arrangement also typically includes terms for indemnification of our company, non-solicitation of each partner&#8217;s employees by the other partner and dispute resolution by arbitration.</div>
              <div style="background-color: #FFFFFF;">&#160;
                <div style="text-align: justify; text-indent: 36pt; color: #000000;">Alliances and partnerships broaden our offerings and make us a one-stop solution for clients. Our team constantly produces services that complement our portfolio and build
                  strategic partnerships. Our partner companies range from digital marketing strategy consulting firms to large infrastructure players.</div>
                <div>&#160;</div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
  </div>
  <div style="background-color: #FFFFFF;">
    <div style="text-align: justify; text-indent: 36pt; color: #000000;">On any given project we evaluate a client&#8217;s needs and make our best effort to meet them with our full-time specialists. However, in certain circumstances, we may need to go outside
      the Company, and in this case we approach our strategic partners to tap into their pools of technology specialists. Project teams are usually composed of a mix of our full time employees and outside technology specialists. Occasionally, a project
      team may consist of a Company manager and a few outside technology specialists. While final accountability for any of our projects rests with the Company, the outside technology specialists are incentivized to successfully complete a project with
      project completion payments that are in addition to hourly billing rates we pay the outside technology specialists.</div>
    <div>&#160;</div>
    <div style="text-align: justify; color: #000000; font-weight: bold;">Competition</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; color: #000000;">The large number of competitors and the speed of technology change make IT services and outsourcing a challenging business. Competitors in this market include systems integration
      firms, contract programming companies, application software companies, traditional large consulting firms, professional services groups of computer equipment companies and facilities management and outsourcing companies. Examples of our competitors
      in the IT services industry include Accenture, Cartesian Inc., Cognizant, Hexaware Technologies Limited, Infosys Technologies Limited, Mindtree Limited, RCM Technologies Inc., Tata Consultancy Services Limited, Virtusa, Inc. and Wipro Limited.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; color: #000000;">We believe that the principal factors for success in the IT services and outsourcing market include performance and reliability; quality of technical support, training and services;
      responsiveness to customer needs; reputation and experience; financial stability and strong corporate governance; and competitive pricing.</div>
    <div style="background-color: #FFFFFF;">
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000;">Some of our competitors have significantly greater financial, technical and marketing resources and/or greater name recognition, but we believe we are well positioned to capitalize
        on the following competitive strengths to achieve future growth:</div>
      <div>&#160;</div>
      <div>
        <div>
          <div>
            <table cellspacing="0" cellpadding="0" id="z46fb6053f3e446378140d1f1b8479598" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 36pt;">&#160;</td>
                  <td style="width: 18pt; vertical-align: top;">
                    <div>
                      <div>&#8226;</div>
                    </div>
                  </td>
                  <td style="width: auto; vertical-align: top;">
                    <div>well-developed recruiting, training and retention model;</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
        <div style="background-color: #FFFFFF;"><br>
        </div>
        <div>
          <div>
            <table cellspacing="0" cellpadding="0" id="z44766b5222554319be036d7abfd5b806" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 36pt;">&#160;</td>
                  <td style="width: 18pt; vertical-align: top;">
                    <div>&#8226;</div>
                  </td>
                  <td style="width: auto; vertical-align: top;">
                    <div>successful service delivery model;</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
        <div style="background-color: #FFFFFF;">
          <div><br>
          </div>
        </div>
        <div>
          <div>
            <table cellspacing="0" cellpadding="0" id="z2268d2ad2bda4fe9a4f12e23f20449b8" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 36pt;">&#160;</td>
                  <td style="width: 18pt; vertical-align: top;">
                    <div>&#8226;</div>
                  </td>
                  <td style="width: auto; vertical-align: top;">
                    <div>broad referral base;</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
        <div style="background-color: #FFFFFF;">
          <div><br>
          </div>
        </div>
        <div>
          <div>
            <table cellspacing="0" cellpadding="0" id="z8e00ecf6289147aa96ca85c5ef203505" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 36pt;">&#160;</td>
                  <td style="width: 18pt; vertical-align: top;">
                    <div>&#8226;</div>
                  </td>
                  <td style="width: auto; vertical-align: top;">
                    <div>continual investment in process improvement and knowledge capture;</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
        <div style="background-color: #FFFFFF;">
          <div><br>
          </div>
        </div>
        <div>
          <div>
            <table cellspacing="0" cellpadding="0" id="z0c72c1151f024f19bd9014ef57275b95" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 36pt;">&#160;</td>
                  <td style="width: 18pt; vertical-align: top;">
                    <div>&#8226;</div>
                  </td>
                  <td style="width: auto; vertical-align: top;">
                    <div>investment in research and development;</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
        <div style="background-color: #FFFFFF;">
          <div><br>
          </div>
        </div>
        <div>
          <div>
            <table cellspacing="0" cellpadding="0" id="zf682a5c14a27430da13e84829c3dea7c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 36pt;">&#160;</td>
                  <td style="width: 18pt; vertical-align: top;">
                    <div>&#8226;</div>
                  </td>
                  <td style="width: auto; vertical-align: top;">
                    <div>strong corporate governance; and</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
        <div style="background-color: #FFFFFF;">
          <div><br>
          </div>
        </div>
        <div>
          <div>
            <table cellspacing="0" cellpadding="0" id="zca9e1135d5244af1bcb3b5a245d47e72" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 36pt;">&#160;</td>
                  <td style="width: 18pt; vertical-align: top;">
                    <div>&#8226;</div>
                  </td>
                  <td style="width: auto; vertical-align: top;">
                    <div>custom strategic partnerships to provide breadth and depth of services.</div>
                  </td>
                </tr>

            </table>
            <div> <br>
            </div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
              <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">- 12 -</font></div>
              <div style="page-break-after: always;" id="DSPFPageBreak">
                <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
              <div style="width: 100%;" id="DSPFPageHeader"><a href="#TABLEOFCONTENTS"><font style="font-size: 8pt; font-style: italic;"> Table of Contents</font></a></div>
            </div>
          </div>
        </div>
      </div>
    </div>
  </div>
  <div style="font-weight: bold;">The Securities We May Offer</div>
  <div> <br>
  </div>
  <div style="text-indent: 36pt;">We may offer shares of our common stock and preferred stock, various series of debt securities and warrants to purchase any of such securities, either individually or in units, from time to time under this prospectus,
    together with any applicable prospectus supplement and related free writing prospectus, at prices and on terms to be determined by market conditions at the time of offering. If we issue any debt securities at a discount from their original stated
    principal amount, then, for purposes of calculating the total dollar amount of all securities issued under this prospectus, we will treat the initial offering price of the debt securities as the total original principal amount of the debt securities.
    Each time we offer securities under this prospectus, we will provide offerees with a prospectus supplement that will describe the specific amounts, prices and other important terms of the securities being offered, including, to the extent applicable:</div>
  <div> <br>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z7196d83e382447b19c7e5e633385060a" class="DSPFListTable">

        <tr style="vertical-align: top;">
          <td style="width: 36pt;">&#160;</td>
          <td style="vertical-align: top; width: 18pt;">
            <div style="text-align: left;">&#8226;</div>
          </td>
          <td style="vertical-align: top; width: auto;">
            <div>designation or classification;</div>
          </td>
        </tr>

    </table>
  </div>
  <div> <br>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zbd7f62b836e14ceea99c418ff3cf9b7f" class="DSPFListTable">

        <tr style="vertical-align: top;">
          <td style="width: 36pt;">&#160;</td>
          <td style="vertical-align: top; width: 18pt;">
            <div style="text-align: left;">&#8226;</div>
          </td>
          <td style="vertical-align: top; width: auto;">
            <div>aggregate principal amount or aggregate offering price;</div>
          </td>
        </tr>

    </table>
  </div>
  <div> <br>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z1dda73269bdc45408d8d35415f772a06" class="DSPFListTable">

        <tr style="vertical-align: top;">
          <td style="width: 36pt;">&#160;</td>
          <td style="vertical-align: top; width: 18pt;">
            <div style="text-align: left;">&#8226;</div>
          </td>
          <td style="vertical-align: top; width: auto;">
            <div>maturity, if applicable;</div>
          </td>
        </tr>

    </table>
  </div>
  <div> <br>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zccf171fa4e1e4dc89e1f3ee4201efb6d" class="DSPFListTable">

        <tr style="vertical-align: top;">
          <td style="width: 36pt;">&#160;</td>
          <td style="vertical-align: top; width: 18pt;">
            <div style="text-align: left;">&#8226;</div>
          </td>
          <td style="vertical-align: top; width: auto;">
            <div>original issue discount, if any;</div>
          </td>
        </tr>

    </table>
  </div>
  <div> <br>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zf604896b3cb64ed2af5be936aa8b4850" class="DSPFListTable">

        <tr style="vertical-align: top;">
          <td style="width: 36pt;">&#160;</td>
          <td style="vertical-align: top; width: 18pt;">
            <div style="text-align: left;">&#8226;</div>
          </td>
          <td style="vertical-align: top; width: auto;">
            <div>rates and times of payment of interest or dividends, if any;</div>
          </td>
        </tr>

    </table>
  </div>
  <div> <br>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z2c96997933a245a6b1b79a2cb2d99394" class="DSPFListTable">

        <tr style="vertical-align: top;">
          <td style="width: 36pt;">&#160;</td>
          <td style="vertical-align: top; width: 18pt;">
            <div style="text-align: left;">&#8226;</div>
          </td>
          <td style="vertical-align: top; width: auto;">
            <div>redemption, conversion, exchange or sinking fund terms, if any;</div>
          </td>
        </tr>

    </table>
  </div>
  <div> <br>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zfa9e543c78fd482a8a7c7f227e8ee34b" class="DSPFListTable">

        <tr style="vertical-align: top;">
          <td style="width: 36pt;">&#160;</td>
          <td style="vertical-align: top; width: 18pt;">
            <div style="text-align: left;">&#8226;</div>
          </td>
          <td style="vertical-align: top; width: auto;">
            <div>conversion or exchange prices or rates, if any, and, if applicable, any provisions for changes to or adjustments in the conversion or exchange prices or rates and in the securities or other property receivable upon conversion or exchange;</div>
          </td>
        </tr>

    </table>
  </div>
  <div> <br>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zdc68da1f33e348f8944a1bfdb54608d6" class="DSPFListTable">

        <tr style="vertical-align: top;">
          <td style="width: 36pt;">&#160;</td>
          <td style="vertical-align: top; width: 18pt;">
            <div style="text-align: left;">&#8226;</div>
          </td>
          <td style="vertical-align: top; width: auto;">
            <div>ranking;</div>
          </td>
        </tr>

    </table>
  </div>
  <div> <br>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z82ef0f7b4c3e4eabb7a3fe4384a5f8b0" class="DSPFListTable">

        <tr style="vertical-align: top;">
          <td style="width: 36pt;">&#160;</td>
          <td style="vertical-align: top; width: 18pt;">
            <div style="text-align: left;">&#8226;</div>
          </td>
          <td style="vertical-align: top; width: auto;">
            <div>restrictive covenants, if any;</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable">

          <tr style="vertical-align: top;">
            <td style="width: 36pt;">&#160;</td>
            <td style="vertical-align: top; width: 18pt;">
              <div style="text-align: left;">&#8226;</div>
            </td>
            <td style="vertical-align: top; width: auto;">
              <div>
                <div style="text-align: left;">voting or other rights, if any; and</div>
              </div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable">

          <tr style="vertical-align: top;">
            <td style="width: 36pt;">&#160;</td>
            <td style="vertical-align: top; width: 18pt;">
              <div style="text-align: left;">&#8226;</div>
            </td>
            <td style="vertical-align: top; width: auto;">
              <div>important United States federal income tax considerations.</div>
            </td>
          </tr>

      </table>
    </div>
  </div>
  <div> <br>
  </div>
  <div style="text-indent: 36pt;">A prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update, or change information contained in this prospectus or in documents we have incorporated by
    reference. However, no prospectus supplement or free writing prospectus will offer a security that is not registered and described in this prospectus at the time of the effectiveness of the registration statement of which this prospectus is a part. </div>
  <div style="text-indent: 36pt;"> <br>
  </div>
  <div style="text-indent: 36pt;">We may sell the securities to or through underwriters, dealers or agents or directly to purchasers. We, as well as any agents acting on our behalf, reserve the sole right to accept and to reject in whole or in part any
    proposed purchase of securities. Each prospectus supplement will set forth the names of any underwriters, dealers or agents involved in the sale of securities described in that prospectus supplement and any applicable fee, commission or discount
    arrangements with them, details regarding any over-allotment option granted to them, and net proceeds to us. The following is a summary of the securities we may offer with this prospectus.</div>
  <div> <br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
    <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">- 13 -</font></div>
    <div style="page-break-after: always;" id="DSPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    <div style="width: 100%;" id="DSPFPageHeader"><a href="#TABLEOFCONTENTS"><font style="font-size: 8pt; font-style: italic;"> Table of Contents</font></a></div>
  </div>
  <div style="font-weight: bold;">Common Stock</div>
  <div> <br>
  </div>
  <div style="text-indent: 36pt;">We currently have authorized 100,000,000 shares of common stock, par value $0.01 per share. As of August 9, 2019, 52,417,688 shares of common stock were issued and outstanding.&#160; We may offer shares of our common stock
    either alone or underlying other registered securities convertible into or exercisable for our common stock. Holders of our common stock are entitled to such dividends as our board of directors (the &#8220;Board of Directors&#8221; or &#8220;Board&#8221;) may declare from
    time to time out of legally available funds, subject to the preferential rights of the holders of any shares of our preferred stock that are outstanding or that we may issue in the future. Currently, we do not pay any dividends on our common stock.
    Each holder of our common stock is entitled to one vote per share. In this prospectus, we provide a general description of, among other things, the rights and restrictions that apply to holders of our common stock.</div>
  <div> <br>
  </div>
  <div style="font-weight: bold;">Preferred Stock</div>
  <div> <br>
  </div>
  <div style="text-indent: 36pt;">We currently have authorized 1,000,000 shares of preferred stock, par value $0.01. 700,000 shares are designated as Series A Convertible Preferred Stock, of which 424,938 shares are outstanding as of August 9, 2019. Any
    authorized and undesignated shares of preferred stock may be issued from time to time in one or more additional series pursuant to a resolution or resolutions providing for such issue duly adopted by our Board of Directors (authority to do so being
    hereby expressly vested in the Board of Directors). The Board of Directors is further authorized, subject to limitations prescribed by law, to fix by resolution or resolutions the designations, powers, preferences and rights, and the qualifications,
    limitations or restrictions thereof, of any wholly unissued series of preferred stock, including without limitation authority to fix by resolution or resolutions the dividend rights, dividend rate, conversion rights, voting rights, rights and terms of
    redemption (including sinking fund provisions), redemption price or prices, and liquidation preferences of any such series, and the number of shares constituting any such series and the designation thereof, or any of the foregoing.</div>
  <div> <br>
  </div>
  <div style="text-indent: 36pt;">The rights, preferences, privileges, and restrictions granted to or imposed upon any series of preferred stock that we offer and sell under this prospectus and applicable prospectus supplements will be set forth in a
    certificate of designation relating to the series. We will incorporate by reference into the registration statement of which this prospectus is a part the form of any certificate of designation that describes the terms of the series of preferred stock
    we are offering before the issuance of shares of that series of preferred stock. You should read any prospectus supplement and any free writing prospectus that we may authorize to be provided to you related to the series of preferred stock being
    offered, as well as the complete certificate of designation that contains the terms of the applicable series of preferred stock.</div>
  <div> <br>
  </div>
  <div style="font-weight: bold;">Debt Securities</div>
  <div> <br>
  </div>
  <div style="text-indent: 36pt;">We may offer general debt obligations, which may be secured or unsecured, senior or subordinated, and convertible into shares of our common stock. In this prospectus, we refer to the senior debt securities and the
    subordinated debt securities together as the &#8220;debt securities.&#8221; We may issue debt securities under a note purchase agreement or under an indenture to be entered between us and a trustee and forms of the senior and subordinated indentures are included
    as an exhibit to the registration statement of which this prospectus is a part. The indentures do not limit the amount of securities that may be issued under it and provides that debt securities may be issued in one or more series. The senior debt
    securities will have the same rank as all of our other indebtedness that is not subordinated. The subordinated debt securities will be subordinated to our senior debt on terms set forth in the applicable prospectus supplement. In addition, the
    subordinated debt securities will be effectively subordinated to creditors and preferred stockholders of our subsidiaries. Our Board of Directors will determine the terms of each series of debt securities being offered. This prospectus contains only
    general terms and provisions of the debt securities. The applicable prospectus supplement will describe the particular terms of the debt securities offered thereby. You should read any prospectus supplement and any free writing prospectus that we may
    authorize to be provided to you related to the series of debt securities being offered, as well as the complete note agreements and/or indentures that contain the terms of the debt securities. Forms of indentures have been filed as exhibits to the
    registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of debt securities being offered will be incorporated by reference into the registration statement of which this
    prospectus is a part from reports we file with the SEC.</div>
  <div> <br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
    <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">- 14 -</font></div>
    <div style="page-break-after: always;" id="DSPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    <div style="width: 100%;" id="DSPFPageHeader"><a href="#TABLEOFCONTENTS"><font style="font-size: 8pt; font-style: italic;"> Table of Contents</font></a></div>
  </div>
  <div style="font-weight: bold;">Warrants</div>
  <div> <br>
  </div>
  <div style="text-indent: 36pt;">We may offer warrants for the purchase of shares of our common stock or preferred stock or of debt securities. We may issue the warrants by themselves or together with common stock, preferred stock or debt securities, and
    the warrants may be attached to or separate from any offered securities. Any warrants issued under this prospectus may be evidenced by warrant certificates.&#160; Warrants may be issued under a separate warrant agreement to be entered into between us and
    the investors or a warrant agent. Our Board of Directors will determine the terms of the warrants. This prospectus contains only general terms and provisions of the warrants. The applicable prospectus supplement will describe the particular terms of
    the warrants being offered thereby. You should read any prospectus supplement and any free writing prospectus that we may authorize to be provided to you related to the series of warrants being offered, as well as the complete warrant agreements that
    contain the terms of the warrants. Specific warrant agreements will contain additional important terms and provisions and will be incorporated by reference into the registration statement of which this prospectus is a part from reports we file with the
    SEC.</div>
  <div> <br>
  </div>
  <div style="font-weight: bold;">Units</div>
  <div> <br>
  </div>
  <div style="text-indent: 36pt;">We may offer units consisting of our common stock or preferred stock, debt securities and/or warrants to purchase any of these securities in one or more series. We may evidence each series of units by unit certificates
    that we will issue under a separate agreement. We may enter into unit agreements with a unit agent. Each unit agent will be a bank or trust company that we select. We will indicate the name and address of the unit agent in the applicable prospectus
    supplement relating to a particular series of units. This prospectus contains only a summary of certain general features of the units. The applicable prospectus supplement will describe the particular features of the units being offered thereby. You
    should read any prospectus supplement and any free writing prospectus that we may authorize to be provided to you related to the series of units being offered, as well as the complete unit agreements that contain the terms of the units. Specific unit
    agreements will contain additional important terms and provisions and will be incorporated by reference into the registration statement of which this prospectus is a part from reports we file with the SEC.</div>
  <div style="text-indent: 36pt;"> <br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
    <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">- 15 -</font></div>
    <div style="page-break-after: always;" id="DSPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    <div style="width: 100%;" id="DSPFPageHeader"><a href="#TABLEOFCONTENTS"><font style="font-size: 8pt; font-style: italic;"> Table of Contents</font></a></div>
  </div>
  <div></div>
  <div style="text-align: center; font-weight: bold;"><a name="RISKFACTORS"><!--Anchor--></a>RISK FACTORS</div>
  <div> <br>
  </div>
  <div style="text-indent: 36pt;">An investment in our securities involves a high degree of risk. This prospectus contains, and the prospectus supplement applicable to each offering of our securities will contain, a discussion of the risks applicable to an
    investment in our securities. Prior to making a decision about investing in our securities, you should carefully consider the specific factors discussed under the heading &#8220;<font style="font-style: italic;">Risk Factors</font>&#8221; in this prospectus and
    the applicable prospectus supplement, together with all of the other information contained or incorporated by reference in the prospectus supplement or appearing or incorporated by reference in this prospectus. You should also consider the risks,
    uncertainties and assumptions discussed under Item 1A, &#8220;<font style="font-style: italic;">Risk Factors</font>,&#8221; in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018, as amended, and any updates described in our Quarterly
    Reports on Form 10-Q, all of which are incorporated herein by reference, and may be amended, supplemented or superseded from time to time by other reports we file with the SEC in the future and any prospectus supplement related to a particular
    offering. The risks and uncertainties we have described are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our operations. The occurrence of any of these
    known or unknown risks might cause you to lose all or part of your investment in the offered securities.</div>
  <div style="text-indent: 36pt;"> <br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
    <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">- 16 -</font></div>
    <div style="page-break-after:always;" id="DSPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div style="width: 100%;" id="DSPFPageHeader"><a href="#TABLEOFCONTENTS"><font style="font-size: 8pt; font-style: italic;"> Table of Contents</font></a></div>
  </div>
  <div></div>
  <div style="text-align: center; font-weight: bold;"><a name="FORWARD-LOOKINGSTATEMENTS"><!--Anchor--></a>FORWARD-LOOKING STATEMENTS</div>
  <div> <br>
  </div>
  <div style="text-indent: 36pt;">This prospectus and any accompanying prospectus supplement, including the documents that we incorporate by reference, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
    amended (the &#8220;Securities Act&#8221;) and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Any statements in this prospectus and any accompanying prospectus supplement about our expectations, beliefs, plans, objectives,
    assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as &#8220;believe,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221;
    &#8220;intend,&#8221; &#8220;plan,&#8221; and &#8220;would.&#8221; For example, statements concerning financial condition, possible or assumed future results of operations, growth opportunities, industry ranking, plans and objectives of management, markets for our common stock and future
    management and organizational structure are all forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of
    activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement.</div>
  <div> <br>
  </div>
  <div style="text-indent: 36pt;">You should read this prospectus and any accompanying prospectus supplement and the documents that we reference herein and therein and have filed as exhibits to the registration statement, of which this prospectus is part,
    completely and with the understanding that our actual future results may be materially different from what we expect.&#160; You should assume that the information appearing in this prospectus and any accompanying prospectus supplement is accurate as of the
    date on the front cover of this prospectus or such prospectus supplement only.&#160; Because the risk factors referred to in this prospectus and incorporated herein by reference could cause actual results or outcomes to differ materially from those
    expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements.&#160; Further, any forward-looking statement speaks only as of the date on which it is made, and we undertake no
    obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events.&#160; New factors emerge from time to time, and it is not possible for
    us to predict which factors will arise.&#160; In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any
    forward-looking statements.&#160; We qualify all of the information presented in this prospectus and any accompanying prospectus supplement, and particularly our forward-looking statements, by these cautionary statements.</div>
  <div style="text-indent: 36pt;"> <br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
    <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">- 17 -</font></div>
    <div style="page-break-after:always;" id="DSPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div style="width: 100%;" id="DSPFPageHeader"><a href="#TABLEOFCONTENTS"><font style="font-size: 8pt; font-style: italic;"> Table of Contents</font></a></div>
  </div>
  <div style="text-align: center; font-weight: bold;"><a name="USEOFPROCEEDS"><!--Anchor--></a>USE OF PROCEEDS</div>
  <div> <br>
  </div>
  <div style="text-indent: 36pt;">Except as described in any prospectus supplement and any free writing prospectus in connection with a specific offering, we currently intend to use the net proceeds from the sale of the securities offered under this
    prospectus for general corporate purposes, including the development and commercialization of our products, research and development, general and administrative expenses, license or technology acquisitions, and working capital and capital expenditures.
    We may also use the net proceeds to repay any debts and/or invest in or acquire complementary businesses, products, or technologies, although we have no current commitments or agreements with respect to any such investments or acquisitions as of the
    date of this prospectus. We have not determined the amount of net proceeds to be used specifically for the foregoing purposes. As a result, our management will have broad discretion in the allocation of the net proceeds and investors will be relying on
    the judgment of our management regarding the application of the proceeds of any sale of the securities. Pending use of the net proceeds, we intend to invest the proceeds in short-term, investment-grade, interest-bearing instruments.</div>
  <div> <br>
  </div>
  <div style="text-indent: 36pt;">Each time we offer securities under this prospectus, we will describe the intended use of the net proceeds from that offering in the applicable prospectus supplement. The actual amount of net proceeds we spend on a
    particular use will depend on many factors, including, our future capital expenditures, the amount of cash required by our operations, and our future revenue growth, if any. Therefore, we will retain broad discretion in the use of the net proceeds.</div>
  <div> <br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
    <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">- 18 -</font></div>
    <div style="page-break-after:always;" id="DSPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div style="width: 100%;" id="DSPFPageHeader"><a href="#TABLEOFCONTENTS"><font style="font-size: 8pt; font-style: italic;"> Table of Contents</font></a></div>
  </div>
  <div style="text-align: center; font-weight: bold;"><a name="DESCRIPTIONOFCAPITALSTOCK"><!--Anchor--></a>DESCRIPTION OF CAPITAL STOCK</div>
  <div> <br>
  </div>
  <div style="font-weight: bold;">General</div>
  <div> <br>
  </div>
  <div style="text-indent: 36pt;">The following description of our capital stock, together with any additional information we include in any applicable prospectus supplement or any related free writing prospectus, summarizes the material terms and
    provisions of our common stock and the preferred stock that we may offer under this prospectus. While the terms we have summarized below will apply generally to any future common stock or preferred stock that we may offer, we will describe the
    particular terms of any class or series of these securities in more detail in the applicable prospectus supplement. For the complete terms of our common stock and preferred stock, please refer to our amended and restated certificate of incorporation,
    as amended and our bylaws that are incorporated by reference into the registration statement of which this prospectus is a part or may be incorporated by reference in this prospectus or any applicable prospectus supplement. The terms of these
    securities may also be affected by Delaware General Corporation Law (the &#8220;DGCL&#8221;). The summary below and that contained in any applicable prospectus supplement or any related free writing prospectus are qualified in their entirety by reference to our
    amended and restated certificate of incorporation, as amended, and our bylaws.</div>
  <div> <br>
  </div>
  <div style="text-indent: 36pt;">As of the date of this prospectus, our authorized capital stock consisted of 100,000,000 shares of common stock, $0.01 par value per share, and 1,000,000 shares of preferred stock, $0.01 par value per share. Our Board may
    establish the rights and preferences of the preferred stock from time to time.</div>
  <div> <br>
  </div>
  <div style="font-weight: bold;">Common Stock</div>
  <div> <br>
  </div>
  <div style="text-indent: 36pt;">We are authorized to issue up to a total of 100,000,000 shares of common stock, par value $0.01 per share. Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of our
    stockholders. Holders of our common stock have no cumulative voting rights. All shares of common stock offered hereby will, when issued, be fully paid and nonassessable, including shares of common stock issued upon the exercise of common stock warrants
    or subscription rights, if any.</div>
  <div> <br>
  </div>
  <div style="text-indent: 36pt;">Further, holders of our common stock have no preemptive or conversion rights or other subscription rights. Upon our liquidation, dissolution or winding- up, holders of our common stock are entitled to share in all assets
    remaining after payment of all liabilities and the liquidation preferences of any of our outstanding shares of preferred stock. Subject to preferences that may be applicable to any outstanding shares of preferred stock, holders of our common stock are
    entitled to receive dividends, if any, as may be declared from time to time by our Board of Directors out of our assets which are legally available. Such dividends, if any, are payable in cash, in property or in shares of capital stock.</div>
  <div> <br>
  </div>
  <div style="text-indent: 36pt;">The holders of a majority of the shares of our capital stock, represented in person or by proxy, are necessary to constitute a quorum for the transaction of business at any meeting. If a quorum is present, an action by
    stockholders entitled to vote on a matter is approved if the number of votes cast in favor of the action exceeds the number of votes cast in opposition to the action, with the exception of the election of directors, which requires a plurality of the
    votes cast.</div>
  <div> <br>
  </div>
  <div style="font-weight: bold;">Preferred Stock</div>
  <div> <br>
  </div>
  <div style="text-indent: 36pt;">Our board of directors has the authority, without further action by the stockholders, to issue up to 1,000,000 shares of preferred stock in one or more series and to fix the designations, powers, preferences, privileges,
    and relative participating, optional, or special rights as well as the qualifications, limitations, or restrictions of the preferred stock, including dividend rights, conversion rights, voting rights, terms of redemption, and liquidation preferences,
    any or all of which may be greater than the rights of the common stock. Our board of directors, without stockholder approval, can issue convertible preferred stock with voting, conversion, or other rights that could adversely affect the voting power
    and other rights of the holders of common stock. Preferred stock could be issued quickly with terms calculated to delay or prevent a change of control or make removal of management more difficult. Additionally, the issuance of preferred stock may have
    the effect of decreasing the market price of our common stock, and may adversely affect the voting and other rights of the holders of common stock. At present, we have no plans to issue any shares of preferred stock following this offering.</div>
  <div> <br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
    <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">- 19 -</font></div>
    <div style="page-break-after: always;" id="DSPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    <div style="width: 100%;" id="DSPFPageHeader"><a href="#TABLEOFCONTENTS"><font style="font-size: 8pt; font-style: italic;"> Table of Contents</font></a></div>
  </div>
  <div style="font-weight: bold;">Anti-Takeover Effects of Certain Provisions of our Certificate of Incorporation, Bylaws and the DGCL</div>
  <div> <br>
  </div>
  <div style="text-indent: 36pt; color: #000000;">Pursuant to our Certificate of Incorporation, we are not subject to the provisions of Section 203 of the Delaware General Corporation Law regulating corporate takeovers through a &#8220;business combination&#8221; with
    a stockholder who owns 15% or more of our outstanding voting stock (otherwise known as an &#8220;interested stockholder&#8221;).</div>
  <div> <br>
  </div>
  <div style="text-indent: 2.25pt; font-weight: bold;">Listing</div>
  <div> <br>
  </div>
  <div style="text-indent: 32.049pt;">Our common stock is listed on The Nasdaq Capital Market under the trading symbol &#8220;AMRH.&#8221;</div>
  <div> <br>
  </div>
  <div style="text-indent: 2.25pt; font-weight: bold;">Transfer Agent and Registrar</div>
  <div> <br>
  </div>
  <div style="text-indent: 36pt;">The Transfer Agent and Registrar for our common stock is Corporate Stock Transfer, Inc.</div>
  <div> <br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
    <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">- 20 -</font></div>
    <div style="page-break-after:always;" id="DSPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    <div style="width: 100%;" id="DSPFPageHeader"><a href="#TABLEOFCONTENTS"><font style="font-size: 8pt; font-style: italic;"> Table of Contents</font></a></div>
  </div>
  <div></div>
  <div style="text-align: center; font-weight: bold;"><a name="DESCRIPTIONOFDEBTSECURITI"><!--Anchor--></a>DESCRIPTION OF DEBT SECURITIES</div>
  <div> <br>
  </div>
  <div style="text-indent: 36pt;">The following description, together with the additional information we include in any applicable prospectus supplements or free writing prospectuses, summarizes the material terms and provisions of the debt securities that
    we may offer under this prospectus. We may issue debt securities, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. While the terms we have summarized below will apply generally to any future
    debt securities we may offer under this prospectus, we will describe the particular terms of any debt securities that we may offer in more detail in the applicable prospectus supplement or free writing prospectus. The terms of any debt securities we
    offer under a prospectus supplement may differ from the terms we describe below. However, no prospectus supplement shall fundamentally change the terms that are set forth in this prospectus or offer a security that is not registered and described in
    this prospectus at the time of its effectiveness. As of the date of this prospectus, we have no outstanding registered debt securities. Unless the context requires otherwise, whenever we refer to the &#8220;indentures,&#8221; we also are referring to any
    supplemental indentures that specify the terms of a particular series of debt securities.</div>
  <div> <br>
  </div>
  <div style="text-indent: 36pt;">We will issue any senior debt securities under the senior indenture that we will enter into with the trustee named in the senior indenture. We will issue any subordinated debt securities under the subordinated indenture
    and any supplemental indentures that we will enter into with the trustee named in the subordinated indenture. We have filed forms of these documents as exhibits to the registration statement, of which this prospectus is a part, and supplemental
    indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from reports that we file
    with the SEC.</div>
  <div> <br>
  </div>
  <div style="text-indent: 36pt;">The indentures will be qualified under the Trust Indenture Act of 1939, as amended (the &#8220;Trust Indenture Act&#8221;). We use the term &#8220;trustee&#8221; to refer to either the trustee under the senior indenture or the trustee under the
    subordinated indenture, as applicable.</div>
  <div> <br>
  </div>
  <div style="text-indent: 36pt;">The following summaries of material provisions of the senior debt securities, the subordinated debt securities and the indentures are subject to, and qualified in their entirety by reference to, all of the provisions of
    the indenture and any supplemental indentures applicable to a particular series of debt securities. We urge you to read the applicable prospectus supplements and any related free writing prospectuses related to the debt securities that we may offer
    under this prospectus, as well as the complete indentures that contains the terms of the debt securities. Except as we may otherwise indicate, the terms of the senior indenture and the subordinated indenture are identical.</div>
  <div> <br>
  </div>
  <div style="font-weight: bold;">General</div>
  <div> <br>
  </div>
  <div style="text-indent: 36pt;">The terms of each series of debt securities will be established by or pursuant to a resolution of our Board of Directors and set forth or determined in the manner provided in an officers&#8217; certificate or by a supplemental
    indenture. Debt securities may be issued in separate series without limitation as to aggregate principal amount. We may specify a maximum aggregate principal amount for the debt securities of any series. We will describe in the applicable prospectus
    supplement the terms of the series of debt securities being offered, including:</div>
  <div style="text-indent: 36pt;"> <br>
  </div>
  <div>
    <div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zed877e2da940491fb58e426ee31de3b1" class="DSPFListTable">

          <tr style="vertical-align: top;">
            <td style="width: 36pt;">&#160;</td>
            <td style="vertical-align: top; width: 18pt;">
              <div style="text-align: left;">&#8226;</div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: left; text-indent: -36pt; margin-left: 36pt;">the title;</div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z67242631482e45308ad8f3e02c7fdfc2" class="DSPFListTable">

          <tr style="vertical-align: top;">
            <td style="width: 36pt;">&#160;</td>
            <td style="vertical-align: top; width: 18pt;">
              <div style="text-align: left;">&#8226;</div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: left;">the principal amount being offered, and if a series, the total amount authorized and the total amount outstanding;</div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zff1873e7e4b945e1a064b8de23e88915" class="DSPFListTable">

          <tr style="vertical-align: top;">
            <td style="width: 36pt;">&#160;</td>
            <td style="vertical-align: top; width: 18pt;">
              <div style="text-align: left;">&#8226;</div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: left;">any limit on the amount that may be issued;</div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z04d640ab7a2c4add9656afdfa45ebf38" class="DSPFListTable">

          <tr style="vertical-align: top;">
            <td style="width: 36pt;">&#160;</td>
            <td style="vertical-align: top; width: 18pt;">
              <div style="text-align: left;">&#8226;</div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: left;">whether or not we will issue the series of debt securities in global form, and, if so, the terms and who the depositary will be;</div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z2af6590ebb8841b6ae7078b23646b420" class="DSPFListTable">

          <tr style="vertical-align: top;">
            <td style="width: 36pt;">&#160;</td>
            <td style="vertical-align: top; width: 18pt;">
              <div style="text-align: left;">&#8226;</div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: left;">the maturity date;</div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">- 21 -</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      <div style="width: 100%;" id="DSPFPageHeader"><a href="#TABLEOFCONTENTS"><font style="font-size: 8pt; font-style: italic;"> Table of Contents</font></a></div>
    </div>
    <!--PROfilePageNumberReset%Num%22%- % -%-->
    <div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z4cc6d93da5694d82bde3c13e80cdfa21" class="DSPFListTable">

          <tr style="vertical-align: top;">
            <td style="width: 36pt;">&#160;</td>
            <td style="vertical-align: top; width: 18pt;">
              <div style="text-align: left;">&#8226;</div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: left;">whether and under what circumstances, if any, we will pay additional amounts on any debt securities held by a person who is not a United States person for tax purposes, and whether we can redeem the debt
                securities if we have to pay such additional amounts;</div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z3fcb894e47d544cc87a6022a925debf4" class="DSPFListTable">

          <tr style="vertical-align: top;">
            <td style="width: 36pt;">&#160;</td>
            <td style="vertical-align: top; width: 18pt;">
              <div style="text-align: left;">&#8226;</div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: left;">the annual interest rate, which may be fixed or variable, or the method for determining the rate and the date interest will begin to accrue, the dates interest will be payable and the regular record dates for
                interest payment dates or the method for determining such dates;</div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="za7e0b85573704df7a635fc3563958aa6" class="DSPFListTable">

          <tr style="vertical-align: top;">
            <td style="width: 36pt;">&#160;</td>
            <td style="vertical-align: top; width: 18pt;">
              <div style="text-align: left;">&#8226;</div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: left;">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt;</div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z8e9ce4b396d2428eb3309cc3506f8b5e" class="DSPFListTable">

          <tr style="vertical-align: top;">
            <td style="width: 36pt;">&#160;</td>
            <td style="vertical-align: top; width: 18pt;">
              <div style="text-align: left;">&#8226;</div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: left;">the terms of the subordination of any series of subordinated debt;</div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zf887689e96a84fb8b1c5b1cb6689cdba" class="DSPFListTable">

          <tr style="vertical-align: top;">
            <td style="width: 36pt;">&#160;</td>
            <td style="vertical-align: top; width: 18pt;">
              <div style="text-align: left;">&#8226;</div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: left;">the place where payments will be made;</div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="za193fc7d960340fa94cd17d61fbad206" class="DSPFListTable">

          <tr style="vertical-align: top;">
            <td style="width: 36pt;">&#160;</td>
            <td style="vertical-align: top; width: 18pt;">
              <div style="text-align: left;">&#8226;</div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: left;">restrictions on transfer, sale or other assignment, if any;</div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zffa082b8e4434341a6a658aee51d61a6" class="DSPFListTable">

          <tr style="vertical-align: top;">
            <td style="width: 36pt;">&#160;</td>
            <td style="vertical-align: top; width: 18pt;">
              <div style="text-align: left;">&#8226;</div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: left;">our right, if any, to defer payment of interest and the maximum length of any such deferral period;</div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z5f0f2d6e2b9748d6a835fc52c6f47948" class="DSPFListTable">

          <tr style="vertical-align: top;">
            <td style="width: 36pt;">&#160;</td>
            <td style="vertical-align: top; width: 18pt;">
              <div style="text-align: left;">&#8226;</div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: left;">the date, if any, after which, and the price at which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those redemption
                provisions;</div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z0360ffcf93314512b967952fa54ed1e7" class="DSPFListTable">

          <tr style="vertical-align: top;">
            <td style="width: 36pt;">&#160;</td>
            <td style="vertical-align: top; width: 18pt;">
              <div style="text-align: left;">&#8226;</div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: left;">provisions for a sinking fund purchase or other analogous fund, if any, including the date, if any, on which, and the price at which we are obligated, pursuant thereto or otherwise, to redeem, or at the holder&#8217;s
                option, to purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable;</div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zffd3aa8108824618bc1289620e94401e" class="DSPFListTable">

          <tr style="vertical-align: top;">
            <td style="width: 36pt;">&#160;</td>
            <td style="vertical-align: top; width: 18pt;">
              <div style="text-align: left;">&#8226;</div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: left;">whether the indenture will restrict our ability or the ability of our subsidiaries, if any, to:</div>
            </td>
          </tr>

      </table>
    </div>
  </div>
  <div style="text-indent: 36pt;"> <br>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z31edc1825746424e9d314d32f4b8f7b8" class="DSPFListTable">

        <tr style="vertical-align: top;">
          <td style="width: 90pt;">&#160;</td>
          <td style="vertical-align: top; width: 18pt;">
            <div style="text-align: left;">&#8226;</div>
          </td>
          <td style="align: left; vertical-align: top; width: auto;">
            <div style="text-align: left;">incur additional indebtedness;</div>
          </td>
        </tr>

    </table>
  </div>
  <div>&#160;</div>
  <div>
    <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z4128758e3ccf4d46b20b3932bf925f5d" class="DSPFListTable">

        <tr style="vertical-align: top;">
          <td style="width: 90pt;">&#160;</td>
          <td style="vertical-align: top; width: 18pt;">
            <div style="text-align: left;">&#8226;</div>
          </td>
          <td style="align: left; vertical-align: top; width: auto;">
            <div style="text-align: left;">issue additional securities;</div>
          </td>
        </tr>

    </table>
  </div>
  <div>&#160;&#160;</div>
  <div>
    <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z752630babe7a423fb2e9465595aa2b1c" class="DSPFListTable">

        <tr style="vertical-align: top;">
          <td style="width: 90pt;">&#160;</td>
          <td style="vertical-align: top; width: 18pt;">
            <div style="text-align: left;">&#8226;</div>
          </td>
          <td style="align: left; vertical-align: top; width: auto;">
            <div style="text-align: left;">create liens;</div>
          </td>
        </tr>

    </table>
  </div>
  <div>&#160;</div>
  <div>
    <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z9ba31d55e8c347e6bdf6f2ec0c39cc27" class="DSPFListTable">

        <tr style="vertical-align: top;">
          <td style="width: 90pt;">&#160;</td>
          <td style="vertical-align: top; width: 18pt;">
            <div style="text-align: left;">
              <div>&#8226;</div>
            </div>
          </td>
          <td style="align: left; vertical-align: top; width: auto;">
            <div style="text-align: left;">pay dividends or make distributions in respect of our capital stock or the capital stock of our subsidiaries;</div>
          </td>
        </tr>

    </table>
  </div>
  <div>&#160;</div>
  <div>
    <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zc2e1507e5bc940f78deab625af8343c4" class="DSPFListTable">

        <tr style="vertical-align: top;">
          <td style="width: 90pt;">&#160;</td>
          <td style="vertical-align: top; width: 18pt;">
            <div style="text-align: left;">&#8226;</div>
          </td>
          <td style="align: left; vertical-align: top; width: auto;">
            <div style="text-align: left;">redeem capital stock;</div>
          </td>
        </tr>

    </table>
  </div>
  <div>&#160;</div>
  <div>
    <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z7e6c558e474146babd305d02525b7c93" class="DSPFListTable">

        <tr style="vertical-align: top;">
          <td style="width: 90pt;">&#160;</td>
          <td style="vertical-align: top; width: 18pt;">
            <div style="text-align: left;">&#8226;</div>
          </td>
          <td style="align: left; vertical-align: top; width: auto;">
            <div style="text-align: left;">place restrictions on our subsidiaries&#8217; ability to pay dividends, make distributions or transfer assets;</div>
          </td>
        </tr>

    </table>
  </div>
  <div>&#160;</div>
  <div>
    <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z82eaac0eae90493db2f2595cee8457e0" class="DSPFListTable">

        <tr style="vertical-align: top;">
          <td style="width: 90pt;">&#160;</td>
          <td style="vertical-align: top; width: 18pt;">
            <div style="text-align: left;">&#8226;</div>
          </td>
          <td style="align: left; vertical-align: top; width: auto;">
            <div style="text-align: left;">make investments or other restricted payments;</div>
          </td>
        </tr>

    </table>
  </div>
  <div>&#160;</div>
  <div>
    <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z9868e04f087e457eb3d2108225d79eb3" class="DSPFListTable">

        <tr style="vertical-align: top;">
          <td style="width: 90pt;">&#160;</td>
          <td style="vertical-align: top; width: 18pt;">
            <div style="text-align: left;">&#8226;</div>
          </td>
          <td style="align: left; vertical-align: top; width: auto;">
            <div style="text-align: left;">sell or otherwise dispose of assets;</div>
          </td>
        </tr>

    </table>
  </div>
  <div>&#160;</div>
  <div>
    <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z7e2a1d4257284852a14c199d4e934f70" class="DSPFListTable">

        <tr style="vertical-align: top;">
          <td style="width: 90pt;">&#160;</td>
          <td style="vertical-align: top; width: 18pt;">
            <div style="text-align: left;">&#8226;</div>
          </td>
          <td style="align: left; vertical-align: top; width: auto;">
            <div style="text-align: left;">enter into sale-leaseback transactions;</div>
          </td>
        </tr>

    </table>
  </div>
  <div>&#160;</div>
  <div>
    <div>
      <div>
        <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zd9774d3c380c42eca0dcb679c67bfe50" class="DSPFListTable">

            <tr style="vertical-align: top;">
              <td style="width: 90pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">
                  <div>&#8226;</div>
                </div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">engage in transactions with stockholders or affiliates;</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
  </div>
  <div>&#160;</div>
  <div>
    <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z2a60504fd3c74496bab7d927dd4e936b" class="DSPFListTable">

        <tr style="vertical-align: top;">
          <td style="width: 90pt;">&#160;</td>
          <td style="vertical-align: top; width: 18pt;">
            <div style="text-align: left;">&#8226;</div>
          </td>
          <td style="align: left; vertical-align: top; width: auto;">
            <div style="text-align: left;">issue or sell stock of our subsidiaries; or</div>
          </td>
        </tr>

    </table>
  </div>
  <div>&#160;</div>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z163624dd165846e1a05ac68aec9a7b9e" class="DSPFListTable">

      <tr style="vertical-align: top;">
        <td style="width: 90pt;">&#160;</td>
        <td style="vertical-align: top; width: 18pt;">
          <div style="text-align: left;">&#8226;</div>
        </td>
        <td style="align: left; vertical-align: top; width: auto;">
          <div style="text-align: left;">effect a consolidation or merger;</div>
        </td>
      </tr>

  </table>
  <div> <br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
    <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">- 22 -</font></div>
    <div style="page-break-after: always;" id="DSPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    <div style="width: 100%;" id="DSPFPageHeader"><a href="#TABLEOFCONTENTS"><font style="font-size: 8pt; font-style: italic;"> Table of Contents</font></a></div>
  </div>
  <div>
    <div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z035a9b9f0e444a2b8ec4e8b50327c936" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">whether the indenture will require us to maintain any interest coverage, fixed charge, cash flow-based, asset-based or other financial ratios;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z0fb808b85fc4483eaa15d813475c48b6" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">a discussion of certain material or special United States federal income tax considerations applicable to the debt securities;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z52445c1fcb134a3ba4d202f1d66c02ee" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">information describing any book-entry features;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z092f5dc4d9c24fa1a9b6ed88f3f43646" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">the applicability of the provisions in the indenture on discharge;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z6f1e6518ac7c4fba88a2754ae71f7592" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">whether the debt securities are to be offered at a price such that they will be deemed to be offered at an &#8220;original issue discount&#8221; as defined in paragraph (a) of Section 1273 of the Internal Revenue Code of
                  1986, as amended;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zf6ac4fa5c33c4bac9aeb65ad220cb37d" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple thereof;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z86e46e8477ce4fc7bf5ffad987324b14" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">the currency of payment of debt securities if other than U.S. dollars and the manner of determining the equivalent amount in U.S. dollars; and</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z4d04ce3aebcb49f793068a1a71e8a6ac" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, including any additional events of default or covenants provided with respect to the debt securities,
                  and any terms that may be required by us or advisable under applicable laws or regulations.</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div style="font-weight: bold;">Conversion or Exchange Rights</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">We will set forth in the applicable prospectus supplement the terms under which a series of debt securities may be convertible into or exchangeable for our common stock, our preferred stock or other securities
        (including securities of a third party). We will include provisions as to whether conversion or exchange is mandatory, at the option of the holder or at our option. We may include provisions pursuant to which the number of shares of our common
        stock, our preferred stock or other securities (including securities of a third party) that the holders of the series of debt securities receive would be subject to adjustment.</div>
      <div> <br>
      </div>
      <div style="font-weight: bold;">Consolidation, Merger or Sale</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the indentures will not contain any covenant that restricts our ability to merge or consolidate, or sell,
        convey, transfer or otherwise dispose of all or substantially all of our assets. However, any successor to or acquirer of such assets must assume all of our obligations under the indentures or the debt securities, as appropriate. If the debt
        securities are convertible into or exchangeable for our other securities or securities of other entities, the person with whom we consolidate or merge or to whom we sell all of our property must make provisions for the conversion of the debt
        securities into securities that the holders of the debt securities would have received if they had converted the debt securities before the consolidation, merger or sale.</div>
      <div> <br>
      </div>
      <div style="font-weight: bold;">Events of Default under the Indenture</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the following are events of default under the indentures with respect to any series of debt securities that
        we may issue:</div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z116143a3cb154fbbb5ffcd2cb35e9a27" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">if we fail to pay interest when due and payable and our failure continues for 90 days and the time for payment has not been extended;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">- 23 -</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div style="width: 100%;" id="DSPFPageHeader"><a href="#TABLEOFCONTENTS"><font style="font-size: 8pt; font-style: italic;"> Table of Contents</font></a></div>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z2caa653490c14eb9b6571d86b77e077f" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">if we fail to pay the principal, premium or sinking fund payment, if any, when due and payable at maturity, upon redemption or repurchase or otherwise, and the time for payment has not been extended;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="ze60bac234d5c49f9ab455bd043458d99" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">if we fail to observe or perform any other covenant contained in the debt securities or the indentures, other than a covenant specifically relating to another series of debt securities, and our failure
                  continues for 90 days after we receive notice from the trustee or we and the trustee receive notice from the holders of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series; and</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z6e432dae33d84f63999adcee5b13231e" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">if specified events of bankruptcy, insolvency or reorganization occur.</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">We will describe in each applicable prospectus supplement any additional events of default relating to the relevant series of debt securities.</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">If an event of default with respect to debt securities of any series occurs and is continuing, other than an event of default specified in the last bullet point above, the trustee or the holders of at least 25% in
        aggregate principal amount of the outstanding debt securities of that series, by notice to us in writing, and to the trustee if notice is given by such holders, may declare the unpaid principal, premium, if any, and accrued interest, if any, due
        and payable immediately. If an event of default arises due to the occurrence of certain specified bankruptcy, insolvency or reorganization events, the unpaid principal, premium, if any, and accrued interest, if any, of each issue of debt securities
        then outstanding shall be due and payable without any notice or other action on the part of the trustee or any holder.</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">The holders of a majority in principal amount of the outstanding debt securities of an affected series may waive any default or event of default with respect to the series and its consequences, except defaults or
        events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default in accordance with the indenture. Any waiver shall cure the default or event of default.</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">Subject to the terms of the indentures, if an event of default under an indenture shall occur and be continuing, the trustee will be under no obligation to exercise any of its rights or powers under such indenture at
        the request or direction of any of the holders of the applicable series of debt securities, unless such holders have offered the trustee reasonable indemnity or security satisfactory to it against any loss, liability or expense. The holders of a
        majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee, or exercising any trust or power conferred
        on the trustee, with respect to the debt securities of that series, provided that:</div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z13d80d2f263c4c7a8b97becc4d323cb9" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">the direction so given by the holder is not in conflict with any law or the applicable indenture; and</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z5bfeb61dd2bb497ba17b1e808786bf1b" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it in personal liability or might be unduly prejudicial to the holders not involved in the
                  proceeding.</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">The indentures will provide that if an event of default has occurred and is continuing, the trustee will be required in the exercise of its powers to use the degree of care that a prudent person would use in the
        conduct of its own affairs. The trustee, however, may refuse to follow any direction that conflicts with law or the indenture, or that the trustee determines is unduly prejudicial to the rights of any other holder of the relevant series of debt
        securities, or that would involve the trustee in personal liability. Prior to taking any action under the indentures, the trustee will be entitled to indemnification against all costs, expenses and liabilities that would be incurred by taking or
        not taking such action.</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">A holder of the debt securities of any series will have the right to institute a proceeding under the indentures or to appoint a receiver or trustee, or to seek other remedies only if:</div>
      <div> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">- 24 -</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div style="width: 100%;" id="DSPFPageHeader"><a href="#TABLEOFCONTENTS"><font style="font-size: 8pt; font-style: italic;"> Table of Contents</font></a></div>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zd7ea54cdddb24bc486a597dec696ef14" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">the holder has given written notice to the trustee of a continuing event of default with respect to that series;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zdae079bd0d6c4c6e973f96b664e8b1d2" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have made a written request and such holders have offered reasonable indemnity to the trustee or
                  security satisfactory to it against any loss, liability or expense or to be incurred in compliance with instituting the proceeding as trustee; and</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z8742a942a45746a89f90262ef4d61aca" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal amount of the outstanding debt securities of that series other conflicting directions
                  within 90 days after the notice, request and offer.</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">These limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest on, the debt securities, or other defaults that may be
        specified in the applicable prospectus supplement.</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">We will periodically file statements with the trustee regarding our compliance with specified covenants in the indentures.</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">The indentures will provide that if a default occurs and is continuing and is actually known to a responsible officer of the trustee, the trustee must mail to each holder notice of the default within the earlier of 90
        days after it occurs and 30 days after it is known by a responsible officer of the trustee or written notice of it is received by the trustee, unless such default has been cured or waived. Except in the case of a default in the payment of principal
        or premium of, or interest on, any debt security or certain other defaults specified in an indenture, the trustee shall be protected in withholding such notice if and so long as the Board of Directors, the executive committee or a trust committee
        of directors, or responsible officers of the trustee, in good faith determine that withholding notice is in the best interests of holders of the relevant series of debt securities.</div>
      <div> <br>
      </div>
      <div style="font-weight: bold;">Modification of Indenture; Waiver</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">Subject to the terms of the indenture for any series of debt securities that we may issue, we and the trustee may change an indenture without the consent of any holders with respect to the following specific matters:</div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z103df01cb1f34f75b1d8504ad070d0b0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">to fix any ambiguity, defect or inconsistency in the indenture;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z58363fa5a11245a884fda1c5cecbc3bf" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">to comply with the provisions described above under &#8220;<font style="font-style: italic;">Description of Debt Securities &#8212; Consolidation, Merger or Sale</font>;&#8221;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z491a550db3cd4664a181d911f31501db" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust Indenture Act;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z90cdbb7fd833439497a2fab0fddc292c" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">to add to, delete from or revise the conditions, limitations and restrictions on the authorized amount, terms or purposes of issue, authentication and delivery of debt securities, as set forth in the
                  indenture;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z896e9920f6414835bc455e633eeb1545" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">to provide for the issuance of, and establish the form and terms and conditions of, the debt securities of any series as provided under &#8220;<font style="font-style: italic;">Description of Debt Securities &#8212;
                    General</font>,&#8221; to establish the form of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add to the rights of the holders of any series of debt securities;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zd8ab5ed3af624e1a975f0d6e34d22afc" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">to evidence and provide for the acceptance of appointment hereunder by a successor trustee;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z4d82cc1133a7442fad35c05fd65e8a29" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">to provide for uncertificated debt securities and to make all appropriate changes for such purpose;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z6be67d9e941f41e5a7d0a793fc69777b" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">to add such new covenants, restrictions, conditions or provisions for the benefit of the holders, to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants,
                  restrictions, conditions or provisions an event of default or to surrender any right or power conferred to us in the indenture; or</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">- 25 -</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div style="width: 100%;" id="DSPFPageHeader"><a href="#TABLEOFCONTENTS"><font style="font-size: 8pt; font-style: italic;"> Table of Contents</font></a></div>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z966620641a60459e9aaf99b3312c7d76" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">to change anything that does not adversely affect the interests of any holder of debt securities of any series in any material respect.</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">In addition, under the indentures, the rights of holders of a series of debt securities may be changed by us and the trustee with the written consent of the holders of at least a majority in aggregate principal amount
        of the outstanding debt securities of each series that is affected. However, subject to the terms of the indenture for any series of debt securities that we may issue or otherwise provided in the prospectus supplement applicable to a particular
        series of debt securities, we and the trustee may only make the following changes with the consent of each holder of any outstanding debt securities affected:</div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zba6c9cc1dded4b238bcf676a004c9310" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">extending the stated maturity of the series of debt securities;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z33f8ce790f7b47e08f28ed00dd2fb22b" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any premium payable upon the redemption or repurchase of any debt securities; or</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z42dd9ff303d44649aec85f745a503852" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">reducing the percentage of debt securities, the holders of which are required to consent to any amendment, supplement, modification or waiver.</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div style="text-indent: 2.25pt; font-weight: bold;">Discharge</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">Each indenture provides that, subject to the terms of the indenture and any limitation otherwise provided in the prospectus supplement applicable to a particular series of debt securities, we may elect to be discharged
        from our obligations with respect to one or more series of debt securities, except for specified obligations, including obligations to:</div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z819ee6da1c0746a2a8a829e13105610a" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">register the transfer or exchange of debt securities of the series;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zc68dd8bc26af4dfcbbe863d80b40ae77" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">replace stolen, lost or mutilated debt securities of the series;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z98d3dbe7a2764923befe5ef6c4323289" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">maintain paying agencies;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z864d83f402f040668e53534085940d84" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">hold monies for payment in trust;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z0320af0996784ff182c296adef7e2803" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">recover excess money held by the trustee;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z7cf44cac8d0c40f28ec21eacf310a846" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">compensate and indemnify the trustee; and</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="za865309e4c634532b53cba70d530d1a2" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">appoint any successor trustee.</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">In order to exercise our rights to be discharged, we will deposit with the trustee money or government obligations sufficient to pay all the principal of, and any premium and interest on, the debt securities of the
        series on the dates payments are due.</div>
      <div> <br>
      </div>
      <div style="font-weight: bold;">Form, Exchange and Transfer</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">We will issue the debt securities of each series only in fully registered form without coupons and, unless we otherwise specify in the applicable prospectus supplement, in denominations of $1,000 and any integral
        multiple thereof. The indentures will provide that we may issue debt securities of a series in temporary or permanent global form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust Company or another
        depositary named by us and identified in a prospectus supplement with respect to that series. See &#8220;<font style="font-style: italic;">Legal Ownership of Securities</font>&#8221; below for a further description of the terms relating to any book-entry
        securities.</div>
      <div> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">- 26 -</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div style="width: 100%;" id="DSPFPageHeader"><a href="#TABLEOFCONTENTS"><font style="font-size: 8pt; font-style: italic;"> Table of Contents</font></a></div>
      </div>
      <div style="text-indent: 36pt;">At the option of the holder, subject to the terms of the indentures and the limitations applicable to global securities described in the applicable prospectus supplement, the holder of the debt securities of any series
        can exchange the debt securities for other debt securities of the same series, in any authorized denomination and of like tenor and aggregate principal amount.</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">Subject to the terms of the indentures and the limitations applicable to global securities set forth in the applicable prospectus supplement, holders of the debt securities may present the debt securities for exchange
        or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required by us or the security registrar, at the office of the security registrar or at the office of any transfer agent designated by
        us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange, we will make no service charge for any registration of transfer or exchange, but we may require payment of any taxes or other
        governmental charges.</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">We will name in the applicable prospectus supplement the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt securities. We may at any time
        designate additional transfer agents or rescind the designation of any transfer agent or approve a change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for
        the debt securities of each series.</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">If we elect to redeem the debt securities of any series, we will not be required to:</div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zab1d1af760cd4d6886fe04772187b54d" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the opening of business 15 days before the day of mailing of a notice of redemption of any debt
                  securities that may be selected for redemption and ending at the close of business on the day of the mailing; or</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z9b4e8dcbd2b84ae6b19575fab70a7065" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except the unredeemed portion of any debt securities we are redeeming in part.</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div style="font-weight: bold;">Information Concerning the Trustee</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">The trustee, other than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those duties as are specifically set forth in the applicable indenture and is under no
        obligation to exercise any of the powers given it by the indentures at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that it might incur. However,
        upon an event of default under an indenture, the trustee must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs.</div>
      <div> <br>
      </div>
      <div style="font-weight: bold;">Payment and Paying Agents</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">Unless we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date to the person in whose name the debt securities, or one or
        more predecessor securities, are registered at the close of business on the regular record date for the interest payment.</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">We will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents designated by us, except that unless we otherwise indicate in the applicable
        prospectus supplement, we will make interest payments by check that we will mail to the holder or by wire transfer to certain holders. Unless we otherwise indicate in the applicable prospectus supplement, we will designate the corporate trust
        office of the trustee as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement any other paying agents that we initially designate for the debt securities of a
        particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series.</div>
      <div> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">- 27 -</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div style="width: 100%;" id="DSPFPageHeader"><a href="#TABLEOFCONTENTS"><font style="font-size: 8pt; font-style: italic;"> Table of Contents</font></a></div>
      </div>
      <div style="text-indent: 36pt;">All money we pay to a paying agent or the trustee for the payment of the principal of or any premium or interest on any debt securities that remains unclaimed at the end of two years after such principal, premium or
        interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may look only to us for payment thereof.</div>
      <div> <br>
      </div>
      <div style="font-weight: bold;">Governing Law</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">The indentures and the debt securities will be governed by and construed in accordance with the laws of the State of New York, except to the extent that the Trust Indenture Act is applicable.</div>
      <div> <br>
      </div>
      <div style="font-weight: bold;">Ranking Debt Securities</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">The subordinated debt securities will be unsecured and will be subordinate and junior in priority of payment to certain other indebtedness to the extent described in a prospectus supplement. The subordinated indenture
        does not limit the amount of subordinated debt securities that we may issue. It also does not limit us from issuing any other secured or unsecured debt.</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">The senior debt securities will be unsecured and will rank equally in right of payment to all our other senior unsecured debt. The senior indenture does not limit the amount of senior debt securities that we may issue.
        It also does not limit us from issuing any other secured or unsecured debt.</div>
      <div> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">- 28 -</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div style="width: 100%;" id="DSPFPageHeader"><a href="#TABLEOFCONTENTS"><font style="font-size: 8pt; font-style: italic;"> Table of Contents</font></a></div>
      </div>
      <div style="text-align: center; font-weight: bold;">DESCRIPTION <a name="OF"><!--Anchor--></a>OF WARRANTS<a name="DESCRIPTIONOFWARRANTS_082132"></a></div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">The following description, together with the additional information we may include in any applicable prospectus supplements and free writing prospectuses, summarizes the material terms and provisions of the warrants
        that we may offer under this prospectus, which may consist of warrants to purchase common stock, preferred stock or debt securities and may be issued in one or more series. Warrants may be offered independently or together with common stock,
        preferred stock or debt securities offered by any prospectus supplement, and may be attached to or separate from those securities. While the terms we have summarized below will apply generally to any warrants that we may offer under this
        prospectus, we will describe the particular terms of any series of warrants that we may offer in more detail in the applicable prospectus supplement and any applicable free writing prospectus. The terms of any warrants offered under a prospectus
        supplement may differ from the terms described below. However, no prospectus supplement will fundamentally change the terms that are set forth in this prospectus or offer a security that is not registered and described in this prospectus at the
        time of its effectiveness.</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">We may issue the warrants under a warrant agreement that we will enter into with a warrant agent to be selected by us. If selected, the warrant agent will act solely as an agent of ours in connection with the warrants
        and will not act as an agent for the holders or beneficial owners of the warrants. If applicable, we will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from a Current Report on
        Form 8-K that we file with the SEC, the form of warrant agreement, including a form of warrant certificate, that describes the terms of the particular series of warrants we are offering before the issuance of the related series of warrants. The
        following summaries of material provisions of the warrants and the warrant agreements are subject to, and qualified in their entirety by reference to, all the provisions of the warrant agreement and warrant certificate applicable to a particular
        series of warrants. We urge you to read the applicable prospectus supplement and any applicable free writing prospectus related to the particular series of warrants that we sell under this prospectus, as well as the complete warrant agreements and
        warrant certificates that contain the terms of the warrants.</div>
      <div> <br>
      </div>
      <div style="font-weight: bold;">General</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">We will describe in the applicable prospectus supplement the terms relating to a series of warrants, including:</div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z3683181d43e7418387d3badb47b3e096" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">the offering price and aggregate number of warrants offered;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z2e8ad485f8084a1d994a405f4ccceb64" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">the currency for which the warrants may be purchased;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zc182be20a1c440efb8fa53ac2cb3d152" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each such security or each principal amount of such security;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zd0ea01b99b264b87b17db5deb77d58cd" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">if applicable, the date on and after which the warrants and the related securities will be separately transferable;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z1892b117642b4634b77c937f5da2c519" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon exercise of one warrant and the price at, and currency in which, this principal amount of debt
                  securities may be purchased upon such exercise;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zd1bf7cd84eb3434bb2dd4ddd7a96b042" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at
                  which these shares may be purchased upon such exercise;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z4d0b2d1038db44caa706a87c2cc8dc4a" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and the warrants;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z31a7507159cd4da588009af7367cb74f" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">the terms of any rights to redeem or call the warrants;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">- 29 -</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div style="width: 100%;" id="DSPFPageHeader"><a href="#TABLEOFCONTENTS"><font style="font-size: 8pt; font-style: italic;"> Table of Contents</font></a></div>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zd690c999946d4d2980eaf931e1d6a2ac" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z917ba4cdb79549dc94b6e779a2a4b5f1" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">the dates on which the right to exercise the warrants will commence and expire;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zaa57ddaf67a6473788b29be5011fa941" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">the manner in which the warrant agreements and warrants may be modified;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z4102d7464a734411b6af2031a9237e42" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">United States federal income tax consequences of holding or exercising the warrants;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z0bde450ea56e4463a0aef28da6f63e95" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">the terms of the securities issuable upon exercise of the warrants; and</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z1aedd185fed44b0d87a9ef7d1a9bfc93" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">any other specific terms, preferences, rights or limitations of or restrictions on the warrants.</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zf49d9bd5749a4716ae8efc8fccd91953" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">before exercising their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable upon such exercise, including:</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z5403033161d848019e1aa53ded8e0869" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">in the case of warrants to purchase debt securities, the right to receive payments of principal of, or premium, if any, or interest on, the debt securities purchasable upon exercise or to enforce covenants in
                  the applicable indenture; or</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z9ccb8c4893ae4d868e488ebaac6799e3" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">in the case of warrants to purchase common stock or preferred stock, the right to receive dividends, if any, or, payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any.</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div style="font-weight: bold;">Exercise of Warrants</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">Each warrant will entitle the holder to purchase the securities that we specify in the applicable prospectus supplement at the exercise price that we describe in the applicable prospectus supplement. Unless we
        otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to the specified time on the expiration date that we set forth in the applicable prospectus supplement. After the close of
        business on the expiration date, unexercised warrants will become void.</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">Holders of the warrants may exercise the warrants by delivering the warrant certificate representing the warrants to be exercised together with specified information, and paying the required amount to the warrant agent
        in immediately available funds, as provided in the applicable prospectus supplement. We will set forth on the reverse side of the warrant certificate and in the applicable prospectus supplement the information that the holder of the warrant will be
        required to deliver to us or the warrant agent as applicable.</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">Upon receipt of the required payment and the warrant certificate properly completed and duly executed at the corporate trust office of the warrant agent or any other office indicated in the applicable prospectus
        supplement, we will issue and deliver the securities purchasable upon such exercise. If fewer than all of the warrants represented by the warrant certificate are exercised, then we will issue a new warrant certificate for the remaining amount of
        warrants. If we so indicate in the applicable prospectus supplement, holders of the warrants may surrender securities as all or part of the exercise price for warrants.</div>
      <div> <br>
      </div>
      <div style="font-weight: bold;">Enforceability of Rights by Holders of Warrants</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">If selected, each warrant agent will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder of any warrant. A single bank or
        trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility to
        initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right to
        exercise, and receive the securities purchasable upon exercise of, its warrants.</div>
      <div> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">- 30 -</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div style="width: 100%;" id="DSPFPageHeader"><a href="#TABLEOFCONTENTS"><font style="font-size: 8pt; font-style: italic;"> Table of Contents</font></a></div>
      </div>
      <div style="text-align: center; font-weight: bold;"><a name="DESCRIPTION"><!--Anchor--></a>DESCRIPTION OF UNITS<a name="DESCRIPTIONOFUNITS_082102"></a></div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">The following description, together with the additional information we may include in any applicable prospectus supplements and free writing prospectuses, summarizes the material terms and provisions of the units that
        we may offer under this prospectus.</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">While the terms we have summarized below will apply generally to any units that we may offer under this prospectus, we will describe the particular terms of any series of units in more detail in the applicable
        prospectus supplement. The terms of any units offered under a prospectus supplement may differ from the terms described below. However, no prospectus supplement will fundamentally change the terms that are set forth in this prospectus or offer a
        security that is not registered and described in this prospectus at the time of its effectiveness.</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from a Current Report on Form 8-K that we file with the SEC, the form of unit agreement that
        describes the terms of the series of units we are offering, and any supplemental agreements, before the issuance of the related series of units. The following summaries of material terms and provisions of the units are subject to, and qualified in
        their entirety by reference to, all the provisions of the unit agreement and any supplemental agreements applicable to a particular series of units. We urge you to read the applicable prospectus supplements related to the particular series of units
        that we sell under this prospectus, as well as the complete unit agreement and any supplemental agreements that contain the terms of the units.</div>
      <div> <br>
      </div>
      <div style="font-weight: bold;">General</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">We may issue units comprised of one or more debt securities, shares of common stock, shares of preferred stock and warrants in any combination. Each unit will be issued so that the holder of the unit is also the holder
        of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included security. The unit agreement under which a unit is issued may provide that the securities included in the unit may
        not be held or transferred separately, at any time or at any time before a specified date.</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">We will describe in the applicable prospectus supplement the terms of the series of units, including:</div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z1474c3adfee04311b60189384fbc8704" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z0d2cb64d6a15496182b37be5e47ef95e" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">any provisions of the governing unit agreement that differ from those described below; and</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z14d91ad3d16f43b7a5d8bb912fdcc39e" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units.</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">The provisions described in this section, as well as those described under &#8220;<font style="font-style: italic;">Description of Capital Stock</font>,&#8221; &#8220;<font style="font-style: italic;">Description of Debt Securities</font>&#8221;
        and &#8220;<font style="font-style: italic;">Description of Warrants</font>&#8221; will apply to each unit and to any common stock, preferred stock, debt security or warrant included in each unit, respectively.</div>
      <div> <br>
      </div>
      <div style="font-style: italic; font-weight: bold;">Unit Agent</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">The name and address of the unit agent, if any, for any units we offer will be set forth in the applicable prospectus supplement.</div>
      <div> <br>
      </div>
      <div style="font-weight: bold;">Issuance in Series</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">We may issue units in such amounts and in numerous distinct series as we determine.</div>
      <div> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">- 31 -</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div style="width: 100%;" id="DSPFPageHeader"><a href="#TABLEOFCONTENTS"><font style="font-size: 8pt; font-style: italic;"> Table of Contents</font></a></div>
      </div>
      <div style="font-weight: bold;">Enforceability of Rights by Holders of Units</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">Each unit agent will act solely as our agent under the applicable unit agreement and will not assume any obligation or relationship of agency or trust with any holder of any unit. A single bank or trust company may act
        as unit agent for more than one series of units. A unit agent will have no duty or responsibility in case of any default by us under the applicable unit agreement or unit, including any duty or responsibility to initiate any proceedings at law or
        otherwise, or to make any demand upon us. Any holder of a unit may, without the consent of the related unit agent or the holder of any other unit, enforce by appropriate legal action its rights as holder under any security included in the unit.</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">We, the unit agents and any of their agents may treat the registered holder of any unit certificate as an absolute owner of the units evidenced by that certificate for any purpose and as the person entitled to exercise
        the rights attaching to the units so requested, despite any notice to the contrary. See &#8220;<font style="font-style: italic;">Legal Ownership of Securities</font>.&#8221;</div>
      <div> <br>
      </div>
      <div style="text-align: center; font-weight: bold;"><a name="LEGAL"><!--Anchor--></a>LEGAL OWNERSHIP OF SECURITIES<a name="LEGALOWNERSHIPOFSECURITIES_082037"></a></div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">We can issue securities in registered form or in the form of one or more global securities. We describe global securities in greater detail below. We refer to those persons who have securities registered in their own
        names on the books that we or any applicable trustee or depositary or warrant agent maintain for this purpose as the &#8220;holders&#8221; of those securities. These persons are the legal holders of the securities. We refer to those persons who, indirectly
        through others, own beneficial interests in securities that are not registered in their own names, as &#8220;indirect holders&#8221; of those securities. As we discuss below, indirect holders are not legal holders, and investors in securities issued in
        book-entry form or in street name will be indirect holders.</div>
      <div> <br>
      </div>
      <div style="font-weight: bold;">Book-Entry Holders</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">We may issue securities in book-entry form only, as we will specify in the applicable prospectus supplement. This means securities may be represented by one or more global securities registered in the name of a
        financial institution that holds them as depositary on behalf of other financial institutions that participate in the depositary&#8217;s book-entry system. These participating institutions, which are referred to as participants, in turn, hold beneficial
        interests in the securities on behalf of themselves or their customers.</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">Only the person in whose name a security is registered is recognized as the holder of that security. Global securities will be registered in the name of the depositary or its participants. Consequently, for global
        securities, we will recognize only the depositary as the holder of the securities, and we will make all payments on the securities to the depositary. The depositary passes along the payments it receives to its participants, which in turn pass the
        payments along to their customers who are the beneficial owners. The depositary and its participants do so under agreements they have made with one another or with their customers; they are not obligated to do so under the terms of the securities.</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">As a result, investors in a global security will not own securities directly. Instead, they will own beneficial interests in a global security, through a bank, broker or other financial institution that participates in
        the depositary&#8217;s book-entry system or holds an interest through a participant. As long as the securities are issued in global form, investors will be indirect holders, and not legal holders, of the securities.</div>
      <div> <br>
      </div>
      <div style="font-weight: bold;">Street Name Holders</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">We may terminate a global security or issue securities that are not issued in global form. In these cases, investors may choose to hold their securities in their own names or in &#8220;street name.&#8221; Securities held by an
        investor in street name would be registered in the name of a bank, broker or other financial institution that the investor chooses, and the investor would hold only a beneficial interest in those securities through an account he or she maintains at
        that institution.</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">For securities held in street name, we or any applicable trustee or depositary will recognize only the intermediary banks, brokers and other financial institutions in whose names the securities are registered as the
        holders of those securities, and we or any such trustee or depositary will make all payments on those securities to them. These institutions pass along the payments they receive to their customers who are the beneficial owners, but only because
        they agree to do so in their customer agreements or because they are legally required to do so. Investors who hold securities in street name will be indirect holders, not legal holders, of those securities.</div>
      <div> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">- 32 -</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div style="width: 100%;" id="DSPFPageHeader"><a href="#TABLEOFCONTENTS"><font style="font-size: 8pt; font-style: italic;"> Table of Contents</font></a></div>
      </div>
      <div style="font-weight: bold;">Legal Holders</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">Our obligations, as well as the obligations of any applicable trustee or third party employed by us or a trustee, run only to the legal holders of the securities. We do not have obligations to investors who hold
        beneficial interests in global securities, in street name or by any other indirect means. This will be the case whether an investor chooses to be an indirect holder of a security or has no choice because we are issuing the securities only in global
        form.</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">For example, once we make a payment or give a notice to the holder, we have no further responsibility for the payment or notice even if that holder is required, under agreements with its participants or customers or by
        law, to pass it along to the indirect holders but does not do so. Similarly, we may want to obtain the approval of the holders to amend an indenture, to relieve us of the consequences of a default or of our obligation to comply with a particular
        provision of an indenture, or for other purposes. In such an event, we would seek approval only from the legal holders, and not the indirect holders, of the securities. Whether and how the legal holders contact the indirect holders is up to the
        legal holders.</div>
      <div> <br>
      </div>
      <div style="font-weight: bold;">Special Considerations for Indirect Holders</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">If you hold securities through a bank, broker or other financial institution, either in book-entry form because the securities are represented by one or more global securities or in street name, you should check with
        your own institution to find out:</div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="ze348addd7dbb4653949df6d097142baa" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">how it handles securities payments and notices;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z0c69b5d8f9294eb2ad9a5bccf6abaad2" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">whether it imposes fees or charges;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z9ca363643b484a9d93bf6fb88a2b7529" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">how it would handle a request for the holders&#8217; consent, if ever required;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z5ad5e3ad7b7b43aabc1bf86330fa64e4" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">whether and how you can instruct it to send you securities registered in your own name so you can be a legal holder, if that is permitted in the future;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z88e655f199d248f0aa44c833c7b43942" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">how it would exercise rights under the securities if there were a default or other event triggering the need for holders to act to protect their interests; and</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z1bfa183be4bf44e6b5ac3ebe6d5206aa" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">if the securities are in book-entry form, how the depositary&#8217;s rules and procedures will affect these matters.</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div style="font-weight: bold;">Global Securities</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">A global security is a security that represents one or any other number of individual securities held by a depositary. Generally, all securities represented by the same global securities will have the same terms.</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">Each security issued in book-entry form will be represented by a global security that we issue to, deposit with and register in the name of a financial institution or its nominee that we select. The financial
        institution that we select for this purpose is called the depositary. Unless we specify otherwise in the applicable prospectus supplement, The Depository Trust Company, New York, NY, known as DTC, will be the depositary for all securities issued in
        book-entry form.</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">A global security may not be transferred to or registered in the name of anyone other than the depositary, its nominee or a successor depositary, unless special termination situations arise. We describe those
        situations below under <font style="font-style: italic;">&#8220;&#8212; Special Situations When A Global Security Will Be Terminated</font>.&#8221; As a result of these arrangements, the depositary, or its nominee, will be the sole registered owner and legal holder
        of all securities represented by a global security, and investors will be permitted to own only beneficial interests in a global security. Beneficial interests must be held by means of an account with a broker, bank or other financial institution
        that in turn has an account with the depositary or with another institution that does. Thus, an investor whose security is represented by a global security will not be a legal holder of the security, but only an indirect holder of a beneficial
        interest in the global security.</div>
      <div> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">- 33 -</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div style="width: 100%;" id="DSPFPageHeader"><a href="#TABLEOFCONTENTS"><font style="font-size: 8pt; font-style: italic;"> Table of Contents</font></a></div>
      </div>
      <div style="text-indent: 36pt;">If the prospectus supplement for a particular security indicates that the security will be issued as a global security, then the security will be represented by a global security at all times unless and until the
        global security is terminated. If termination occurs, we may issue the securities through another book-entry clearing system or decide that the securities may no longer be held through any book-entry clearing system.</div>
      <div> <br>
      </div>
      <div style="font-weight: bold;">Special Considerations For Global Securities</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">As an indirect holder, an investor&#8217;s rights relating to a global security will be governed by the account rules of the investor&#8217;s financial institution and of the depositary, as well as general laws relating to
        securities transfers. We do not recognize an indirect holder as a holder of securities and instead deal only with the depositary that holds the global security.</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">If securities are issued only as global securities, an investor should be aware of the following:</div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z4788fede96414e5d9ba1711afee21178" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">an investor cannot cause the securities to be registered in his or her name, and cannot obtain non-global certificates for his or her interest in the securities, except in the special situations we describe
                  below;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zcf576429740042499df3d9de15dbbc98" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">an investor will be an indirect holder and must look to his or her own bank or broker for payments on the securities and protection of his or her legal rights relating to the securities, as we describe above;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z5bb104877ce04807a6ed93741dd73a06" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">an investor may not be able to sell interests in the securities to some insurance companies and to other institutions that are required by law to own their securities in non-book-entry form;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z3cc5936386b844b9abfdb61307308fac" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">an investor may not be able to pledge his or her interest in the global security in circumstances where certificates representing the securities must be delivered to the lender or other beneficiary of the
                  pledge in order for the pledge to be effective;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z8e2e7e1da9bc46449c0650b1cd161a44" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">the depositary&#8217;s policies, which may change from time to time, will govern payments, transfers, exchanges and other matters relating to an investor&#8217;s interest in the global security. We and any applicable
                  trustee have no responsibility for any aspect of the depositary&#8217;s actions or for its records of ownership interests in the global security. We and the trustee also do not supervise the depositary in any way;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zf814e3bc83fa4d5f9df30fffa0b0424d" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">the depositary may, and we understand that DTC will, require that those who purchase and sell interests in the global security within its book-entry system use immediately available funds, and your broker or
                  bank may require you to do so as well; and</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zc9b388350f0b49fb94941c79b2d982c3" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">financial institutions that participate in the depositary&#8217;s book-entry system, and through which an investor holds its interest in the global security, may also have their own policies affecting payments,
                  notices and other matters relating to the securities. There may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the actions of any of those intermediaries</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div style="font-weight: bold;">Special Situations When A Global Security Will Be Terminated</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">In a few special situations described below, a global security will terminate and interests in it will be exchanged for physical certificates representing those interests. After that exchange, the choice of whether to
        hold securities directly or in street name will be up to the investor. Investors must consult their own banks or brokers to find out how to have their interests in securities transferred to their own names, so that they will be direct holders. We
        have described the rights of holders and street name investors above.</div>
      <div> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">- 34 -</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div style="width: 100%;" id="DSPFPageHeader"><a href="#TABLEOFCONTENTS"><font style="font-size: 8pt; font-style: italic;"> Table of Contents</font></a></div>
      </div>
      <div style="text-indent: 36pt;">A global security will terminate when the following special situations occur:</div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z6c59bf0ee5b947408cf9aa4a70428b3e" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for that global security and we do not appoint another institution to act as depositary within 90
                  days;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zf860644d415147419450e42761b4240b" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">if we notify any applicable trustee that we wish to terminate that global security; or</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z83ce1c6b3d51495ca23877c766df7135" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">if an event of default has occurred with regard to securities represented by that global security and has not been cured or waived.</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">The applicable prospectus supplement may also list additional situations for terminating a global security that would apply only to the particular series of securities covered by the prospectus supplement. When a
        global security terminates, the depositary, and neither we, nor any applicable trustee, is responsible for deciding the names of the institutions that will be the initial direct holders.</div>
      <div> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">- 35 -</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div style="width: 100%;" id="DSPFPageHeader"><a href="#TABLEOFCONTENTS"><font style="font-size: 8pt; font-style: italic;"> Table of Contents</font></a></div>
      </div>
      <div style="text-align: center; font-weight: bold;"><a name="PLAN"><!--Anchor--></a>PLAN OF DISTRIBUTION<a name="PLANOFDISTRIBUTION_082302"></a></div>
      <div> <br>
      </div>
      <div>We may sell the securities being offered hereby in one or more of the following ways from time to time:</div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zbadd479c5a034e058515b4f02e06e6b5" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">through agents to the public or to investors;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zebdb3bffea054840b31d86f04c28265b" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">to underwriters for resale to the public or to investors;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z1d845c31f9ee454daf4e1bf81ba033c8" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">negotiated transactions;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z42bdfcb4a58d49d59b7fdf8fc58dc36b" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">block trades;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="ze371d10efb064bb1b0d5bb61e79a6e1f" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">directly to investors; or</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z59be3010150b476e9b378abd8a305d45" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">through a combination of any of these methods of sale.</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>As set forth in more detail below, the securities may be distributed from time to time in one or more transactions:</div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z60a1e40611e7438f9f628c50a1c8e259" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">at a fixed price or prices, which may be changed;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z512b12eae6d74bc9a4386aeae2d01397" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">at market prices prevailing at the time of sale;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z0daa03a63479428988044aa160887779" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">at prices related to such prevailing market prices; or</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zed35f79aed4944cd9b2a6e6133c550d5" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">at negotiated prices.</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>We will set forth in a prospectus supplement the terms of that particular offering of securities, including:</div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z4f0daef0e0914390bc49179d3982d12b" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">the name or names of any agents or underwriters;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zed4abc0d088748c3807b6d58090c14ef" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">the purchase price of the securities being offered and the proceeds we will receive from the sale;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zf938db78e0d4450bafc97804026ab06e" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">any over-allotment options under which underwriters may purchase additional securities from us;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zef2db99a97624388b78226fe513c1d3f" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">any agency fees or underwriting discounts and other items constituting agents&#8217; or underwriters&#8217; compensation;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z1c7940b371df4930a7fe8675977a1b61" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">any initial public offering price;</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zc3d265804f894fd0ba497bdc5db81797" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">any discounts or concessions allowed or re-allowed or paid to dealers; and</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zf7b0e012f7f247c2aa4a490ca05d869c" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;">any securities exchanges or markets on which such securities may be listed.</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">Only underwriters named in an applicable prospectus supplement are underwriters of the securities offered by that prospectus supplement.</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">If underwriters are used in an offering, we will execute an underwriting agreement with such underwriters and will specify the name of each underwriter and the terms of the transaction (including any underwriting
        discounts and other terms constituting compensation of the underwriters and any dealers) in a prospectus supplement. The securities may be offered to the public either through underwriting syndicates represented by managing underwriters or directly
        by one or more investment banking firms or others, as designated. If an underwriting syndicate is used, the managing underwriter(s) will be specified on the cover of the prospectus supplement. If underwriters are used in the sale, the offered
        securities will be acquired by the underwriters for their own accounts and may be resold from time to time in one or more transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined at the time
        of sale. Any public offering price and any discounts or concessions allowed or re-allowed or paid to dealers may be changed from time to time. Unless otherwise set forth in the prospectus supplement, the obligations of the underwriters to purchase
        the offered securities will be subject to conditions precedent and the underwriters will be obligated to purchase all of the offered securities if any are purchased.</div>
      <div> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">- 36 -</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div style="width: 100%;" id="DSPFPageHeader"><a href="#TABLEOFCONTENTS"><font style="font-size: 8pt; font-style: italic;"> Table of Contents</font></a></div>
      </div>
      <div style="text-indent: 36pt;">We may grant to the underwriters options to purchase additional securities to cover over-allotments, if any, at the public offering price, with additional underwriting commissions or discounts, as may be set forth in a
        related prospectus supplement. The terms of any over-allotment option will be set forth in the prospectus supplement for those securities.</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">If we use a dealer in the sale of the securities being offered pursuant to this prospectus or any prospectus supplement, we will sell the securities to the dealer, as principal.&#160; The dealer may then resell the
        securities to the public at varying prices to be determined by the dealer at the time of resale.&#160; The names of the dealers and the terms of the transaction will be specified in a prospectus supplement.</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">We may sell the securities directly or through agents we designate from time to time.&#160; We will name any agent involved in the offering and sale of securities and we will describe any commissions we will pay the agent
        in the prospectus supplement. Unless the prospectus supplement states otherwise, any agent will act on a best-efforts basis for the period of its appointment.</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">We may authorize agents or underwriters to solicit offers by institutional investors to purchase securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery
        contracts providing for payment and delivery on a specified date in the future. We will describe the conditions to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement.</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">In connection with the sale of the securities, underwriters, dealers or agents may receive compensation from us or from purchasers of the common stock for whom they act as agents in the form of discounts, concessions
        or commissions. Underwriters may sell the securities to or through dealers, and those dealers may receive compensation in the form of discounts, concessions or commissions from the underwriters or commissions from the purchasers for whom they may
        act as agents. Underwriters, dealers and agents that participate in the distribution of the securities, and any institutional investors or others that purchase common stock directly and then resell the securities, may be deemed to be underwriters,
        and any discounts or commissions received by them from us and any profit on the resale of the common stock by them may be deemed to be underwriting discounts and commissions under the Securities Act.</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">We may provide agents and underwriters with indemnification against particular civil liabilities, including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters
        may make with respect to such liabilities. Agents and underwriters may engage in transactions with, or perform services for, us in the ordinary course of business.</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">We may engage in at the market offerings into an existing trading market in accordance with Rule 415(a)(4) under the Securities Act.&#160; In addition, we may enter into derivative transactions with third parties (including
        the writing of options), or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If the applicable prospectus supplement indicates, in connection with such a transaction, the third parties may,
        pursuant to this prospectus and the applicable prospectus supplement, sell securities covered by this prospectus and the applicable prospectus supplement. If so, the third party may use securities borrowed from us or others to settle such sales and
        may use securities received from us to close out any related short positions. We may also loan or pledge securities covered by this prospectus and the applicable prospectus supplement to third parties, who may sell the loaned securities or, in an
        event of default in the case of a pledge, sell the pledged securities pursuant to this prospectus and the applicable prospectus supplement. The third party in such sale transactions will be an underwriter and will be identified in the applicable
        prospectus supplement or in a post-effective amendment.</div>
      <div> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">- 37 -</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div style="width: 100%;" id="DSPFPageHeader"><a href="#TABLEOFCONTENTS"><font style="font-size: 8pt; font-style: italic;"> Table of Contents</font></a></div>
      </div>
      <div style="text-indent: 36pt;">To facilitate an offering of a series of securities, persons participating in the offering may engage in transactions that stabilize, maintain, or otherwise affect the market price of the securities. This may include
        over-allotments or short sales of the securities, which involves the sale by persons participating in the offering of more securities than have been sold to them by us. In those circumstances, such persons would cover such over-allotments or short
        positions by purchasing in the open market or by exercising the over-allotment option granted to those persons. In addition, those persons may stabilize or maintain the price of the securities by bidding for or purchasing securities in the open
        market or by imposing penalty bids, whereby selling concessions allowed to underwriters or dealers participating in any such offering may be reclaimed if securities sold by them are repurchased in connection with stabilization transactions. The
        effect of these transactions may be to stabilize or maintain the market price of the securities at a level above that which might otherwise prevail in the open market. Such transactions, if commenced, may be discontinued at any time. We make no
        representation or prediction as to the direction or magnitude of any effect that the transactions described above, if implemented, may have on the price of our securities.</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">Unless otherwise specified in the applicable prospectus supplement, each class or series of securities will be a new issue with no established trading market, other than our common stock, which is listed on The Nasdaq
        Capital Market. We may elect to list any other class or series of securities on any exchange or market, but we are not obligated to do so. It is possible that one or more underwriters may make a market in a class or series of securities, but the
        underwriters will not be obligated to do so and may discontinue any market making at any time without notice. We cannot give any assurance as to the liquidity of the trading market for any of the securities.</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">In order to comply with the securities laws of some U.S. states or territories, if applicable, the securities offered pursuant to this prospectus will be sold in those states only through registered or licensed brokers
        or dealers. In addition, in some states securities may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and complied with.</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">Any underwriter may engage in overallotment, stabilizing transactions, short covering transactions and penalty bids in accordance with Regulation M under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange
        Act&#8221;). Overallotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum. Short
        covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities
        originally sold by the dealer are purchased in a covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of
        these activities at any time.</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">Any underwriters who are qualified market makers on The Nasdaq Capital Market may engage in passive market making transactions in the securities on The Nasdaq Capital Market in accordance with Rule 103 of Regulation M,
        during the business day prior to the pricing of the offering, before the commencement of offers or sales of the securities. Passive market makers must comply with applicable volume and price limitations and must be identified as passive market
        makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security. If all independent bids are lowered below the passive market maker&#8217;s bid, however, the passive market maker&#8217;s
        bid must then be lowered when certain purchase limits are exceeded.</div>
      <div> <br>
      </div>
      <div style="text-align: center; font-weight: bold;"><a name="LEGALM"><!--Anchor--></a>LEGAL MATTERS<a name="LEGALMATTERS_082335"></a></div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">The validity of the issuance of the securities offered hereby will be passed upon for us by Sheppard, Mullin, Richter &amp; Hampton LLP, New York, NY. Additional legal matters may be passed upon for us or any
        underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement.</div>
      <div> <br>
      </div>
      <div style="text-align: center; font-weight: bold;"><a name="EXP"><!--Anchor--></a>EXPERTS<a name="EXPERTS_082357"></a></div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">The financial statements of the Company as of December 31, 2018 and 2017 and for each of the two years in the period ended December 31, 2018 incorporated by reference in this Prospectus have been so incorporated in
        reliance on the report of Ram Associates, CPA, an independent registered public accounting firm incorporated herein by reference, given upon their authority as experts in accounting and auditing.</div>
      <div> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">- 38 -</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div style="width: 100%;" id="DSPFPageHeader"><a href="#TABLEOFCONTENTS"><font style="font-size: 8pt; font-style: italic;"> Table of Contents</font></a></div>
      </div>
      <div style="text-align: center; font-weight: bold;">WHERE YOU <a name="CAN"><!--Anchor--></a>CAN FIND MORE INFORMATION<a name="WHEREYOUCANFINDMOREINFORMATION_082359"></a></div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">This prospectus constitutes a part of a registration statement on Form S-3 filed under the Securities Act. As permitted by the SEC&#8217;s rules, this prospectus and any prospectus supplement, which form a part of the
        registration statement, do not contain all the information that is included in the registration statement. You will find additional information about us in the registration statement. Any statements made in this prospectus or any prospectus
        supplement concerning legal documents are not necessarily complete and you should read the documents that are filed as exhibits to the registration statement or otherwise filed with the SEC for a more complete understanding of the document or
        matter.</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">You may read and copy the registration statement, as well as our reports, proxy statements, and other information, at the SEC&#8217;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC
        at 1-800-SEC-0330 for more information about the operation of the Public Reference Room. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically
        with the SEC. The SEC&#8217;s Internet site can be found at http://www.sec.gov. You can also obtain copies of materials we file with the SEC from our website found at www.ameri100.com. Information on our website does not constitute a part of, nor is it
        incorporated in any way, into this prospectus and should not be relied upon in connection with making an investment decision.</div>
      <div> <br>
      </div>
      <div style="text-align: center; font-weight: bold;">INCORPORATION OF <a name="DOCUMENTS"><!--Anchor--></a>DOCUMENTS BY REFERENCE<a name="INCORPORATIONOFDOCUMENTSBYREFERE_082402"></a></div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">We have filed a registration statement on Form S-3 with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) under the Securities Act of 1933, as amended. This prospectus is part of the registration statement,
        however the registration statement includes and incorporates by reference additional information and exhibits. The SEC permits us to &#8220;incorporate by reference&#8221; the information contained in documents we file with the SEC, which means that we can
        disclose important information to you by referring you to those documents rather than by including them in this prospectus. Information that is incorporated by reference is considered to be part of this prospectus and you should read it with the
        same care that you read this prospectus. Information that we file later with the SEC will automatically update and supersede the information that is either contained, or incorporated by reference, in this prospectus, and will be considered to be a
        part of this prospectus from the date those documents are filed. We have filed with the SEC, and hereby incorporate by reference in this prospectus:</div>
      <div> <br>
      </div>
      <div style="text-indent: 15pt; margin-left: 36pt;">1.&#160; &#160;&#160; <a href="http://www.sec.gov/Archives/edgar/data/890821/000114036119005573/form10k.htm">Our Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on March 26,
          2019, as amended on April 30, 2019;</a></div>
      <div style="text-indent: 15pt; margin-left: 36pt;"> <br>
      </div>
      <div style="text-indent: 15pt; margin-left: 36pt;">2.&#160; &#160;&#160; <a href="http://www.sec.gov/Archives/edgar/data/890821/000114036119009043/form10q.htm">Our Quarterly Reports on Form 10-Q filed with the SEC on May 14, 2019 and August 14, 2019;</a></div>
      <div> <br>
      </div>
      <div style="text-indent: 15pt; margin-left: 36pt;">3.&#160; &#160;&#160; <a href="http://www.sec.gov/Archives/edgar/data/890821/000114036119003195/form8k.htm">Our Current Reports on Form 8-K filed on January 25, 2019; February 14, 2019; April 2, 2019 and June 17,
          2019; and</a></div>
      <div> <br>
      </div>
      <div style="text-indent: 15pt; margin-left: 36pt;">4.&#160; &#160;&#160;<a href="http://www.sec.gov/Archives/edgar/data/890821/000119380517001663/e616570_s1-ameri.htm"> The description of our common stock contained in the registration statement on Form S-1 (File
          No. 333-220499) originally filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;) on September 18, 2017, as amended.</a></div>

      <div><br>
      </div>
      <div style="text-indent: 36pt;">We also incorporate by reference all documents (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such form that are related to such items) that are subsequently filed
        by us with the U.S. Securities and Exchange Commission pursuant to Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act prior to the termination of the offering of the securities made by this prospectus (including documents filed after the date
        of the initial Registration Statement of which this prospectus is a part and prior to the effectiveness of the Registration Statement). These documents include periodic reports, such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q,
        and Current Reports on Form 8-K, as well as proxy statements.</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">Any statement contained in this prospectus or in a document incorporated or deemed to be incorporated by reference into this prospectus will be deemed to be modified or superseded to the extent that a statement
        contained in this prospectus or any subsequently filed document that is deemed to be incorporated by reference into this prospectus modifies or supersedes the statement.</div>
      <div> <br>
      </div>
      <div style="text-indent: 36pt;">You may request, and we will provide you with, a copy of these filings, at no cost, by calling us at (770) 935-4152 or by writing to us at the following address:</div>
      <div> <br>
      </div>
      <div style="text-align: center; font-weight: bold;">AMERI Holdings, Inc.</div>
      <div style="text-align: center; font-weight: bold;">5000 Research Court, Suite 750,</div>
      <div style="text-align: center; font-weight: bold;">Suwanee, Georgia, 30024</div>
      <div style="text-align: center; font-weight: bold;">(770) 935-4152</div>
      <div style="text-align: center; font-weight: bold;"> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">- 39 -</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div style="width: 100%;" id="DSPFPageHeader"><FONT STYLE="font-size: 8pt"></FONT></div>
      </div>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="form424b5_002.jpg" ALT="" STYLE="height: 47; width: 195"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>1,610,679 Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Pre-funded Warrants to Purchase up to 610,679
Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 50%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Prospectus
Supplement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>January
12, 2021</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 50%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>














</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>form424b5_001.jpg
<TEXT>
begin 644 form424b5_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0S!WT# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *2EIA)W@4GL ZD(I:#460,!TI:**T0!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)2T@I,!:***
M8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(:6D- F<KXK;
M_1C]*\N<CSR:]2\5K_HI^E>7,H\YJ]##)''58T,-V/6I6*A<5%MY)]*,YKTU
M%'(WJ*I#<TT_*3[U(%"TU@#3Y43=B*>,4'DY]* ,"GX&*.5#N-ZTW;@8-2<
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M61H6/L,?TK7KQ:OQ,]*E\(4445F:A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#2TAH$SF/%7-J?85Y
M4W^O8UZIXK.+;\*\NDQYQKT\+LCCK"#@_6EI%ZTM>JC@>XF:7-%% !1FBB@
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M80T4<TIHYD%A*FL%Q>)]:A%3:?G[6N?6LJLM"X+4]=T(_P"AH/:M?-9&A_\
M'G']*U^U>+5^(].GL+11162- HHHI@%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 (:*6B@1ROBQO\ 1OPKRUW_ 'I-
M>K>*(C)!QZ5YC/9R?:#@<5V4)6.:JBL#@_6EW<X]*G%G(3TI?L4F>E=RJ:'+
MR%??QGTI=W'UJ?[%)CIQ1]CD Z57M Y"ONYQ1NXSZ58%G(>W-'V-_2CV@<A7
MW\9]:1GQQ5@V4FWI3192GJ.:7M!<A$)-P^E(LV&S4QLI >!]:7[$_7%-5 Y"
M)I-H^M)YFY<59^Q.5Z4?87"=*?M$)Q*\;8&:5Y<#ZU.MH_I2?8G.<CZ4I5 Y
M"LCY.*&DR<^E6!92 ]*4V3^E3SCY2N7^4'UI0W.*E^Q2>E#64N. <TO:#42$
M/G/M1NXS4ZV4F.GUI19R8Z4>T&H$&[M1NYQ4_P!BDSTH^Q2>E+V@<A7W<9I=
MWZU-]BDQTH^Q2>E'.'*0[N<5-8M_I:GWI?L4G/%/L+5_M:Y'>HG.Z*C$]9T'
MFR0^U:]9&A*5LT!]*V*\VKN=M/8****S1H%%%%, HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBBB@ HHHH **** "BBB@ HI <TM !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E%!.!20,,48I:*8K"
M8HQ2T4#L)BC%+10%A,44M% "8HQ2T4 )5>Z_U=6:BG&8S1<5C)MF)N@:VAR*
MQ[?'VP8Z5LCI3N"0WO2XI:*06$Q1BEHH'83%&*6B@!,48I:*!6$Q1BEHH'83
M%&*6B@+#6.*44$9I:7484444Q!1110 4444 %%%% !1110 4444 %%%% !11
M10 444A.* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **3-!.* %HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JMU<")>M
M6JPM:+^9A330%X7@V YH^VC'6L:&*9H^]/\ LMQL[T@-6.^# \]*=]L&!S6,
MEK<9XSBGBUN,GKB@#7^V#=C-"W@)/-9'V6XV]\T&VN.,9]Z -G[6,=11]K7/
M45C_ &>XW=\4GV:YP>M(#8-VOK3!>#&<UDFVN2!UH^RW /?%5H3U-?[8..>M
M'VP9QFLC[+<<]?:C[+<X[YI,9L"\&T\TGVT<<UCBUN<]Z#:W.>]*XS9^V#=C
M-+]L7GD5C?9;G'?-'V:Y]Z%N,V/M@V@YH-X,@9K'-K<^]'V:YV]\U3V$;'VM
M<]:#> #K6.;:YP.M(UM<$]ZA"U-G[8,CGK1]L7?C-8WV:Y]Z/LUSG/-6,VC=
M@*3F@78P.:QVMKD],TBVUR!SFIZ ;/VQ=^,T&[7!Y%8OV:YSGFG-;7)'&:8&
MP+L%<YI#>+N S6.EM<CKFD-K<Y[T@-D7BY//2C[8-N<UC?9;GWI/LMS[TP-K
M[6N1SUI_VI?45A_9;GWI_P!GN=H&33T UOMB[2<TAO5P/F'-8D\-PG.3BJT<
M=RTG4T.P'3"Z4<9H-VN#S6/]GN=G?-(+:YSSFD!L&\&T'-+]K&X#-8S6USGO
M2BVN=O?- &N+Q<GGI3?MH]:R!;7.>]*]I<9R,TP-<W@XYH6]![UDBUN-O.::
M+6Y![T ;'VP;>M*;P8'-9'V6XW=\4?9KCGK[4@-<7@W8S0+P<\UD?9;C;WS0
MUM<<8S0"-<W@P#F@W@W8S6.+:X[YH^RW..^:+@S9^UKZBC[4OK6,UM<\=:46
M]SGOBF2;!O%W 9I/M@SUK&-M<YSS3C;7&!UI%&N+L$9S2F[&1S60+:X#=\4"
MVN.>OM3$;/VI<=13!>#!YK(^SW.S&31]FN,CK2&:YO!M'- NQNQFLC[-<9/7
M%'V:XV]\TQ=39^UKZBC[4,=:QOL]SQUI3;W.[OBD!L&[7U%-%X"3S61]GN=I
MZT?9KGCK3 US> #K3OM:X'-8QMK@MWI1;W.#UH UOM:E\9IQNE]16&+>YW=Z
MD:WN,CDT#L:DUZJ ?,*<EXI'45SEW%<C')J2UAN6CZFGH%CH!=CGFC[4.N:R
M/LUQQC/O2&"X#=\4GN)FP;P;@,T&['K6-]FN<9YH^S7.!R:D#8%X"N<T&\&>
MM9'V:X![XI/LMSSUH V/M@W'FD^VC!YK(^RW..^:/LMQGO3N!L?;!@<]:/M@
MW8S60+:XYSFC[-<X[YI7&:XO!@\T?;!M!S61]EN..OO2-;7.>^*I ;7VI?44
M@NU)/-8XM[G;WI!;7(/>FK"-DW8"]:0W@!'-9/V:YSWQ2"VN,'K28(UOM@SU
MI/MHQUK)^RW..^:/LMQGOBI8&M]L&,YH%V&XS64+6XYSFC[+<!>^:$,UUNQ@
M\]*7[6N,YK':VN,#&:06]SWS0Q,V?M:YZTAO .]8WV:Z]Z7[-<G'6@#8%X".
MM'VP9ZUD?9KC=WI/LMQSUIAJ; O 6(S3OM8QU%8WV:YP.M+]GN-_>@#8^UCC
MD4&['K6/]FN<GK2K;W&.<T :HO!@G-13WH$).>U9_D38[U'-;S&$]>E QEG>
M#[7@GO6]]J 7.17&6]M/]IXSG-;@M[@Q]Z -878*YS2BZ7U%8J6UP#WIPM[G
M!ZT :PO!N(S2F[ 7K6/]FN !US2_9K@MWQ0!K_:Q@<TANQNQFLD6UQSU]J3[
M+<;>^:.HC6^V#!YH^V# YK)-K<9'6E^S7&3UIA8UOM@W8S2"]'/-8_V6Y]Z/
MLMS[T ;'VT;<YH-Z,@9K(%K<>]--K<Y[U+ V?MHR>:3[:,9S60;6YQWI/LMS
M[TD,VOMBY'/6G?:UW8S6)]FN?>E-M<X[U?0$;'VP8/--:] QS62+:YW=\4C6
MMP3WJ.HV:YO0.]"WH(/-8YM+DCO1]DN1ZTR39^V#;UIWVI?45C+:W(ZYH^SW
M.#UJ@-G[6OJ*0W8 SFL<VUS@=:7[+<9[XI7%8U_M@R.:/M@SUK'^RW'/6C[+
M<X[T#U-?[:,'FG?:UP#FL9K6X]Z!;W('.: Z&P+Q=V,TOVM?6L7[+<Y[TOV:
MY)'6@&;7VM?45')>*#C-97V>XW=ZJ74=PIQDYI@=(MTNWJ*/M2XZBL&"*Y=!
MR:E^SW.[O0#-@W8R.:4W:^HK%^S7/O2?9[GWI ;/VP;2<T&\&!S6-]FN?>C[
M-<^]5H,VOM8W8S2?:P03GI6-]FN?>E%M<Y[T@-@W@VCF@W8SC-8YMKG/>C[-
M<[>^:-!,U_M@YYH^V#;UK(^S7''6E^RW&>^*&!KF\ (YH%X,GFLC[-<8/6C[
M-< #K4C-;[:,=:4W@XYK(^RW&[OB@6UQSU]J -?[8-V,T"\&#S6/]FN<=\TO
MV:X]Z8C7-X-H.:/M@W8S61]FN,GK2?9KG'?- [FQ]L'/-'VP;<YK(-M<<=?>
ME^S7&[OBD!K?;!D<TINQZUC?9KGGK2FVN<#DTQ,V!=@CK2&\ (YK(%M<@]Z3
M[+<\]: -C[8,]:07@P>:R/LMSCOFC[+<9'6F&IKF\&!S2_;!GK6/]EN,]Z/L
MMQCO28:FP+P'/-'VH>M8_P!FN.,9I5M[C?WI7#4U_M0#=:8UZN[&X5E26]QM
M/7-462X\P#)SFJ0'3?;!LSFC[8..>M8R6]P0.N*46UQSUHZ@;/VL;B,TGVP;
M3S6/]FN<=\TOV6XSWI#-?[8,#FE^UC=C-8XMKCGK2?9KG'?- C8^V#GFD^V#
M;G-9/V6XR.M+]FN-QZXI@:HO1G&:47@YYK&^RW.>]'V6Y]Z0S9^V#;G-!O%R
M.>M8Z6UQGG.*0VUSGO0!L_;!NQFD%X#WK)-M<%1US1]FN-W>DQ&Q]K'K1]K'
MK6/]FN=W>AK:XQWH%J:XO >]!O .]8_V:X]Z/LUQG/- &P;P;AS0+P'/-8_V
M:YQWS1]FN..M S8^V#;G-.^UKQS6,;:XSWQ0+:YVGK1<9K_;!D\TGVP8ZUD?
M9KG ZYH-K<]LTT(V/M@XYI?M8W8S6,+:YQWIWV:XV]\U0(US=C!YH%V,=:R#
M;7&1UH%O<9/6D,U_M8W8S2_:Q@\UC_9KC;WS0;>XXZT :XNP5ZT?:QZUD?9[
MC=WQ2"&<9R30)FNEX&<C-6D<,.M<N?.23J:V[ NR@FD"-"BBB@84444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;'K0!K;!CI1Y8]*>.E% #-@]*-@]*?12 9L'I2[!C&*=13 ;L'I1L&>E.HH
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M2[!GI3J* &;!CI1L&.E/HH 9L'I1L'I3Z* &;!Z4;!Z4^B@!FP>E&P>E/HI
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MO>@1E7L C;=ZFK=B0(\57U0D*/K4NG ^3S2"Y?HH[44QA1110 4444 %%%%
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MYA])D4FX4P@[J+%$M%%%( HHHH **** "BBB@!FW+9I)7V+FGU5OFQ;.?:E
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MU7[3* #FMY3E<UYEX3NVD?YCDYKTF _NEKFJ1L=$'<EHHHK(T"BBB@ HHHH
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MZ<SA^.E:=OI1*$X[4VTB;:G-V-L7G"XI^H61MLL!UKI-.TDI=\CO5C6=.#*
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MR;]AVK-'0"M372#?L*S0>17L4#S*FX[[JYJ,DE\"GR.,4MM"9'Q7;T,4)DG
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M.F\(#_2U)]:]5B^X*\K\*\WB8[&O4HON"O&Q*U.^BR6BBBN4Z@HHHH ****
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M=8G_ $I<^M>O>'R39+FO(;+F[4>]>P:#_P >2_2O+Q)W89FO1117"=H4444
M5K[_ (]FKQK6R?[3D_WJ]EOO^/9OI7C>MG.I/_O5V88YJVQ3;YC3>1Q3@<-F
MC(KU8/0\Z6XTT+DD>N:*FLE\V\4=J;V&CM='MRMJC8ZCFK=Y%YL>.U+#(MMI
MX_W:9:7:W";:Y6W>YHB.U7R;=^QK/@G+7K#WK3N"$A8BN?L),ZFY]ZHUN;+D
MB[7TQ5N64% A[TCP[Y!CTJO<1E98SGH:6YFQMW/]DA7!QS5B!1=0Y/-4M4MV
MN(59?6K>G_Z-;8:A[70[]R>=EM84'2JEV#-;Y'-0ZQ/YB1[3T-6M/82VV326
MBU"Y!I<920@CO4VM(OV9OI5F"()(?>JNN<6K"B]Y:#.1T9B-2Q_M5K>)\B",
MBL;1C_Q,P?\ :KI]:M?/MXR*TD]17*_AMS]E.:S_ "]VK,3_ 'JV=*MC#;;:
MKM;>7>!_?-1YA<?KBLNEKMZUQ,?F ,".]>BW40N+0#K7-76F^2C<5<&!AKD]
M:4DXS3V&TD>E1YXS70C.6XJDU&Y.X4_=S]::Y^85G5V""._\%?ZL?6N]%<'X
M+.4'UKO:\:N_>/1I+0****P-@I#2TAH$SF/%7_'JWTKRPD^<3WKU+Q4<VI]A
M7ECG$Q/O7J838X:^H%B'!I9I"4%!Y0FF*/,7'I7IK8X['2>'#N7WS5S5MWFQ
M@=SS6=X<E".![UOW40FD4X[US3W+6P^UM5:V&15ZTM51&;TIJ+Y5L*?'< PM
MCM7.VS1,;<E& 7O5:8"W3<*IRW!6XR3QFK5W^_M]J]2*I7L/<=9R&Z8YYQ4U
MX1;QYZ5'I,)@#%JJZ]<93Y:6O-8M(6RF,TN%YYK0N)GA'S<"LWPVGSY;G)K1
MUT@J%7J#2E+WK%6(7Q/;EAR:I63,EUM]3S5O3UQ 2U206>;@N/6B]A-$/B"(
M-:DUYW*6$K#WKT;63F#R^]<?-IY.Z3' K2G?E,I1N/T'B?/<UUAS),JG[N*X
M[29?+OMOJ:[9\1HK>U.3"*&7=P+=XD!ZU-]F$J^9CFL:_D,T\1!^Z:VK*Z7R
ML'TK-II:%M&+J=ZULVT&N8U"9[H ]:ZG6-/:Y)9:PEL#&"&[5T4V9R,9=RBG
MDDXJ>X0)DXJ"+YC6K>A%AWW>*GL2?M:'WJ"48XJ>Q8?:DK*IJC2&C/7=#_X\
MHSWQ6M6/H/\ QYH?:MBO$J_$ST:;O$****S+"F2_ZMOI3Z9+_JS]*:W$]CRO
MQEG[2Q[US&3M6NH\8\W;&N8)PH]Z]6@]#@JG9>&E+0+GIBM.]NQ#QGFJ'AQ@
MMB/4"LG7;X_:N#P*TDKR,XG26\_F1%L]158S!IO+S5729=]KG/45%;N3JNS-
M-*Q=S85AC:>],>TVGS .M074VRZB ]:V)&7[ ']JF3:)N4%(+#%6XQN7FJ&G
M?OMP]ZTW'EICTJ9/H-$4LY2,J*AM1]YJ9(/,;(J>W7;&P]:6PQ\DJ^4P)[5P
M&KG.H@KZUUE\653@UR=S\]\K&M8:".JC)_L5?]RN?TK<-1YZ5TUJ@DTT(/[M
M9UM9>7<YQ33$;D*ABI/:HGN?*NB,TZ%\$>U9-TY;4&P>]0]P-6XN0"!GK4B(
M)$#5C7;$.HSVK:LV'V4>PJ7H%QH?RY..M0S2%YT!IKR@W'6GR1;2K46"Y>DQ
M';+52-E8$]ZDG;?:A0>E9D+D7 7-);#+4LI21<53UR3=9\U;EA+.IJAKBE;/
M;5P"Z./+9#UT'A/_ (^Q7.$<M]:Z/PHV+L5E7V+@M3U>+_5K]*DJ.+_5K]*D
MKS&=T=@HHHI#$KE?%I(M'KJC7*^+3_HCGVK2GN8U-CRY<F=_K2E2),=J(V"S
MR9[FGF5=Y%>K16AP3>HW[QIKKMY% ?#$T[=NY]:Z%&QFI$7+<58"_NCGTJ$<
M'%2A\C'I56&GJ5E7$F>]6%3S#BF'@[JNZ5'YLX'O2:&-\@HO(IJ0[N<5J:G&
M(5'%16<?F1[\4K%HSID"KBJ:LP..U:=Q&6E*@=3318L%QCFE9#,X2,QJ]$C,
M@XI@M"LF<=*U;2,8QCK2LB;&+=1.O04D3DI\W:NF?2_-CZ5A7ML8'VXHT+16
M=LJN.N:=<G$6T=Q3XX&V[B.*:4,C[<4K .TV%F#<=J>\127..:W-)L_W1XZ"
ML[4L13FK21+9F[-Q:FJ,-CM4@<+GWIH89I-:DMBE/FS4AX48IC2 \TTR=/>F
MHBN#%@,=JC0LS?2K.1LQ3(L D^E+E+3'6@(O5]<BO8M%&+)?H*\?LY0=07ZB
MO8](_P"/)/H*\[%Z'32W-+M24=J*\][G6A:3O2TG>F C_=->6>+,_:V]S7J3
M_=)KR_Q6?]+;ZUT4-S"KJ<J>#BKNGM_ID>?6J1;YL58L7_TM#Z&O5IO0\^2N
MSK]5+?V8"O7%<+:O*;[:0<$UZ&5%S9!>N16$NC^3<[B.])=BTC=TA/W: ^E7
M+V,*_%-LE"(GM4MZX)W5E)^\45WZJ!4\<FRH%(WK[TVX;#8%(I,>TOGS &JF
MH2?963;W/-*S^1.K'TJ.^0W85EII";+T(6XM58U%?W?V:+:#CBBS;R+<(3R*
MSM;!E *GI3MJ1(U8) ]@)NY%16<HN8V4GO52&?R](5#UQ4>C,8XV8GO328)V
M-'R,))^E0Z?GS\5<\U71L4VR@_?[^U#>CN41>((A]B;'I7GV"DC5Z3JP\R I
M[5PU[:%-QQ3I/04[,DT-LW(/>NMVAW0&N/T+BY!]ZZU9 '4UI)W)1--.()/+
MSQ5@QB2/S.X%8FH.6N00>];UL0;+/M6#T*V.?U6Z:/ 'K7-W<IEDSVKH]5M&
MERPK%%BWDG-=">A+V,Q'()IIR6SWJ21-KGVIA< YI-Z&=]3H_">?MB_6O4XO
MN"O+?")'VI?K7J47^K%>9B=SNHDM%%%<AUA1110 4444 %%%% !56]_X]7^E
M6>U5;X?Z*_TIQW(GL>1:YC[>Q[UE@"M/71_Q,&-9@'RGWKV<.KGFU!^\8Q5_
M1YO*G#$\@UE!26Q4\;&-@0:ZY1T,E*QJZU=^:.M/\/W@C8 GBL:5S+D$]:2U
M9H6V@USN)HI:'>OJ28^]6>^HKO;YNM<TUV^X?,>*C:9@V[)YHY+!S7-)YU74
M%?-;AODEB0%NE<A+N)!SS4JW#*%Y/%'*.YO:A=KY/E@TEC>+#&?FZU@23---
MUXIAE93MSUHY1\QU,&IA[@J6XIU[<K%<JRGM7*H[QN&R:GN;HR@/GH*.0.8W
M;V\66WQGM46D2)$^[-8)N&V=>M26]P0F :?(%SL%O$F?D]*R];5/*R.IK*LK
MLAV)/0U+?S>;%UHY2+ZB:-.L3X)XS6O-J .0&KE(V:,\&I5N&<,<]*?*/F-R
M"X7[1O)YJZNI 3+\W%<OYK"'S >M(LS>66R:7+<KF.SNKJ)X<EA6:)H_+//-
M8GVIY(0-QXJ..Y.>M5%61-R&Y(-V?K3'P),TYP6ESZFFR+SBK9$F+U6N]\%@
M?I7!*/EKO?!8YS[5P8C8Z*+.]'2EI!TI:\L]%!1110 5RWBO_CU:NIKEO%8_
MT1C6M'XC.KL>7C_CX;ZTV3F4^E+_ ,MG'J:79R17LT]CS:FX9WI[BM31;CR9
MQS61;@EC]:?!(8YW.:&KD)G3ZS?"4X![56T^^$$3G-8CSM)U--1V\M\'I2C#
MH6I=3IGOA/;DD\XK-TRX5+W)/&:SXYS'!R>O%1KNBR^?>J<!N1V%Y=H0K9Z5
M/9WL;+O+5R$MPTEN.>@HBO&BM-V>]2X:"4CI[[4U'RJW%6+2ZB:V4EA7%F9I
M5+9/-2)?-%$J;CQ2Y1\QU%YJ"K(,-5BVO4@A:7=RPKC9[AI7#9J:2[:2V\L-
MT%)QZ#N=!_:0N9_O9%:1O(DMC\PSBN"LYV@;#$YJRVH,_P#$>*.05SJ4=)8R
M2>HKF]15$N<BK5M=8M\YZBLN[8RR]:M(5^IMV-Z%AP3VI\VH@)C=6 LA10N>
ME17$C$9S1RCOH=#9WJQDD'K6I;Z@KLVYN,5QQ+1Q#GJ*>MTT<:_,:EQ%S:'3
M2SQC)R,UGWEPK1$ ]JRI+II.0:B:1BO)ZU:1#9&T8+$TU.AS4D?*XI@&2?:J
M>Q)-9C_25QZUZ[H'_'FOTKR*R^6Z4GN:]>T 8L5KS<5L=N'W-BBDI:X#N"BB
MB@"M??\ 'LU>-ZYC^TG_ -ZO8[[_ (]FKQO6QC4Y/]ZNO#G/6V*9Q0,8I&]*
M2O5I['G3'5-9L(KE6J >M* 2>*U:T)3.CN-3S:[0W:H=)ORLN":PT9G+#/2E
MAE,<W!K!Q-%W.NO;Y/+P&ZBL6QG"WS,3QFJ%U<MP,]:B@<Y)STI<K+YCN8=0
M0L,MS3+R\0C(;I7()>,'W;CQ3FO696&[K1RDMG66]Y'+" S#BJ]Y?JHVJU<S
M:W3ABFX\"HC=-)<8)-/E%S&XUX)$PQZ58L=16*/&[BN:,I#L,TSS'"X!HY.X
MN8[NWU%&.2U5=8O5D@(#5R\=VR)G<>*:]VTPZTE#4.<DTYA'?ANV:["6YC>!
M03TKAE8QOFKG]H$QXSTJI1N'.=7#=QK%C<,YIE[<1 *P(KDH[YB_4XHN+]G&
MW)J>0.8ZRUU",KAF&*BU.>(P'!'2N46Y=5 W'BGSWC/'C-5&&H^<CD(+FH\#
MIVIJY(SZTN#MQ718FXN!FFR8R/K3@*9(#D&N>KL73/0?!6/+&/6N\K@?!7$8
M'O7>BO&K?$>C2>@M%%%8FH4AI:3O0)G+^*N+4_2O+' ,Y':O5/%7%JP]17EC
M#;,U>GA7H<59#N/*84V$@+2GD$4Q4(->HOA.+J6]/N/)N1@\5U=K>HX^9OI7
M$^64;.:N1W+*O!/%8RC<:9V=Y?QK:\,,U0M-15MPW<5S$]Z\D>-QI+61T1B6
MZUC[.QHF=3?/&(PX-16.HAW"LU8,M^9(A'GI44+,C;\U<8:%<YV5UJ201C:P
MYK*N+M9XP6/&:PKB=Y?XC3!(S1B+/(.:7(-2.[T;"Q;E_"K=PIF8EJP]$O0D
M0!/2M.XU!$0GCD5DXN]RN<J7E\EJ?+5JFL-50@[FKD=3N&FNMP/%003N&^\>
M*?+T#F.RNKA;B;KFJM\(X[!SGM6/#?$-N)I;^[\VV9 >HK2,2&RG9X$_F>];
MQU,2*%W<XKFXGV0A>]$197\PG@53BF-2-R6Z42(,]:G^W"(@!N*YMYFDDR#T
MISRL5SFIY!N5SM(KZ.6'YF&:S+B6-G;::PX;A_+)W'BHDN6\ULGK6D(V,VR:
M^V[B!5*/Y2:DE8N>M,*X /I6G**XYL-]:DLL?;$';-0+R=U3V0_TM?K6-31%
MQ>IZYH7_ !YIZ8K7%9&@_P#'D@]JUQ7B5?B9Z%/86BBBLS0*9+_JS]*?3)?]
M6WTIK<3V/+/&/_'XP'2N9P"!FNG\8C%RPKF N0IKU:"NCSZKU-[3+WR(-F>U
M9NHN)9\YJ%6*DX-1Y+YKJ<>IDF;VG7*Q6Q&>@J.VN1]N\S/-8\4K#<N:5)"L
MF[--PT$Y&Y<7@DND.>AK0FU3%ILW5R8E/F=>M.EF8@+FIY04CIM(O@C'<>IK
M1O\ 4E$8VMUZUQD<[1D,#TI9+MI>-U0X:E)ZG46M^A3EJ5-242[=W4UR8G:,
M;-QIHN',JMNZ4<@[G7:A<(T&0>37)22_Z3GMFI9-0+?*3561"3GUJXPL+F.N
MTJ]7R-I;M4\ES&A+;AFN2@N&BVC-%W?L&QFFX"O<Z+^T )>&X-5'NU-V6)K%
M\UB <]::69FZ]*AQ%<W+J[5G!S6A!J(6W #=JY)G8N#GI4RS,HQGK2Y!W-A]
M0Q=]>*U)=07R5.[M7%RNWG8S5B>Y;8HW=!3Y0N=;%?H\6"U9TMVL=V"#Q6&E
MXT<8.>M0S7#,N<TN07,=Q#>QLJDL*S=<ND>$A36"+QDA0[NU0S7+3+DFFH!<
MA;&UC70>$\&[%<VX.PCUKHO"8/VE17/66AO3>IZS%_JU^E25%%_JU^E2UY;.
MZ.P4444BA#7*^*\&T?/I75&N4\7<6;_2M*?Q&-38\O(_?/CUI GS9I8OGG?V
M-.=MCUZU(\ZIN(54"G(%QS32A/XTA!''I7:EH8IDK!<>],&T'ZTS))W42H5
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M**R1J%%%% !61J]K]HB*XS6O3&4,,$5479D35T<!_P (_N=B4_2D_P"$?/\
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M4?)S2_\ "/#</DKNO*3^Z*00KC[HI>V8>S.&_P"$>&3\E)_PCWR_<KNC"O\
M=%+Y2?W11[9A[,X4^'AQ\GZ4?\(\-Q^3CZ5W7E)_=%(85Q]T4>U8>S.$_P"$
M?.?N4?\ "/G^Y^E=[Y28^Z*3R4_NBCVS'[,X/^P#C&S]*5?#PVGY*[PPI_=%
M'DI_=%/VS%[(X/\ X1X;!\G/TI3X>&X?)^E=WY*?W12>2G]T4>V8>R.#.@8;
M[E*= R/N?I7=F%/[HH\E,YVBCVS'[,X3_A'_ /8_2C_A'LG[E=WY*?W12B)!
M_"*3JME*%F8VB:?]E7IBMT$4BJ!T%"KAB:Q;N:I6'4444AA1110!EZI:"XA(
MQGBN4_X1[+DE*[XJ#UJ/R4_NBM(3Y2)1N<"WA\ -\E1Q:""V-E=W-$JHW JO
M;1J[XVBM_:W5S%0[G)GPZ"N=G/TI#X>&!\GZ5WGE)CH*3R4_NBL_:L;IG"CP
MZ-WW.*0>'1GE/TKN_)3^Z*7R4_NBCVK%[,X0^'AC[E+_ ,(^,_<XKN?*3^Z*
M3R5Q]T4>U8U3.&'AX9/R4O\ PCX"\)S7<>2O'RBCR5S]T4_;,/9HX7^P./N4
MP: <_<XKO?)3^Z*/(3'W135=A[,X1M!)7[G- \/X'W/TKNQ F?NBE\E/[HH]
MNQJGH<)_PC_^Q3AX?&W[GZ5W/DIC[HH\E?[HI>V8>S1P@\/#/W*5O#P_N5W7
MDK_=%)Y*X^Z*/;,.0X=?#XQ]RC_A'AUV<UW'DK_=%'DKG[HI^V8O9G#GP\-P
M^2C_ (1Y>?DKN1"O]T4AA7T%+VS%[,X3_A'AC.SFE/AT8&$^O%=UY*?W10(5
M_NBE[5@J9P@\/#D;.*?9Z"8YPVSH:[CR5Q]T4X0H#G:*'5=A^S(;*+RH%&*M
M4 "EK!ZLWBK(*0TM%"&%,D&48>U/HH Y'5-*-Q(3MS6:?#NW&$_2N\,2ELD4
MC1(1]T5K&HT92A?4X,^'@?X/TH_X1X8^Y^E=V(5Q]T4ODI_=%4ZHE X,>'AG
M[E!\/#=@)Q]*[OR4_NB@0H.PI^V=A>S.%'A_(.4I!X?('W/TKN_*3^Z*7RD_
MNBE[9B]F<'_PCP)Y3]*4>'QR-E=UY*X^Z*3R%_NBG[9B]F<+_P (\,9V<T[_
M (1\<?)7<&%,]!0(5Q]T4>V8^34X?_A'QN/R4#P^/[GZ5W'DKZ4&%?04.JQ<
MFAPS>'QQ\E+_ ,(\O]RNX\E?04GDKTP*/:L7LSAAX>&>4I6\/#'"5W/DK_=%
M A7/04>V8*GJ<./#JC^#]*0>'02<I7=>4N/NBCRD_NBDJS'[,X8^'AM^Y^E'
M_".CCY/TKN?*7/W11Y2^@I^V8>R.%_X1X;C\GZ4-X>&T_)^E=UY2?W1084_N
MBDZK#V9PJ^'AC[GZ4A\/#.-G%=T85Q]T4>2N/NBFJS0*D<(WA_CA*T=&THV\
M^2N*ZOR4S]T4JQ*K9 %3*I<T4;"J""![5)116)J%%%% !67K-F+FV88S6I36
M4,,&FG9B:NC@G\.CJ$Z]>*1?#X QL_2N[$*XZ"F_9U]!6RJF3IG"'P\,YV?I
M3CX?&T83]*[GR%_NB@0K_=%/VQ/LSAE\/+_<H'AX'.4Z=.*[GR5]!1Y"^@I^
MV%R'!_\ "/C.=G-2_P#"/*1]RNV\A<_=%.\E<8P*3JAR'"CPZH/W/TI#X>!/
MW/TKNO)7 X%+Y*Y^Z*:KM%<APS>'QP-GZ4Q_#V#@)Q7=F%<_=%!A3'W12=9D
M\AP3^'SMSL_2G+H!" [/TKN_)0_PBCRDQC:*/;,/9G!KH.6^Y3AH'7Y*[H0(
M!]T4ODI_=%)U6+V;. ;P^<[@G/TJ230-V/DKO/)3^Z*00I_=%+VK*Y#@QX?P
MI^2F+X=)Y*?I7?\ E)_=%+Y2?W13]LP]F<&WA\8 "?I0OAX9QLX^E=SY"YZ"
ME\A?057MA<APG_"/#^YS2GP^./DKN?(7/04>0N>@H]MH+V9PW_"/#.-G'TH'
MAT<_)^E=UY"^E+Y*?W14NJ-4SAH= V3!@G>NQL(/L\(4"K A7=G:*DVU$IWT
M+4-;B]J6BBLS8**** &N-RXKF-7TD7#$[<UU-1O&&ZBJB[$R5SS_ /X1T?W/
MTH.@@#[GZ5WODIC&T53NE5'' K>-7H8.%CD$T#(SLI7\/CIL_2NW@C1H@=HY
MIWD+_=%+VNH^0X=/#H/5.GM3_P#A'E_N5W B3'04GDKG.!2]LP]F<,?#PS]R
ME'A\#^#]*[?R5]!1Y*XZ"FJS0>S.'_X1X8SLY^E(?#HX^3Z\5W7DKG.!2>2O
M/RBG[9A[,X?_ (1Y<XV<?2F'0#G[G2N[\E<=!2^2G]T5+JL/9G"'0#C[E)_8
M!QC97>>2G]T4>2G3:*%6:%[(X9= XY2C^P/ESLYKN?)3^Z*/*3/W13]LP]F<
M.-  _@IA\/?,3L_2N[\E/[HH\E/[HI>U8>R.%_X1\;,[.:0>'AC[G6NZ\A?0
M4"%<?=%5[9C4#AE\.@C&SBE_X1X8^Y7="%-OW11Y*^@J?:L?LSA/^$= YV?I
M2?\ ".+N^YQ]*[OR5]!0(5_NBCVS$Z9PH\/#GY.G3BA?#HQDIS]*[OR4_NBC
MRD_NBAUFT'LSE])T@6LXPN!FNH3Y>*41J#D"G,N<5E)W-HJR'>]%%%24%%%%
M !1110 4444 %%%% !33TIU-(R*:$S*G(^T?C6E']P?2LR=,W&/0UJH/D7Z4
MV]"4API:2EJ2T%%%% "8I<444 %%%% !1110 4444 (:*6B@+"=Z7%%% K!1
M110,**** "BBB@ HHHH **** "BBB@ HHHH ,4G>EI#0)@:!1BC% "44N.*,
M4Q6$HI<48H"PE%+BC% 6$HI<48H"PE%+BC% 6$HI<48H"PE+1BC% 6$HI<48
MYH"PF*,4N*,4!83%%+BC% 6$I11CBEH&D%%%%(84444 %%%% !1110 4444
M%)2T&@!M%+BC'-,FPE%+BC% 6$HI<<T8H"PE%+BC% 68E%+BC% 68E%+BC%
M6"@T"@TAV 4M%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH KW1'EFJ
M]EC=[U/=KE":K6/^L-5T)>YHTM%%2,****!B8HI:*!6$H[TM% 6$HI:* L)B
MEHHH&&**** "BBB@ Q2=Z6D- FA**7%&*8K!WH- HI#MH I:**!A1110 444
M4 %%%% !1110 4444 %(:6D[T"8E%+BC%,5A**7%&* L)12XHQ0%A**7%&*
ML)12XHQ0%A**7%&.* L)12XHQ0%F%)2XXHQ0%A*6C% H&D+1112&%&*** "B
MBB@ HHHH **** "BBB@!.])2XHQ3)L)12XYHQ0%A**7'%&* L)2T8HQQ0%A*
M*7%&* L)12XHQ0%A**7'-&* L%)2XHQ0%A**7%&* L)12XHQ0%@I*7%&* L)
M12XHQ0%@I:**104444 %%%% !24M)0 &LO46_>K6H:R=17]XHJHD,OVN/(6I
MS5>T&+=15FD]QK804M%%(H0T4M% K!1BBB@88HHHH **** "DQ2T4 %&***
M"C%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%-!S3J "BB
MB@#(N2?M7'K6JGW!]*R+CB[S[UKI]P?2FV)#J***0PHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@""Y
M_P!6:IV)_?'TJW=_ZEJI6)S(13Z :M%':BD 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2"EHH 0TM%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (:S;X?
MO%S6D:S+\_O5IH3+MM_J%J>H+7_4J:GI,$%%%% PHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!
M ,4M%% !1110!C3D?;2#ZUL)]P?2L:<9OC]:V$^XOTH =12 <TM !10>E Z4
M %%%% !1110 4444 %%%% !1110 4444 %%%%( HHHI@%%%% !1110 4444
M%%%% !29&<4M-V_-F@!U%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\><?KBO)=,C*7:MBO5]-8_98_<5P55KH=$"^.E+116!N%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5EWP)G6M2LR]/[]*: NVW$0%3
M5!;G* U/0P"J]U_J&^E6*KW7^H;Z4X[DRV/(O$DC+?'!XS64)&V#FM+Q*?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** *]Y_J&^E4M-SYA]*O77^I8>U4]/.)2M4M@-.BBBI 0]*Y/Q&07'
MK76'I7%>*93&V[TK6DKLSJ;"0@M9(!U%6K>;:P4GBL?3+\/;C)[5'<ZCY<O!
MKT8PNCC;.@N'&W(K)>4B3DU!'J?FK@GI5:ZN@!N!YS5QC96!LVHGW+Q5"[9Q
M)UXS4,=_Y:#!ZTUKH3'D]*:0F:L<9DL2.],D!^S&,>F*KC41!;DYZ55MM4\V
M<@G@FIY6.Y8TRW:VN/,/2M*]D,UJXS52\NTBAX(K.35-T$F3TI<MPYA+!F^T
M.@/-9^NVSI+O/3%.L[W9>L_K4FM78N!L]16L8,ER,BVB>8X3KVKM='5X+14E
MZURVE.(IUSTS73W%VBQ[@PHE#6Q"D6[DB6)E6LRS@^SW+,PZU FI[9<9SFI9
MKP."V>E)0:'<U99-T60:A@S)D5C)JQ*$5-9ZD!)C/4T<K2*N:0@,<Q:DDWM$
MRCK27%ZBQY!%48M2#YYZ4E%L&PMXF2XR?6M9Y./;%8[W@1MWK2#4 PQFGRB<
MB9K61)O,'<YK35R;/&?FQ5*:^4VX.1P*HQZKG*YI<C:#F&1LZWO7C-;8;*@F
MN8^V_P"E >IK134<D+GI3<03N;<$8:<'O756XQ"OTKBK6^'G+S796DF^%3[5
MYM=:G33>I:HHHKF.H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4445F:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM*:*@]3=TZ]WW2C->I:;G[*A]17CVD#_ (F"+7L>G\64?^[7DXC0[J6I<HI
M<BEKD.D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K,
MO_\ 7)6G67?C$RTX@7;;/EBIZAMO]2*FH8!4-QCRFSZ5-4-R,PM]*([DRV/(
M?$F!J!^M91QL'K6KXDYU ^QK([5[6'V/,J[C?O-[4XA0: -HII^8_2NNYB/R
MOXTDDL9P%_&HF#=0.M$=N<Y/>IN*Q*A"\BG/(\R[2<TTJ =M.;]VNZDV4F,A
M<P/Z>M7OM:R+UXJG.@**1_%38HB!CM4M#YBPDJB3)IK3DRG!J CYOI0?E.?6
MI*4KER.Y*L#FI);]C&06[<52[5$WS?A18+LNQW):';GFH[638[$^M06^?,/T
MIK$QR[1T-*P$QN)%N2<\9JY]O8+][FH# ##O/855C_>*2>U*UREH7_[38\;O
MK2_;3G.>*S3%M;ZU(4^3%/E!RN6I]19OD#=:K%6;YC4"QDON/:KH(V 544D9
MMD(X-(V>U/(P:(L/G/:M.A*5R,YVCUI\>#3B!NHVA12OH588X -=GX)QYR^M
M<6?F)]J[/P2O[Y37G8@Z:2U/2!TI:0=**\UL[UL+1110,*0]*6D/2@#'G4_:
M\^]:Z?<7Z5EW+@7'XUIHPV#GM38#Z0]*,TTL*20F]#/UCFRD^E>/ZCQ?O]:]
M?U=O]"?Z5X_J?-^_L:[L,CAK/4B4$'WIDH/F+]:=N.X&FR-\Z^]>FMCFB]3L
MO#S9BV^U,N-.SJ"R$=ZHZ/=^2X7-;$E\K?-D<5GRN]RN8MLX2-%]*SM9D+Q8
M!JM-J&7&#WJM?7>X@9XQ0HAS'2:&XBM,-W%33G>#MKF8=4,<04'H*OP:D&AW
M$\FHY-;C4R8L3=*#T[UKHJA,K7+S7H23(/6KUEJN[(8]!4RB5>YL$C:0>M<3
MXAW&X'/&:U[C5L38!K"U:X$Q!!YK2$;";(]-&+H&NMO+<S6@XSQ7&:=+F<9[
M5UT>HAH-I/054D^A*8NG(8D*^U*+(_;1)CBJHOA'(,'J:NO?A%Z]JB2?0%+4
MUH)=I"9IFI*=F5ZUEV-X9[CKT-:UPWF9!]*Q:M*YJG=&7:!H\L>F:L3D7415
M?2LV^O! C*#4&F:EEVW&M4KZDN13DT^2*ZW8[UT<"EK4+[<UGW5VKMN!%.BU
M 1IC/6J=Q)]2K>6&68XKFKR(Q7 !KLS.)4)KD=6?-T"*UA=Z"F56R<4G(<4H
M;O2$_O *BJM!0>IZ=X.'^C'/I77"N1\'G-M^%=<*\:M\1Z%)Z!11161L%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ+1DJ3%!P>:=]LD;^*JK\"A5P/K2L.Y-]H8/DFEEF9X^O-5_O-@]J<>!2Y=
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG)7L>F_\><?^[7D8D]"@7:***XSJ"BBB@ HHHH **** "BBB@ HHHH ****
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MH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P!VO'=))-ZAKV+3>+./_=KQ\3N>A1+M%%%<9U!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5!=<PM]*GJO<_P"H;Z54
M=R9;'D7B4'[<?K66!B+-:GB4G[:1[UE@YB KV,/L>?6&1@]*FLE+7:_6HD;'
M-6-/_P"/M<=S6\C".YTEU;@VF<5FVFELX<D=3Q702)NM5%6[:!(XLG%8MV1J
M<9<6#JY7'2I-/TUI)@Q'%=#<VP>4E1G-2VT*VYP>*+Z%(:MILC Q6;?6NX\"
MN@E8%!BJ,Z9YQ0I#, :<74G%9=];/;GT!KN;6W##;ZUSWB:'RAP.AIJ6I#.?
M\LF.NCT"$/VKFXY6\@Y]:Z;PTY+T-Z"2.DDC39L(K U*P548A>M=%(/WW/2H
M;F%)HS65RS@HK*26ZVKZUUUGHY6WY7M5>WM/)NBV.]=1"Z_9_P *ER:0TNYY
MSJUD8ISD=^*TM%B#PXQSBH/$DP\_\:N>'#NCW>U4B;%*[M_^)B@QQ6Y/IB_V
M<&"]16;J#!=5C%=5*5.DI]*<I6:L"U.!CL)#*1SUKI+&Q\F DCM3K>W&PR'U
MK24J;<@'MS5.8['"ZNI6\8]JI;2>!WJ]KC?Z8R]JH1L00373'8QDM2((R.V3
M7;^"1F93VKC96STKL_!'$JBN'$['12/1ATIU-':G5Y;.]!1112&%%%% !111
M0 4444 9VKG_ $*0>U>/:@?^)A(/>O8=6 -E(?:O'M1 _M&0^]=V%..N5P><
MT9 /UH8 &DQFO5CL</4=QMI >:*4@#I57)$)&:*2BBXQ:0X I>*, T7'8.,9
MII?> %[4X_=Q3539S6<MQ]!2X4<TBG!R>_2D9=S^U.8#;QVIV&'!:GMM&#Z5
M I.<T]N2!ZU+B-,TGNLV00'M68BE5);UIP)^[V%/QNC]Z$D#=B(0^:"5J1"$
M7RSU%-@D\IBI[TC@^<6[5HC-CZ7@BF4[M5<P6&YS031BG!00?:DWH'4;0#FE
M[4K*%Z4H@Q"0#S2-R0*7&32'AP:SK[&M-V9Z9X-_X]OPKKZY+P:!]EX]*ZVO
M$JN\CTJ3T"BBBLC0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@""[_U##VJCIW$I%7;OB!C[52T[F0FFA,U:***0Q#TKB/&G,1/H*[<]
M*XCQIQ$1ZBM\/\9C6V/.4^\33^U,3&XBG]17L1V/.EN+V^E .3FCC%  %:ID
MB$X.*6C ZT<8JKBL(6&,GI6WX?D'FD>M8;+\N!6OX>Q]HY[&LIR&MS0UVW,C
M].]:&D+LML5:NX(Y1DXIL2I , \&N>]S9$LLGEH35>*X_=G)YS27<JE>#5."
M12AYI7&7[&??.RY[U=NV$*UC6$BK=]>]:.I2JRX!J9/481RF2)AFIK(8=L]J
MJV93RF)-689$5FYZTMT%Q+RY ^E*T@^R$CKBJ]X$,9.>*;:RI*A0M[570=R&
MS:1W;D]*YK7!F<GTKMD@B@B9@1G%<3K#AKD@'O6E.5V3,S./+%-"_+3RORTY
M<&+-="9@T-'"TH.>:.,4  55Q6#..*9)CBGXR<TV3&142V*1>T<C[>E>PZ;_
M ,>D?TKQ[2@!?I7L.F\V<?TKR<2=U NT445QG4%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !5>Z.(&^E6*KW0S P]JJ.
MY,CR+Q(?]-;ZUEY'E 5I^)/^/T_6LS'[H5Z]#8\^L,8@#-6=+_X^03W-5RH/
M%6M/PLXSV-;LP6YVA^:V4>]%Y/Y,:C/:HTF7R%.:KZI(I,>#VK"6YLC3T\"1
M=S<Y%5-3)5\+Q3[&Y6.W&3VI[;+ELDU.MRD(A/DQY]*DE4&/-+,(XXT (IJR
MHPVYXH3';0L:>GS\UB^*(A+\H'0UT-LT:+NR.*R-147$S8YI)^\0]CA9D\I.
ME=/X5Q@DUE:M:A#M K0T%_*0U>XD=!J5XL"DUG:=JJ7,^S/>LO7;PME0>:HZ
M$2EXI)[U-M+%H[VXM@(?, ZU6MY&\AAFI;J]066-W05GZ=<I)$V3WI*]M1M'
M)Z_N:Z^AK;\-?ZD?2JNMP(6+"K/AIE&%)J[:$#-3A;^T$:MR1F_LZ(9Z"FW=
MO').K'%69%C^RJN>@J6-%>/_ (\"1ZU#8.Q64$_2K-OL,9BSQ3_*CMXW(/6I
M3U*>QQ.LKF]8>]4GP ,5>UEP;IB#S6:6RP%=47H<\A%;DYKMO!AS(H'6N+9
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %)2T4F@$HI:*5F 44450!1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!!=_\>[?2J&FC$I-7[O_ (]V^E4--SYIH UJ*** $I:**5@"BBBF
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444@"BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!!=_\>[?2J6FL/,(J[=G_ $=OI5+30-Y]: -2BBB@
M HHI <T +12=Z6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBDW"@!:*3<*,C- "T444 %%%)F@!:*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*XJT;(ZJ4G<T**1>E+7,=*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*LCMH,NH<KFG4BC I:X6=R"BBBF 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@""[_P!0WTJCIPPY
M-7;O/D-]*I:=GS#GI5+8#5I*7M25#W #7"^-%_=GZ5W)KAO&N?+/TKHH?$85
M=CSU!V]*?[U&,X]ZD[5[--:7/.GN)2,,BE&<TX#)K6Q BK\N?2FH,S+]:D<@
M#BG6*>9<#TS6<RHG=>'X@D2DBJFOP":3@=#6EIJ%;48ZU'>0EV!(KF^T;15T
M9&GZ<#$"15W^R!UQ5B(K",=JM>>OD,<TY-E<O4Q+G2MR8 J"UTG:^<5T$&)A
M4YA5.0*.>V@<IS5WI7MUJ2WT@"W!(K5G*LX%+<N(;($4W)B:*IA"6;$#I69I
ML@6_8GN:UH)!/928YKFHI3%JC*?[U%PL;VM$2D+ZBGVH%M:;O:J]\277/I4M
MYN&G9']VHOI8HMV4HNSBI[^(6D6[VK(\,LS3<UM>(PPL&(Z@5#DU)(+&9!<_
M:HV7T%<KJ:B*[-;WAX^9Y@/4"L'7<_VKM'2NBF[Z$,H]./6EQ@8IN#W[4'.W
MWKK1C(6FD4ZF9.XYJ*FQ*W+^CK_IRBO8=-YM(_85X]I!/V]/7->QZ<,6<?\
MNUY&)9Z%%%RBBBN(ZPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_I321BM+V(:$MT+R;?4UMPZ66CSBF:18F1MQ'>NH!@MX=KXSBLYU+%*)Q-S
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MO'M*(%ZM>Q:8/]#C/M7CXH]&@7:***XCJ"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:TE<WR+7L&F "SC'H*\>TC/V]?K7K^EY^R)]*\K$NYW478T****XCK"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH8"48I:*2 0]*0BG44Q6&T8IU%,+"44M%(+#>U%.HH"PG>DIU% 6&XHQ3J*
M=Q<HW%':G44#L)12T4@L-[44ZB@+"=Z2G44!8;2]Z6B@+"8HQ2T4!83% ZTM
M% 6"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !2&BBD]@#O2T44( HHHI@%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
6444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>form424b5_002.jpg
<TEXT>
begin 644 form424b5_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0B!W8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 3O110>E2 44G:
MCM0%QU%(*6J **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ I*6DJ6 4444FQA1110(8/O5)3<<TZFMQL****H04444 %%%%
M!1110 4444 (:04II*9+ 4#K110 ZBBBD4%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%(3S030 M%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M(:6BBP"8XHQQ2T4K!804M%%, HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "DI:*3 2BBBI&%+24M4D(3%+1118 HHHI@%%%
M% !1110 4444 %%%% "44M% 6$Q12T4!8**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** &'K0>M.Q1BG<=Q1THHHI""BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH 0T4M)4VU 6BBBJ **** "BDS0#0 M%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4AI:* 8"BBB@ HHHH *04M)0(6BBB@84444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 )2T44@"BBBF 4AI:* &,>*$/%!%"\4R4Q]%%%(H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HI**5P%HHHI@%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%)2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%%  :3M0:.U A***7M3$ I:04M(:"BBB@8444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M112&@!:*04M !1110 44E%*X"T444P"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBD[T,!:**2@!:*** $[T4M%38 HHHJ@"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *3=0W2H2QH D+<TX=*K@\U,M(0XT"EIHZT!U'4444QA1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(: #O2T@I:
M!(****!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !332FFTT2Q13J04M(:"DI:*3&)2TE+0@"BBBF 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !12=Z.] KBT4G>EH&%%%% !1124K@+1113 **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI#0 M%(#2T %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 AJ%QS4QZ5&>:EC(\<U,O2H@,FI%
M/.*!$E)CFBEI@%%%%%P"BBBF 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 444E !2444R!PHHI,TBQ:**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "D-+2&@3$H[T=J2F2.I:04M(I!
M1110,*2EHI6 ****8!1110 4444 %%%% !1110 4444 %%%% !12$T9H 6BD
MS1GB@ SS36-'>FGK3*2' TN:92CK0#1)1112)"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@!#TIN.#3LTE)C&*N*51S3J6DA!112T(!**,T9HZC%HI,T9
MIA86D!I":0=::V"P^BBB@04444 %%%% !1110 4444 %%%(32N M)29HS2;'
M86EIN:3=0F%A]%)FC-4%A:*3-&:!"T4F:,TAV%HI :6F(**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D/6EI#0)@:2C-%,EA
M12 \TM D+VI*,T4#%%+313J12"BBB@84444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(U12TQ#Q3ZP9NG=!124M)#"BBBF 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC.14F:JP/D5+N^;%4<<HZDM+48/-24T0T%%%%,04444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %(:6D- F5[@X0UQ?B)LPL:Z^\?$9KA?$$V8F&:W@CFFSS#5#^_)]ZKQ#
M<N:GU(YF/UJ& X7%;Q6IS-ZD4JYIL76II>*8@P:Z$C-O4EW<56<DM4K'%,"Y
M.:.74+@#@4T'+TYABA%YS4M%7-&S;# 5Z#X9?E17GEOPP-=YX6?,B5C-&L9,
M]0MAB-?I4]0V[9B7Z5+7&]SK6P8IP%)2BIL6MQ:***"@HHHH **** "BBB@
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M'4444R0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *::=2&@3,S43B(FO/->DX:N_U=L0
M&O-=<DX:NFGL<DCB+T;IL^]0H.:LW!!)J*,<5U11RS>HR89(H"\5(0#2G %;
MI:&7,5W&:<HXIRC)-"\-3L',1NN>*DC3Y:<%RU28 %38I,6,X%=GX4?YUKAR
MWS5V/A1OWJ5SS6AT0U/7;0_NE^E6A5.S.85^E6UKBEN=,&.%*.M!H%0;(6BB
MBD4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 AIIZ4X]::U-$29GZC_ *A_I7CWB=?W[_6O8M1_U+?2O(_%
M(_>-6\-CFGH<6%PY-28YI7 %.'W:Z8;'*WJ)BFLN:D_AIR@%:V6PT]2 )Q4+
MCYQ5W;\AJHP^:LYHU4BW;GYEKN_#0)=?K7!6OWQ7H/A4?O%KD:-$>FV7_'NM
M6^U5[3_4+4_>L6=*V"E[4TG!IPY%2QI **6DI,I 32$\4C&F;J&]"DBM*3FF
MIG-22#)IO05-S5+01GP:SKZ7"&K$\FT=:Q-2N0(FYJ&SJI0U.?U6X)W<UQ.I
M2$R5T&H70)(S7,7K;F)K)L]*E$I,-QH"T^/!SFG@"LSJC#08V2*=CY:4=>:=
MQ2N-Q&@<4XK\M"_>J? H3,Y1*Z*<UW'A0$%:XP >97;^%P,K6J>AQ5UH>F6A
M_=+]*N)5&U/R+]*OKTKHB>/4W'44459D%%%% !24M)4M@%1R#(J2FO\ =-0R
MEN8M^=H-<OJ<_!&:Z359 JM7#ZA<C<PS639WTEH9=Y.<GFL2XEW$U;O9QS@U
MCF7,E2V>E26@UZ5%^3%#$9I\?6HN=D!JKBAA@5,P -,?FD5(@3.:F7@4S;S4
MC?=%0]Q%:3.ZGP9W9HEQMIT>-M5<=BRP^6HU^]4HYCJ,<4RU$)AQ6;*OSUI.
M<K5-@,T]D3*(V,8(JWYI '-0(*'.!5Q.2K WM)NCYH&>]>BZ5<YB49KR?2I2
M)^O>N^TBZY49K:)Q5(Z'HULVZ$5+5#3Y=T0YK0)K4\N2LQRFG5$#S4M29M"'
MI5.;@&K;&J=VP5#1T+I[F'?3;,\UR&I7/S-S6[K%P%!P:XN_N<D\UFSU:<"A
M>39SS60S9DJQ<2Y%4\UBSMBM";JU.*Y-1J>*F0C%9,WBM".1:9BK#C(J)1UJ
M&PL %(PXIZ8S2]Z9I$A44R3-3#&^D9<M5&EB./.VIDI,8%.CY85:*<27;\M5
MFXS5N3 %5)6&:I,PG 8K$-6QI]P58<UBDBK-O+M8<UHF>=5B>B:1<G(YKL[*
M7<!7FVCW'W>:[C2Y]Q S5IG#5B=,OW:D3I449RM2ITK1:G!(=2T44R HHHI@
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %-:G4UNE-$RV,#67Q$U>9:Y+RPKTG7CM@8UY7K4F
M6:NRFCBJ;G,S2'S,5(G2JTG,M6X5RF:Z8Q.63&,<&D=C3F&32%<UORF+8X#"
MYJ%C@U./NU!C+T[!<LQCY<TR8X6I(NF*;*N>*EK0I/0K*V1FNQ\)M\ZFN,;Y
M6Q75^%WVRH*YZAT4V>R:<V85^E7UK)TU_P!TOTK6'2N":U.R(^E%)2BLS9!W
MI:2EI%(****!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY%'M730?=%<4SK@RQ2BD[4HK Z$+1112+"BBB@ HHHH **** "BBB@ HHHH
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ME+2-]VI;*15==QIK<"I1QFHI>*@VCN1M)Q5.YG^4C-/F?:*Q[JYY/-*3.JG
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(*AA.4%3"N-[G=#5"T445)H%%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5'>JDUT/6K43.4M"ZLO-.\WFLI;H>M.^U#/6JL*,C85^*D#9K+CNEV]:LQ7
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M KEO#I_<+]*Z93D"M8L\6MJRPE25&G2I*V1QO<****8@HHHH **** "BBB@
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MKXB;Z5>;I65J;;8F^E:0W,9O0\W\139D<5Q<[Y<BNI\1/^\>N/E;YZ[('#4
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M'&ZM>_'+5B@_,:YY'OX8G6GO]VF1\T,:YVSTDQ21BE&,5 &^;%2 \U(GL(V
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M@^04]AQ21_=%/K=;'CMZ@.E+113)"BBB@ HHHH **** "BBB@ HHHH ****
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M(3P*EJYJ@ZFF[>:E5>,T[9Q7-4.N!=TV+=(.*[;3+08'%<WHL&YUXKOM/ML
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MYPPKOO#9^=:XZIV0V/1K,?N5JU5:T_U*U8KS);G7#8<****DU"BBB@ HHHH
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MPV*[(;')(4?=IA'%.S\V*5A5,42-:OZ;_KU^M4:OZ=_KU^M<TSHAJ>M>&/\
M5K76K7*>&A^Y2NK3I7FU=ST**T)!2T@I:P.M#369J7^I:M1NE9>H_P"H:M*>
MYC5/)_$_^L;ZUQI&7-=GXG_UC?6N/4?.:].GL>=4'*O%2$<4J"@?>-=<=CF:
MU(\4C5*/OTUOO50(K,*T=.Z50?[U7]/^\*YZB-H+4[WPYU6O0[0_NA]*\]\/
M]5KT*T_U:_2O.K:G;3)3UJ4?=J-Q4@^Y7,=.YEWW0UP'B)OE:O0-2P(S7G7B
M)OD:NJDKG+4//[K_ %^:$-+<_>)ID?2O0IG-(D8985,HIJ#BI4Z5THQ:&OTJ
MI<'BKG7-4Y>2:HAB6I_>"NRT8?=KC+3_ %_XUVNCD#;7)45RZ:/2-'_U"UMK
MTK TB0"(<UM"9?6O,JK4[*;L3T5#YRYZTOFKZUE8VYB8&D)J+SE]::TP]:+#
M<M"1C\IKC/$(^]76-,NT\UR?B!U*-S6]):F,I=#SG45RYK!DC_>UT5]@DUCR
M*-U>C2B<LF,08%-;K4ZCY*B:MS%/493).HJ1:8W6N>HM3HC(Z#PU_P ?"_6O
M8M);_1EKQWPT<7 ^M>O:0W[E:X*B.REL;J=*4TU#Q2]ZY>IT7T%'2LK4S\IK
M5[5CZIT-73W%-:' Z]T:O/;W_6-]:]#UX<-7G]\/WI^M>A2.*97@X-3GFHE&
M!4O:NE'+-!BE6G$?)1T2J,Q/XJ1SS2@_+4;-Q428(@E3?(*VM*@.Y>*S(5WN
M,UU6CVX..*YJCL=,$==H41&WBNV@&(A7,Z+#C%=1&/E KCFSHBB044"G8K(W
M2 4X4@ZT^DS2*"D-.IIZ4BVM#-U'_4M]*\D\3?ZU_K7K>H_ZIOI7D_B@?.U=
M=+8X:O4Y GFF@'-./6GX&RNZF<,MQ,U&X.:D[4N,K73T,R'M4;#YJG(XJ/O6
M<C6+U+MC]X5W_APY=:X/3QS7=>&.91]:Y:IVTSTJS_U*U:JM:_ZI:L5YDMSK
MAL**6BBI-0HHHH **** "BBB@!&Z5GW?W36@W2J-Y_JC4R-:6YQNM'Y&KS;5
MC^^/UKTG6#^[:O-=6/[X_6N:9[^'T1GH,FI6' IL53=JPEL=\2,4['%$?WJ>
M.M1?0Z([#6^[BHBIQ4O\5.*C%7%F<D$%=KX9!RM<9%]^NW\-#[M=$'J>;B=C
MT:S_ -6/I5]*H6?^K'TJ^G2NB*/ J[CZ8.M/I,51D+5=Q\U6*BE'RYH'%ZG-
M:Z?W35Y)K@S='ZUZUKG^I:O)]9YG/UK&9Z^'V1CXJ0#-(O2GQC@YKG9[%+8*
M:W-./%-7EJDZH@1\M-<_)BI"*A/WL4">P1BMBQZ"LN,<UJV7WA5)ZG)5T1VG
MA_JM>@V?^K'TK@="'S+7?VO^K7Z5O!G@XLMBEH'2BMD><%%%%,",]:H7?0UH
MM5"[^Z:+F]%^\<?K*\-7FVM?ZT_6O3=7 \MJ\RUK_7-]:PF]3W\.C.@&34TH
M^45':]ZG<<5RS/2AN5QTIXIO>I$ZUBSLB %(XXQ4B_?H8?-BI->A$HXHQ4F,
M-BAQ0A/4CHI3255B1R"DZ-4BCBFR=*9F*GWJCG%214ES]RJ1SS1'I_\ Q^+]
M:]-T0?*OTKS33?\ CY7ZUZ?H?^K7Z5M!'DXD["U^Z*TX^E9=IT%:D?2NB)X=
M?<DHHHK8YPI&Z4M(: (6^[7(^(ON-77R=*Y'Q!_%42.JAN>:WWWF^M8Y^\:V
M]2&)#]:Q9.&KFFSW</V$J-AS4_\ #4;]*RN>I#8:G!J9.6JN*L15+5BV-D'S
M5"PJW(.*@QQ51.:IL00+_I:?6O5_"@_=I7E]N!]H7ZUZGX3_ -6M=$3Q\2SN
M$^XM2]J;']P4^NA'CR'?PT\=*8M2"J9FPHHHI""BBB@ HHHH **** "BBB@
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MU+C J-UQ63>IZ<-A$&34Z<-44?6I\8&:DN0.><5 YP<5-UYJ)UYS6D3EJL2
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M(/E%2U$A^45**W/)84444R0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI@>7B3TJS.8A]*O1FL^SXC'TJ_$*Z4>!56K):***# *C;GBI*81S0-&+J_\
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MQJ]5U#_4M]*\G\1Y\UZ[Z"T/-J[G*O2J.*:>7IX%=BT.9B]J</NTTBCFK1+
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MYK[?.U:4S*9YWJPRQK+@4@UL:D,N:SD3!KT*6AQSW)P/EIJU(.E)C%=L#FD
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MK_\ UK?6O0M=/WJX#4!^\/UKNI'%,@@XIS EJ1.!4P&:ZXLPD,0$&G\YJ0J
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M=$7%LE0QQ9T,?2G]ZCCZ4_O6+W.B+T%/3-8NJ<@FMEONUC:E_JVJH+451Z'
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MLZI_K6-8;'YZ[(LX9EA#4O45 AXJ=>E=<#FD,*_-2/3VZ5%G-$AH0"K^F_\
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MZA1113,@HHHH **** "BBB@ HHHH **** "BBB@!!0.M%+0*P4444#"BBB@
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M5J>;69*E.IJTZM#E84444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKFK:IA*T(^!5:!<+5E>M;(\ZH[DM%%%48A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 (>E9UXV%-:+=*Q]3?8IJH[F50Y'7
MGRC5Y=JAS<,*]%UR;]VW->9ZG)^_8UU0.:?8A7I4T?WL541^,U/&W>NI,R2+
MP44R48I4?(ILAR,U38K:%=^#5BUXD7ZU6<Y-36;9F4>]0Y#C&YZ5X>CRB&N]
ML$PHKBO#"[D2NYM>,"N6H=$#07I2TU:7O7*=2>@M%%%(84444 %%%% !1110
M WO3)%RM2&FN?EIHAG'^)(OW+_2O'-63%PWUKVOQ -T#_2O'M7C_ '[_ %KK
M@<LT9,8P:G;[M0=#3B_&*ZTS":)UZ4WHV:B23G%(9/FQ5W.:2)B<FG;,IFH0
MW-6,_NZAR"**7_+8?6NW\.-PM<*[8F'UKK- GVE1FN5G3'8]6TAL@5OJ/EKE
M]%DX6NH3[@-<TF=4$5[T9B/TKS[7?OL*] OCB$_2O.]=;]XQJX!):G!ZB/WI
MK-'W\5H:DWS$UEHV6S77!G--%Y5XI<8IJM\N:3?DUK?0R0YZ3&!FFDYIAD[4
MFS1(AF'S UV?A4?,M<2S[GQ[UVWA0_O%%<TV4EJ>LZ:G[H&M0"LO3F_= 5J"
MN66YU4T+VI*=25)JQ&^Z:Y+Q+_JF^E=:WW37)>)?]4?I5PW,JAY5J?\ KFK'
M?DUKZM\LC&L1GYKJ3.62)H^N*D/6H(SWIY>M4S-H>12 4 Y&:%.:&Q)#77!J
M]I@Q,OUJBYS5K3'S.H]ZSF]#1(]A\+_ZM:ZT5R'A0Y1:[#M7'+<[*:T#M2BC
MM14FHUJH7X_T9C[5><\5F:C)BW85<3&H>5>)QF5OK7)H,L:ZKQ*W[YOK7+9V
MFNR+.=H<14/5C3RU1YP<ULF820H^]BI<<8J#/.:E!^7-7<FQ%*.*L6'&!5:9
MOES4VGG/-8S=S>FCN_#O^M2O4;'_ %*_2O+?#I_>)7J%@<Q+]*XIG7 NTM%)
M6)L+36I>](:8GL1D9-5KB$,IJQGYL4KC(JDS*2T.2U.U&UN*X+6H<%N*]0U*
M+*GBN"UNW^8\5U4Y'+*)P4D7S&F(O-:D]OM)XJA(-AKKB]#"2U(U&6Q4V<#%
M5M^TYI3)QFM(LB1(>:55YQ40?/-2*>]:IZ&31,JX.*)4&*9OYI7?(I7(MJ0A
M>:LHN!5<'FID;BE<NVI#-UI5&%S44S?-0LO&*Q<C1;%D#BHIE^7-*CYXIY&X
M8KGFS>"N48P3**[#1+;>5XKG[>UW3#BN[T*TQMXKFDSH@CJ]'LP%7BNFABVJ
M*SM-AV(O%;"C K%LZ(1%QQ12TG>I-+!BDIU(:8-"&LK4>AK48\5E7_*DU<-S
M*>IQ&N<(U>;:B,3'ZUZ/KA^1Z\TU)_WQ^M=46<TT1@<"I!4$3[A4BM\V*Z$S
M"VI,!WJ0=*C4YXH+8-2WJ"0KKQFHH!_I"FE:3M1#_KUK-O4JQZ#X?&0M>@Z<
M,J*\[\/M@+7H.G-\JUE-Z'1 VUZ"G4U/NBG5RLZUL%%%%(84444 --(12TC=
M*9FS.U(?N6^E>3>)A^\:O5M2;]TWTKRCQ(<R-6\-#EFCE,?-2E<#--S\^*=N
MSQ74I'+*(+3R/ES4);!Q1YG&*N^A+0C"H2,M3V;BH"^'K.3*BF:UDO(KO?#
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M^I,U]+@V '%;\2U1LXL**TD&!6J1PU9#Z***T.<**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0U@Z\I,)QZ5O&LK58
M]\9^E5$SF>4ZM"Q=N*YBXM&+'BO0]0L]SMQ6,=.#2=*V1A,Y2.Q;'W:LK9MM
MZ5U,>EC/W:D_LW#8VULG<A+0YA;)MO2F-9-@\5UXTT?W:5M,']VF"T.':R;G
MBI;"T83KQWKK)=, 'W:CMM.VS#CO429<4=?X6B*HN178KTKG]$@\N->*Z)>E
M<\V;00AH%+0:@NP=Z6D%+2&@HHHH&%%%% !1110 4R3[II](PR*$)[&#J*[D
M:N#U:W)+<5Z+?1Y!KE=2M<D\5T0,)'FEW:-YAXJ**S8GI76W>GC/2DBTT8^[
M6BD82.7-FWI2+9-NZ5UC:<,=*5=-&.E:IF31SD=FV>E+-9MCI75)IPQ]VB73
MAY9.*EL$C@9K-M_2K]A;,LBX%;C:<"Q^6K=EIX##BLVS>*-[P]&1MXKO(/\
M4K7+Z-;;,<5U40Q&!7/+<W@5KX?N:X+7(20W%>@W*[DKE-5MMV>*(L<CRV_M
M6+'BH(+-MG2NMNM/W.>*;#IPZ8KJILP:.7>S;'2F1V;9Z5UTFG#TID>G#=TK
M5NQFCFC9-CI5.:S;TKNSIHV]*ISZ8/[M0Y%K4X^WLVW]*[30+<JR\5!'IH!Z
M5T>E6@4CBL9,JQTFGH016['PM4+*'" UHKP*QDSHBA:***@L@FZ&N7UR,E#Q
M75L,BL;5( R&K3T,)H\NU.V+%N*YU[)O,/%>AW-CN=N*S#I@,I^6M$S-G,I9
MMY?2HI+-L=*[ :<!QBHI--&?NUK&1%CDXK1MO2K<-D=O2N@73@#TJY%IPV]*
M&[CL<H]DVT\5!:63"Y''>NU;31C[M10Z8%F!V]ZSDRTCJO"\92%,^E=6*Q='
M@$42\=JVQ6,F;0#O2T45):(Y1\M<_J2$YKHG'RUF7<.Y":N+(DCS?68"6/%<
MI=6K%NE>BZE:[B>*P7T\,3Q6T68R./\ LC>E3+:''2ND.G#TIR6 STK9,AQ.
M;%HV>E2?9#LZ5TJZ<-W2E:P&<8JFS.QQDMHV[I6CIUJ<#BMF33AN^[5RSL-I
M'%83-(Q-+0H"N.*[NP!"#-<[I=L$(XKJ;==JBL),Z4B?M4+=:G[5$XJ#02/K
M4U,0<4^@"+^.GTN.:#0)C&%4[F/(-7344BY%:1=F8S1R&K6N[.!7)7UB<GBO
M2;FV$@/%8-YIX.>*W4CF>K/-;ZR.WI62]J0.E>@WFG Y^6L*XL,,>*V4C.43
ME_*('2HV! K8GMMI/%9\T>*TYKD-%/=\M,#<TYP0:8!S3N1;4GC)JQ&#4"#D
M5?CCX%-2T'8IO"6/2HEM&+]*W%M<J.*O1:<"H.*SEN5%:F1963;QQ78:19G<
MO%)9Z8-H.VNFTZQ"XXKGF=,4:^FVP"CBMZ*,**J64.U*T .*YF=,$ &*6BBI
M-0HHHH C>G)TI2,T 8H!#7Z5GW8^1JTB*HW8^4U<69R1PNM1%@U<!?6;&0\=
MZ]1U*WWYXKF;G3@6/RUT)ZG/):'&16;9Z59CLVSTKHUTT#^&IUTX =*T>QF<
MO]D;=TJ*:S;TKK_[.'7%1R:<".E0V-G&"S;=TK1M+,[AQ6Z-,']VK=MIX!'%
M3<?F+IEN0R\5W.EJ0HK#L;0 CBNFL(\ 5G)FT#47[M+2#I2UB= 4444 %(>E
M+10 T4Q^AJ6FL.*$2UH8.IJ3&WTKSC5[=FE;BO4K^+*&N-U2S!8G%;1V,)(X
M1K0YZ5!]D._I75/8C'2F#3QUQ5HQM<Y=[-O2H19,9.E=@=.!7I2Q:6"<[:M,
MFQS7V%@G2J<EDV_I7=_V8-OW:IRZ8-WW:ELI+0YNVM"&7BNX\/PD%>*SX-/&
MX<5U.B6P5AQ64C5+0ZFT&(EJUVJ.%<(*?WK,W6PHH;I2T4BT4+M?W9KC=7B)
M#5W,R94US6J6V<\5F]S>!YI>6I,AXJI]D;TKK+FR!DZ5&VGC'2H9VP9R1M&W
M=*<+0^E=,VGCTI38#9TJ3>,CFTLSNZ4][0^E=-'IXVYQ2OIXQTIV-%(XN2T;
MS.E3)9MCI73'303G;3QIX"]*&AN>AR<EF2>E'V-N.*ZM=.!SQ0-.']VH:$IG
M+M:-M'%!M&V]*ZE=/!/2E_LX$XQ4M%J9RZV;8Z4/9MCI76+IPSTH.F@MTJ;"
M]H<DEFP'2G?9&]*ZHZ< >E)_9X]*0^<Y5K5MO2JXM&W=*ZY[ >E1_P!G#/2F
MD)S,".T..E(;0YZ5TZV QTI'L!CI6T5<S<KG)FT.[I6GI5N1<#BM.2P 7.*N
MZ=98<'%;):'))ZG0:5&0RUUMN/D%8-A#MQQ706X^6J1RU63T444SG$Q5>=>*
MLTQUR*35RHNS,:ZARO2N>U"VRIXKKY8\BL:Z@W,1BHFCOHU#SC4[4X/%8+VQ
M"GBO0-2L<L>*P)['&>*QDCT*=0Y3R2&J4# K3GM=IZ50F7;4-&_.0EABH2_)
MI)&(J!VII$<X]7^>GF2J;.1S3E?(J[!>Z+D9RU3D$U7@'2M"*/=1U)YM"LD!
M+CBKR6Q++Q5RWM,C.*U+:RSCBAD28EA:G"\5U.G6V"O%5M/LQQQ71V5L!CBB
MQQU7U-"VB 0<5H(ORU! F.*LC@5K%'GU&+28I:*T,PHHHH 0]*8.]24F*3&F
M56'-02Q@BK<@J.1?DJ3:,CD-9MMRMQ7#7%D?M'2O4+ZW\Q3Q7-W&G#>3MK-H
M[(3.)N+4@=*QYX&$G2N[N['Y3Q6%<674XK-H[*<]#!V[14;]:N7$>VJ9!J$M
M33F%+<4UWXJ/)S498DU21I&1.6^2G*?EJ 'M4B'G%#*YRR@R*D\HE>E.MDW,
M*TA;=.*ED2D9L-N2.E:>GVAW=*LP6?(XK=L;  KQ0D<]5C]-LR".*ZFQM\8X
MJ*UL@JKQ6U# %45O$\^I(L6Z8%6A3(UP*DK5(XY.["BBBJ)"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $-4;]<I5X
MU6N5W+5+<B1RUU:[B3BL\67[SI71RQ98BH$MLOTK6YA)%.'3P5SBGMIXZXK:
MBAPN,4KQ<8Q5*5B3%2Q![4\V QTK46/!Q4OE<=*?,-+4Y][$$'BH8[ "3IWK
MH&A'I4:P8;I43D6D6;"+8@K2%5[=-JBK(K%LU0=Z***!A2TG>EI#04444#"B
MBB@ HHHH *#THHH IW,>X&L.\M]Q/%=(ZY%9L\.3TK6+T,I1.9ELMQZ4^.P&
M.E;36WM3A!@=*M,PDM3$6QR^,4\6 W8Q6TEMALXIWD?-G%6I:DN)C"RP^,4^
M6R'ED8K7\CYLXH>+*]*3D"C8Y1K'#=*L06>UAQ6NUKELXJ6.UY'%1<T2U)K*
M#RP.*UD^Z*K0QX JR.E9RW-8JPR896L6]@W \5N.,BJ<T6>*2"1S$UCE<XJ&
M*SYZ5T$D&1C%1I;8/2NB#L926ADM8@KG%-BL>>E;I@^7&*9'!@]*MRN0HF>M
MED=*KS6 ]*Z%(,#I4<MOGM4.1<4<S]BP>E:6G08D Q5M[;':K5E;;6SBLY,T
M<32@3:@%3TU1@4ZLF:Q6@4444AC35*]CW+5XU!.N131$D<W-9_,3BJ_V$;LX
MK>>'/:F"#GI6B,K&&UECG%-^P@C.*WFMLCI41AQQBKBQ6,,67/2KT%B"G2KH
MM^>E6XH=JXQ0V)HS!8@J>*@2R'F=.];XB !XJ%8,-TJ6R[$MDFU0*OBH(4VU
M.*S9HD+1114EC3S4$R90U8[TR0?+31$EH<O?V_S'BL_[%STKI+F#><XJK]GY
MZ5HI&+1BR6 "YQ4/V/':NB>#<O2HOLOM6ZDB>ADK9\9Q2&SYSBMH0<8Q1]G]
MJ3D+E,,V (SBIX++'.*UOL_&,5(D&.,5E*1:0VRAQ6U$/E%5+>';5U!@5DS=
M#Z81FGTW'-2RA1TI:2EH0!1113 ::8PJ0TW%-&<D5WCS5.>UW=JTR*8Z9%6I
M&,H',W=@,'BN?O;#&3BNZGAW#I6)>6NX$8K:,C*QY]>6N,G%8MQ;G!.*[J\L
M<Y&*QYM-SQBM.<EP.+> GG%0^2<]*ZU])Q_#4!TD@_=HYR>0P(HB6'%:T$!(
M'%78])((^6M.#3B,<4^8:@5[:UW #%;%M99 &*L6UAM .*V+6SQ@XIN2!1L,
MLK'@#%;5O:["!BG6MOM[5H)'\U83D;01+$FT5-30*=7.SJB@HHHI%!1110 4
M444 %5+E<J:MU#*N5--$R,">'?FL][(,3Q6^\7)J,V^.U;J1SM,Y];$$]*<M
MG\V,5M_9\'I0MOSG%7S$6,C[%[5$;/+8Q6\8..E1_9^<XJ+CL8WV >E21V>U
MNE;'D\9Q3DM\\XJ&QI7(+:VQCBMB"/:!4,,57%'%*3-8H?11169L%%%% !11
M10 4AI:* *UQ'N0US5[;[F(Q75N,J:R+F#+$XJXLRDCFOLF3C%.^Q^U;'V;!
MSBG?9^.E7S&3B8ZV>>,5:AT\>E:<=KWQ5E(<=JI2T%RF;]@&WI5&XL &Z5T_
MEY7I52:WW'.*EL:1SXLPN.*UM-CV-TI[0>U6K2'!J2XHTD^[3Z:HXI:@T%%+
M2"EI%(8XR*RK^#<IK7-5+E,@BH:-(,Y*2US)TIZV>X=*U9+;#=*D2# Z4K:'
M7"6AA-9#/2F"TRV,5N208YQ4:6_S9Q4V-5,STLP.,4&SR<8K6$7/2G>3WQ3:
M'[0Q38@'I339#TK:,7M33#[46#GT,A;(#M2FQQVK7\KVIWD[ATJ&A\YB"RP>
ME.^QCKBM@0<]*3R<G&*30_:&5]DP,XJ1;+Y<XK5^SY&,4\0X&,5%B'5,-K/V
MI!9\=*VS;]L4W[/@=*GE&JIA-9 CI4:V>3TK=>'':HE@P>E6HC=30S%L_:@V
M>>U;2V_'2D:WQVK6*(]H8#V6>,5/:6NV0#%:C6_&<4^"WPV<5JMC!R)K>/:0
M*UH1A:J1Q<YJZ@P*9C-W0^BBB@R"FM3J0C- (@<<50FBRV:TV'%59%I2U-Z<
MK&%>6@8$XK"NK+Y2<5UTJ9&*S;BVRI&*RE'0[J<[(X:YMN"<5AW,/7BNZNK+
M@C%8=SI_7BHL;*IH<7/&<GBJPC+'I73R:823Q48T@C^&A(7.<O)&?2B)"3BN
MBGTHCG;38M*(YVTQJIH48(CQQ6O:0EF Q4\.FD=JV+/3\$'%"0N<=:6G XK8
MM[+&.*DM;3 !Q6K;P9QQ3L0Z@VUMMN.*W+>+"BJT4.,<5HQ#C%-(Y*LR1%Q4
ME)2UI$Y&[A1115""BBBD 4'I110!"W)ICCY:FV\TC+D46+3*+1;SBJ4]D,]*
MV F#FHY%SS6;1I&>IR-]9XR,5@W=IA3Q7;WEONR<5B75KE3Q6;1UPJ'GU[;X
M?I6;- 5[5V5UIVYLXJA-I>[^&E8W530Y%XB.U0>6<UUCZ22/NU7_ +).?NT6
M+A4.?\L@=*?'&2>E= -))XVTY-*(;&VBQ3F5[&WS@XK:2VSCBI;/3]N!BM>.
MSZ#%)QU)]HBM9VFX@XKH;*SZ<5#:VNP@8K>M8=JCBDD[G/4J$D$' XJ\J\8I
M(DQ4P'-;Q1P3E=B@8%+116ID%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !44O2I:BEZ4T)E!H\N:=%!\V<5/
MMS4RH,55R&KD2Q\TCIS5C%,<<47(<+(K!,L#4Y3BA%J7%-O4:179,U&(^:M[
M>*8B<U+92V'H,**DI *6I+0AH%+10,**** "BBB@ HHHH *0TM(W2@$&>* <
MTT?=I4H'84]*KR1Y-6:0BFF)E1HLBD,?%6MM)MJKF+CJ0;/EI-E6"M)BBY+B
M1;.*:8^*L 4$<T^8?*5/*J2.+%3E:4+2YBN4:@Q3\XHQ2/2W+2#K4;+DU(O2
MEQ1L(J&+YJ/*YZ5:VT;:I2)Y="HT=)Y?-6MM&VGS$V(PG%(T>:F IVVIYBDB
MB\6>U6(4VK3]G-/ Q2;+MJ.%%%%24%%%% !43C-2TA%-"97V4T1_-5G%)MII
MD<I%Y=5Y(OFS5[%,91BFI!RE58^<U,%YIZKQ3E%-L%'0:5I-E2XHQ4W'8%'%
M.I!2U)2"BBB@84UAD4ZB@"LT>:A\GFKI%)M%.YFXZE/RJ;Y7/2KI44TK5J1$
MD5/*YIWDU9"TX+1S!&)4$/-.$7-6MHHVU-RTK"(N!4E(!2U):"BBB@844G>E
MI( HHHI@%)2TAH$Q*0TXTE,EHB=<BL^>#)Z5J$5&Z BK3,W'4YR>RR<XJDVF
MY/2NJ> %>E,%LN.E5<GE.4?2L\[:A;2?F^[79_9EV]*B^RKZ4*0W$Y0:5_LU
M9CTS&/EKI5M5]*>+=?2AS)Y=3$CLL #%7H;?  Q5Y81GI3UC -',"@,BCQ5@
M"@#!IU0V:1C844M-IU0:H****!A1110 4444 %-89%.H- ,J-'EJ&CXJQMHV
MU5S.Q5:.E$?%3E:4+3N1RE9H\BCROEJSMYHV\T7#E*OE<4^-,+4^WFC;2N-*
MPV-<5**0"G4F:104444B@HHHH *0]*6D;I0  YI:8E/IL!#TJM-'FK5-90:$
M2U<SS%GBE$7:K03YJ GS51-B-(\+TIVRIL4N*5PY2(+Q33'Q4^*,47#E*#18
M-6(4Q3G7FGJ,"BX)6'4C'%.[5&_2D,<IS3ZC3I3Q0-"U#(N34U(12+3L49(L
MD4X1\58VTH6D:<UD4)H\BD$7%6V3FDVT6+4RL(Z?Y?&*G5>:7;\U%@<RIY7-
M'E8JV5^:D9>:0^<JF*G+'@58*\TI7BDD+G*PCP:01X.:M%>!2%>*EH.<B"8Y
MI=O.:D(^6C'RTK"YB/9DYH9,FI57BG;:7*+F*<D6:9Y//2K^P4;!3L'.5Q'Q
M2/%D=*LXQ2[<UH@YRF8<KTIT<6*MA!1M&ZJ)YA$7 J6DQ2TB&PI"<&EIC=:I
M"'T4@Z4M(!K=*KN*L/TJ)AQ2+BRJ8\\U#)#GM5_;\M,*<4MS93,.XM=QZ5GS
MZ=N!XKI_)!/2FF!<=*FQI[0XS^R_F^[3CI?'W:ZO[*N>E'V5?2I2'[0XV;2M
MPQMI$TG QMKL/LBYZ4"T7=TH:&IG*QZ9@XVUHP6.T=*V?LJ[NE3+  >E5% Y
ME"*UPN,5<@AV]JLB,>E2*@IM&3F-5<5-'Q2%:<!P*(HR;N29IPIAZ4Y>E4C,
M6BBBF(**** "BBB@ HHHH :PXJ(CBIJ9CFH:N4F5)HLC%9LUMU&*W&7)J"2(
M%NE38UC,YJ33\GI5=M.]JZIK<>E1/; GI2Y313.6.F?[-0?V5S]VNO:V7'2F
M_95]*$M"U,Y9-+P<[:7^R_FSMKJS;+MZ4?9EV]*$A^U.;BL-K=*N+:X8<5J_
M9P.U'DCTIV#G*L<'S XK4B7"BF118%3J,4K&,Y$J5)4:5)6D3G>X44450@HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *81FGTF*!-$*CYJE%)MP:6FR0IC4\]*8>E-"8+3Z8G(I]#!(*4"@4
MM(M!1112&%%%% !1110 4444 %%%% !1110 F*!2T4 %%%% !28I:* $--IU
M)WID,**** "E%)2B@:%I"*6BD4- IU)2T"2"DI:0T Q"*2G4E,EA2TE**!H,
M4M%%(H**** "BBB@ HHHH **** "FFG4AH$Q,4H% I:8(****0PHHHH ****
M "BBB@ HHHH 0TW%.-)3(>X 4=Z*44 A:***184444 %%%% !1110 4444 %
M%%% !2&EI#0)B4F*6BF2)MHVTM+0%ANVDV"GBEHN.PS;1BGTE -#=M&*6B@0
M4444"%%+3:=2+04444#"BBB@ HHHH **** $-!H-%,EB8HI:*!"4=J6B@=@%
M&*6BD.P4444#"BBB@ HHHH **** $ Q2T44 %%%% #2*4"EHIW%80T"EI.](
M - H-%,.HTC-**7%% K!2$9I:*!V$ IU)2T@2"BBB@8F**7M35/- Q&6F8J4
MTSO3Z#3$Q2XXS3L4N.*70+C .*;4N.*81S2&F(!Q0!3P.*:W%(5Q *,<T\"C
M% 7&8YQ1CG%/QS1CFI"XF*7%+10D(,48HHI@-84X#BC&:6J07$Q1BEHIB"BB
MB@ I",TM% !1110 UNE1U(_2FX^6@I#:,4['%-I# K3".:EZBDQFD-,B*4%.
M*EQFD(I#N,*#;3-E3@9&*:1S3L"D1;*7;4F*7;5)#YA@'RTY!Q3@*,8H);%
MR:=B@"G4B&Q,4M%%,04444 %%%% !1110 4444 %)BEHI6 3%-*Y-.HJ1C2H
MQ3-F:EI *!ID6RC94N*,4#YB+;3=OS5,PP*;CO3&F0LG-)LYJ?&13<4FBN8
MN!0.M%.45)-QXZ4ZDHJT9BT4450!1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 (:.U+0:!#3TI".*":
M:HD11BGT@IU)C0@I:**104444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 E%+10*PF*,4M% 6$I:**!A1110 4444 %%%% "48I:#TH%8;2BF
MYYIPIB6XM%%%(H**** "BBB@ HHHH **** "BBB@!!2T44 %%%% !1110 44
M44 %%%% !1110 AI*4T"F2]PQ2T44AV"BBB@84444 %%%% !1129YH 6BBB@
M HHHH *0TM% "4E*:3-!+"E[4TFG Y%%QH!2T44#"DI:0T"848I:* L)BBB@
MTQ *6D%+2&@HHI*!BT444 %%%% !1110 4E+24""BBEH *3%+10,**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ I.]+32W.* %I:** "BBB@ HHH
MH **** "BBB@ IH'-.HH *;CFG44 %%%% !32.:=10 4TC-.HH 0#BEHHI6
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M1110 4444 %%%% !1110 4444 %%%% !1110 4AI:* (VZ4JCBEQS2@4[DI
M*6BBD4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !2'I2T4 1@<T[.*7%->GN*P\44B]*
M6D,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@!#2BBB@ HHHH **** "BBB@ HHHH *9_%3Z3% "T444 %%%% !1110 AIM.
M-%)B:(VZ4Y.E'>G 4@04444#%HI,TM, HHHI@)WI#2FCM3)$%.I!2TAH*0TM
M% PHHHH **** "BBB@ I*6B@0@ZTM%% T%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 444F: %J,CYZDI,<T +1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )3%'S4\T 46
M%?46BBB@84=Z** "JL^=U6JKS"FB9#%.<597I52+[U6UZ4 AU%%%(H0]*3M3
MJ3M2L(!2T4AIH-A:***!A1110 S'S48^:G8HQ3N.XM%%%(04444 %%%% !11
M10 4444 %%%% !1110 4444 (:C8?-4AZ4T"I:"X[M333J;2$PIPI!2U2$+1
M2=Z6F-"&DS2&F<[J74$R6BBEI)#$I:**I %%%% !1110 4444 %%%%( HHHI
M@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)2TE2P%HHH
MI@(:!2T4Q=0HHHH&%%%% !24M%( HHHI@%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4A&:6B@ %%%%
M !1110 4444 %%%% !1112 ****8!1112 ****$ 4444P"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***2DP$-':EHQQ20
MF(*6C%+188E!Z4M)2L,:IYI](!2U8,****!"=Z3O2T=Z9-@[TM)2TAH****!
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4S/S4^DQS3&A:***0@HHHH **** "BBB@ HHHH **** "D%+24
M"8M%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH 2@=:**8K"T444AA
M1110 5#**FIC+F@3*Z+@U:7I3 E2#I0""BBB@8AZ4#I2TF.*.H@HHHQ3"P"@
M=:**0"T444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MF]Z=28YI,3"BEHI6&)2T450"&CM2FFTR6':D IV.*!2ZC2%HHHH&%%%% !11
M10 4444 %)2T4F 44E%(!:***H HHHH **** "BBB@ HHHH **** $HI.E**
M8KBT444AA1110 4444 %)2TE2P%HHHJ@"BBB@!#0#2,>*130.V@^BBB@0444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 44A-)NH =1110 4444 %%)2TD 4444P"BBB@ HHHH *
M*** "BBDI +1110@"BBBF 4444 %%%% !1110 4444 %%-SSBG4NH!1113 *
M**0T %%)13)N+111WH'<*6FTM($Q:*2EI#"DI:*& E+110@"BBBCJ 4E+10P
M"BBBF 4F:6FT";%H[TE+3%<6BBBD4%%%% !1110 4444 %%%% !1110 4444
M %%)2TD 4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ I*6FT"8HI:04M (****!A1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444AH *
M*!13)N%+2"EI#04444#"BBB@ HI*6E< HHHI@%%%% !1110 4444 %%%% !1
M110 444E)@+32:6F,>:5]1I$E%-4\4ZJ$%)2T4 %%%% !1110 4444 %%%(:
M $SS2%N:0GG--SELTQM$U%(#D4M2Q"4445(Q:***L04444 %%%% !1110 44
M44 %%%% "&@4@I1UIDH6BBBD4%%%% !1110 4E+25+>H"T444[@%%%(W2F!&
MQYI <FFL>*2(Y-(M%D=****9 444G>@!:*** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH ***3O0)BT444#"BBB@ HHHH **** &MTJ(-S4DGW
M:K*>:I;"+:G(I:CC-24F,****E@)2TS^*GT(;"BBBF(**** "BBB@ HHHH *
M::<:8>E F.!I:CC.:DH&%%%% !1110 4444 %%%% !0>E%(U $6?FJ4=*@/6
MIDY6EU =1113 *0TM-IB844=J0=:";CA0:04&@=] S1FHR?FH)^:D!(#3JB)
MY%2=J&-"T444#"BBB@!*6D/2@=*2 6BBBF 4444 (:.U'>DIDB9IPIG>G"@2
M8ZBBBD6%%%% !1110 4444 %%%% !1110 444E)@+124=Z+@+1113 **** "
MBBB@ HHHH ***1NE !G-+4:'-24NH!1113 **** "BBB@ HHHH **** "BBB
M@ HHHH **** "D-+24"8"EI!UI: 04444#"BBB@ HHHH **** "BBB@ HHI&
MZ4  .:6F(<T^FP"BBBD F:6F _-3Z $S1FFY^:@GYJ!V'9HS32>:":=@L.S1
MFFDT$\46"P^BD'2EI""BBBD 4AH/2D%,3%I":.U1D\TT@W1**6FKTIU)@@HH
MHH&%)FEIC'F@:'9HIA-/'2H"P4M)2U2$%%%%, HHHH **** "BBB@ HHHH *
M0FEIC'F@:%)J,FC-,<X-2BDB534E5\X J=?NU0I+J+11102%%%% !1110 44
M44 %(W2EI&Z4 B%SQ4:O1(>:K[OWF*;*9H1]*?4<72GU-R0HHHJ1BT4458@H
MHHH **** "BBB@ HHHH **** &BE'6BBF2A:***104444 %%%% "&BBBH>XP
M[4M%%-;B"D;I115#6Y7;H:(>M%%(99HHHIDA2=Z**3 6BBBF 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !33UHHH0F.HHHH&%%%% !1110 444
M4 ,D^[55.IHHJNA++$=2T44F4%%%%2P(_P".I***%L-A1113$%%%% !1110
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L%%%-C9HQ?=I]%%9] "BBBD M%%%:""BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
